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ABSTRACT
Cervical cancer is the second most common cancer among women worldwide.
Cervical adenocarcinoma accounts for 15-25% of all cervical cancers and the
incidence appears to be increasing. Although some of this increase may be due to
better recognition by pathologists, there is evidence that the incidence of both endo-
cervical adenocarcinoma and its preinvasive precursor lesion cervical glandular
intraepithelial neoplasia is actually increasing in real terms. In this study, tissue
microarray technology was used to study the morphological features of cervical
adenocarcinoma archival donor blocks, to evaluate the immunoprofile of a large set of
cervical adenocarcinomas with an extended panel of antibodies to compare the profile
of AIS with invasive subtypes of cervical adenocarcinomas. The prevalence of HPV
16&18 in cervical adenocarcinoma cases was assessed to evaluate its relation to
cervical adenocarcinoma.
Using haematoxylin and eosin staining method 273 samples (blocks) were obtained
from 177 biopsies composed of 16 normal cervical biopsies, 139 different patients
with endocervical adenocarcinomas, and 22 patients with second biopsies. Pathology
reports and cervical smear history reports were reviewed. Morphological and
histopathological features of 139 patients with cervical adenocarcinomas revealed that
there were 20 patients with adenocarcinoma-in-situ and 119 with invasive
adenocarcinoma. Sixteen of 119 patients with invasive adenocarcinoma had early
invasive adenocarcinoma which met criteria for FIGO stage IAi carcinoma of the
cervix.
The tissue microarray technique has been demonstrated to be efficient and applicable
to various tumour types, but methodological evaluations are few. A tissue microarray
was constructed using paraffin-embedded, formalin-fixed tissues from 273 samples
(blocks). Two paired 0.6-mm cores were obtained from selected regions of archival
donor blocks and subsequently were arrayed into a recipient paraffin array blocks.
More than 2 areas were taken from some tumours. The novel array blocks and some
whole sections were used for immunohistochemical analysis and H&E staining.
Results revealed that the tissue microarray method yields staining of good quality and
v
is feasible for histopathological and immunohistochemical studies in cervical
adenocarcinoma. In general, the average staining pattern agreed with the whole
section in each. Analysis of two TMA cores achieved 100% representation for
histopathological type and greater than 97% representation for immunohistochemical
studies.
Tissue array sections were immunostained with 8 antibodies, carcinoembryonic
antigen (CEA), Cytokeratin7 (CK7), Cytokeratin20 (CK20), estrogen receptor (ER),
progesterone receptor (PgR), phosphatase and tensin homolog deleted on
chromosome ten (PTEN), MIB-1 proliferation marker, and p53 suppressor gene
utilizing the "Power Vision" technique for ER only and "Envision" technique for all
other antibodies. Our findings support that all of these 8 antibodies are of potential
biomarkers of a panel of antibodies for diagnosis of cervical adenocarcinomas.
HPV DNA was extracted from paraffin-embedded, formalin-fixed tissues of 161
specimens of 139 patients excluding 22 patients with second samples and 16 normal
cervical tissues. HPV DNA was detected by PCR test using type specific primers
from the E6 gene and E7 gene of HPV type 16 and HPV type 18. Out of a total of 257
cervical biopsies from 139 women with various cervical adenocarcinomas lesions,
HPV DNA was identified in 87 cases (62.6%) in which, HPV16 was positive for 65
(47%) patients and HPV 18 was positive for 41 (29%) patients. Genotyping by RFLP
and PCR revealed that HPV type 16 was the most frequent type of infection
comprising 46 cases (33%), followed by HPV type 18 in 22 cases (16%), and both
HPV typel6 and HPV type 18 in 19 cases (14%). HPV typing in all cases of 16
normal cervical biopsies was negative with both HPV typel6 and HPV type 18. The
findings support that HPV 16, along with HPV 18, may play a possible role in the
pathogenesis of adenocarcinoma of the uterine cervix.
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Cervical cancer is the second most common type of cancer in females worldwide. The
2 most common histological types of cervical cancer are squamous cell carcinoma,
which comprises approximately 75% of cases, and endocervical adenocarcinoma,
which comprises approximately 20% of all cases. Other less common malignancies of
the cervix include adenosquamous cell carcinoma, adenoid cystic carcinoma, small
cell neuroendocrine tumours, and other rare histological types (Bonds et al., 2002).
An absolute increase in prevalence of adenocarcinoma and its precursors has been
documented, both in the USA and Europe; therefore interest in cervical
adenocarcinoma has grown in recent years. It has been proposed that this may be
related to the increased use of brush sampling of the cervix, but may also be a
function of increased diagnostic awareness and recognition of glandular pathology in
cytological and histological preparations (Mathers et ah, 2002).
1.2 AETIOLOGY AND RISK FACTORS FOR CERVICAL NEOPLASIA
1.2.1 Human papillomavirus (HPV) and other sexually transmitted agents
More than 35 types of HPV are associated with anogenital disease, and 30 or more are
associated with cancer (Munoz & Bosch, 1997). Although a strong and consistent
association between HPV and cervical neoplasia has been clearly established, the
discrepancy between HPV prevalence and the incidence of cervical neoplasia suggests
that other cofactors are necessary for the development and progression of the disease.
(Brinton, 1992).
The functional status of the immune system is closely associated with the
development of cervical dysplasia and cancer in women with HPV infection
(Kobayashi et al., 2000). HIV-positive women have been reported to have higher
rates of cervical abnormalities, larger lesions, higher grades of lesions, and higher
recurrence rates than HIV-negative women do. Mandelblatt et al., (1999) concluded
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that HIV is a cofactor in the association between HPV and cervical neoplasia, and this
association seems to vary with the level of immune function (Ruche et al., 1999).
Interaction between HSV-2 and HPV 16/18 was detected by several studies however;
several recent studies continue to provide conflicting evidence. Serologic studies
showed a higher prevalence of HSV-2 antibodies among women with cervical
neoplasia than among controls (zur Hausen, 1982).
An association between the presence of antibodies for Chlamydia trachomatis and
cervical neoplasia persisting after controlling for HPV status and other potential
factors has been reported (Boyle & Smith, 1999).
1.2.2 Oral Contraceptives (OC's)
Endocervical glandular lesions have been associated with the use of OC's for quite
some time (Dallenbach-Hellweg , 1984;Valente & Hanjani 1986 ; Ursin et al.,1994;
Parazzini et al., 1998; Ljuca et al.,2000 ). Since the early 1960's, when OC's use
began, the incidence of cervical adenocarcinoma has increased, especially in young
white women (Schwartz & Weiss, 1986; Zheng et al., 1996). Over the past fifty
years, the proportion of cervical carcinoma which is adenocarcinoma is almost 25%.
The World Health Organization's Collaborative Study of Neoplasia and Steroid
Contraceptives confirmed this increased risk, especially in younger women on OC's
for more than 5 years (Thomas & Ray, 1996).
1.2.3 Dietary Factors
Several lines of evidence suggest that some nutrients may have a protective effect
against cervical neoplasia, particularly vitamin A, carotenoids, vitamin C, vitamin E,
and folic acid (Schneider & Shah, 1989). In addition, a subclinical folate deficiency
may act as a cofactor in the integration of the HPV genome into host DNA
(Butterworth, 1992). Several studies indicate HPV is more easily contracted when
folate levels are low (Li et al., 1995; Durand et al., 1997; Lewis et al., 1998). Reports
indicate that high levels of folic acid appear to provide a protective effect against the
initiation of HPV-related dysplasias (Butterworth, 1993; Harper et al., 1994; Grio et
al., 1993; Liu etal., 1995).
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1.2.4 Genetic Factors
Genetic predisposing factors that may influence HPV's behaviour more than
environmental factors such as multiple sex partners, smoking have been reported by
Magnusson et al., (2000). The common inherited folate gene mutation, MTHFR 677
C—>T, which greatly impairs folate metabolism, has recently been found in
association with cervical and endometrial neoplasms (Piyathilake et ah, 2000;
Thomson et ah, 2000).
1.2.5 Sexual Behaviour
In preinvasive cervical disease, the effect of the number of sexual partners is
substantially reduced after adjustment for HPV (Becker et ah, 1994). However, in
invasive lesions, the association with the number of sexual partners remained
statistically significant or on the borderline (Herrero et ah, 1990; Bosch et ah, 1992).
Moreover, no association is observed between number of sexual partners and cervical
neoplasia among HPV-positive women, whereas a positive association remains
among HPV-negative women (Bosch et ah, 1992; Koutsky et ah, 1992; Schiffiman et
ah, 1993).
1.2.6 Reproductive Factors
An association between parity or number of live births and cervical neoplasia has
been reported in six case-control studies after controlling for HPV status (Herrero et
ah, 1990). However multiparous women found to have approximately 80% higher risk
of AIS and invasive cancer compared with nulliparous women (Schiffman et ah,
1993; Munoz et ah, 1993; Eluf-Neto et ah, 1994). In addition, a strong association
between invasive cervical cancer and early age at first birth reported by Bosch et ah,
(1993), and coupled with the absence of an association with parity.
1.2.7 Smoking Habits
Several epidemiologic studies have provided evidence supporting an association
between cigarette smoking and cervical neoplasia. Wilkenstein, (1990a) reported that
two-fold increased risk among smokers and a dose-response relationship with
duration and intensity of smoking. Although the mechanism of carcinogenesis of
smoking in cervical tissue is not fully understood, current biologic, epidemiologic,
and clinical studies suggest that cigarette smoking may be a risk factor for cervical
neoplasia (Szarewski et ah, 1996).
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1.3 EPIDEMIOLOGY OF CERVICAL ADENOCARCINOMA
The epidemiology of adenocarcinoma of the cervix has changed substantially over the
last two decades. Malignant and premalignant endocervical glandular lesions are
relatively rare but their incidence appears to be increasing. Most of this increase is
more apparent than real because of the better recognition of premalignant endo¬
cervical glandular lesions by histopathologists and the realisation that some poorly
differentiated cervical carcinomas are glandular in type. Moreover, there has been a
decrease in the incidence of invasive squamous cell carcinoma in many countries
because of the success of cervical screening programmes. However, there is evidence
that there is also a real increase in the incidence of malignant and premalignant
endocervical glandular lesions, which are therefore assuming increasing importance in
diagnostic surgical pathology (McCluggage, 2003).
Some believe endocervical glandular atypia (EGA), purportedly composed of cells
that are less atypical than cells of adenocarcinoma in situ (AIS), is a preneoplastic
precursor of AIS. The precursors of invasive adenocarcinoma of the cervix were
recognized in the 1950s (Friedell & McKay, 1953). The best defined precursor, if one
exists, is adenocarcinoma in situ, which occurs infrequently in comparison with
HGSILs. Adenocarcinoma in situ is associated with HPV DNA, mostly HPV 18, as
opposed to HPV 16 in SILs. Adenocarcinoma in situ is less likely to be detected by
Pap smear than are SILs (Andersen & Arffmann 1989). In the majority of cases;
adenocarcinoma in situ involves the transformation zone and is unifocal (Cullimore et
al., 1992). Carcinomas of the cervix, regardless of histology and size of the primary
tumour, may contain highly malignant clones of cells that can prove unpredictable and
spread extensively (Eifel et al., 1990).
1.4 BENIGN LESIONS THAT MIMIC ADENOCARCINOMA
A wide variety of benign endocervical glandular lesions maybe confused with CGIN
and even invasive cervical adenocarcinoma, especially the mucinous variant of MDA.
These are listed in table 1. Many of these benign mimics are rare and in everyday
practice the lesions most likely to be confused with CGIN (Young & Clement, 2002).
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Deep glands and cysts
Lobular endocervical gland hyperplasia, not otherwise specified
Diffuse laminar endocervical gland hyperplasia
Glandular hyperplasia, not otherwise specified
Mesonephric hyperplasia*
Metaplasias and ectopias of endocervical glands












Changes secondary to mucin extravasation
*Not a hyperplasia of endocervical glands but an important benign glandular lesion
of the cervix
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1.5 PREMALIGNANT CERVICAL GLANDULAR LESIONS
Endocervical glandular dysphasia (EGD) (also known as atypical hyperplasia) and
AIS are categorised as premalignant endocervical glandular lesions. A category of
glandular atypia is also included. This refers to atypical glandular epithelial changes,
such as those associated with inflammation or previous radiotherapy, which are felt to
be reactive and less severe than EGD. In the UK, the term cervical glandular
intraepithelial neoplasia (CGIN) is in widespread use. CGIN is divided into two
grades, low grade CGIN (LCGIN) and high grade CGIN (HCGIN). HCGIN is usually
synonymous with AIS and LCGIN with EGD (McCluggage, 2003).
1.5.1 Morphological features of CGIN
In HCGIN, the morphological features of CGIN which are more pronounced than
LCGIN are nuclear stratification and loss of polarity, nuclear atypicality and
hyperchromasia, macronucleoli, loss of intracytoplasmic mucin, increased mitotic
activity, atypical mitoses, apoptotic bodies, goblet cells (also neuroendocrine and
Paneth cells) ,and abrupt transition to normal. Not all of these need be present in any
individual case. An abrupt transition from normal glands to glands involved by CGIN
is often present and this may be seen within individual glands. Both the surface
epithelium and the underlying crypts may be involved. Most of the morphological
features of CGIN are those expected with any premalignant lesion. The cribriform
areas and a microglandular growth pattern may occur in CGIN, their presence
(especially when extensive) should prompt consideration of an invasive lesion
(Biscotti&Hart, 1998; Moritani, 2002).
A variety of subtypes of CGIN have been described, including endocervical,
intestinal, endometrioid and mixed adenosquamous types. The endocervical type
retains a basic resemblance to the normal endocervix, with at least focally vacuolated,
often granular, pale, basophilic to eosinophilic cytoplasm .The intestinal type displays
distention of apical cytoplasm by a large mass of mucin, resembling intestinal goblet
cells. The endometrioid type is characterized by cells with densely eosinophilic
cytoplasm containing no apparent mucin in routinely stained sections, resembling
hyperplastic glands of the endometrium (Zaino, 2000). Moreover, a ciliated variant of
CGIN has recently been described (designated endocervical adenocarcinoma in situ of
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tubal type). The cases described were associated with typical and atypical tubal
metaplasia and with residual tubal morphology, in the form of apical cilia, in the areas
of CGIN (McCluggage, 2003).
Park and colleagues (2000) recently described a variant of CGIN, which deserves
mention, and has been designated stratified mucinous intraepithelial lesion' This lesion
is characterised by a multilayered epithelium resembling CIN. However, numerous
cytoplasmic mucin globules are also present throughout the full thickness of the
epithelium, creating an appearance reminiscent of atypical immature squamous
metaplasia (AISM).
1.5.2 Low grade CGIN (LCGIN) or Endocervical glandular dysplasia (EGD)
Although, diagnosis of LCGIN is difficult, the management should be similar to that
of HCGIN. Currently, the natural history of LCGIN is not known and there is some
controversy as to whether this is a precursor lesion of HCGIN and invasive
adenocarcinoma (Goldstein, 1998; Kurian & Al-Nafussi, 1999). The morphological
features of LCGIN are similar to those of HCGIN but are less severe. Some authors
have attempted to define precise diagnostic criteria for LCGIN (Brown & Wells,
1996), however it has been proposed that when one gland shows features of AIS a
diagnosis of EGD should be made (Jaworski, 1990) .
1.5.3 High grade CGIN (HCGIN) or Adenocarcinoma in situ (AIS)
Adenocarcinoma in situ (AIS) of the cervix was first described by Friedell and McKay
in 1953. Good evidence supports the existence of AIS as a precursor lesion for
invasive adenocarcinoma (Zaino, 2000). Cytologists increasingly encounter atypical
endocervical cells, because of the increasing incidence of endocervical adeno¬
carcinoma and the use of improved endocervical sampling devices. These atypical
endocervical cells can cause diagnostic problems, especially in recognizing
adenocarcinoma in situ (AIS) and distinguishing it from a variety of nonneoplastic
changes (Biscotti et al; 1997).
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1.5.4 Glandular dysplasia
Brown and Wells in 1986 further distinguished low-grade from high-grade glandular
dysplasia on the basis of the paucity of mitoses, absence of vesicular chromatin, and
restriction of stratification of nuclei to the basal two thirds of the epithelium in low-
grade lesions. In addition, Gloor and Hurlimann in the same year divided dysplasia
into three grades on the basis of almost identical criteria. Although it is reasonable to
attempt to make the distinction of dysplasia from AIS in the setting of research
investigating the pathogenesis of adenocarcinoma, Zaino, (2000) suggested that
glandular dysplasia may exist, but no one knows what it is biologically or how to
recognize it in a reproducible fashion.
1.5.5 Distinction of invasive from preinvasive adenocarcinoma in the endocervix
The presence of invasion in endocervical adenocarcinoma can be identified by
presence of an individual cells or incomplete glands lined by cytologically malignant-
appearing cells at a stromal interface and malignant-appearing glands surrounded by a
desmoplastic host response. It is critical first to determine that the glands are lined by
cytologically malignant-appearing cells, because endocervicitis, microglandular
hyperplasia and rupture of mucin-filled glands all may have incomplete glands that at
times may be associated with a host response of dense inflammation and,
occasionally, oedema or fibrosis. In addition, there are other features whish may help
to identify invasion in other cases such as architecturally complex, branching, or small
glands, which grow confluently or in a labyrinthine pattern, a cribriform growth
pattern of malignant-appearing epithelium and the presence of glands below the deep
margin of normal glands (Clement & Young, 1989; Zaino, 2000).
1.6 EARLY INVASIVE ADENOCARCINOMA
1.6.1 Introduction
The definition of early invasive adenocarcinoma remained controversial until 1997
when the International Federation of Gynaecology and Obstetrics (FIGO) defined
stage IA1 cervical cancer of either squamous or glandular type to be invasive to a
depth of less than 3 mm beneath the basement membrane and less than 7 mm of
lateral spread (Michael et al., 2001). Clement & Young, 1989 and Yeh et al., 1991
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concluded that there is no consensus regarding the criteria for the diagnosis of
microinvasive adenocarcinoma (MIA) of the cervix. However, Qizilbash, 1975 and
Zaino, 2000 described three patterns of MIA: glandular budding with an associated
inflammatory reaction, confluent glands in a complex pattern with little or no
intervening stroma, and intraluminal tufting resulting in a papillary pattern. All of the
lesions had to be less than 5 mm thick. However, there is no consensus in the
acceptable depth of invasion for a diagnosis of early cervical adenocarcinoma
(McCluggage, 2003).
1.6.2 Identification of early invasive adenocarcinoma
Identification of the early invasion in HCGIN is more difficult than with squamous
lesions. The morphological patterns of early invasive cervical adenocarcinoma are an
obvious small adenocarcinoma, a cribriform or solid appearance of glands and the
presence of early stromal infiltration from glands involved by HCGIN of small buds
of cells, often with a squamoid appearance. In addition, loss of the normal smooth
peripheral glandular outlines and a microglandular growth pattern may also be useful
features of early invasion. Once early invasive adenocarcinoma is identified,
calibrated optics should be used in measurement of this invasion (McCluggage, 2003).
1.7 MORPHOLOGICAL SUBTYPES OF INVASIVE ADENOCARCINOMA
The subtypes of pure endocervical adenocarcinomas are classified in Table 2 in
descending order of their frequency; other tumours that have a glandular component
but also a nonglandular component are listed in Table 3 and benign glandular tumours
in Table 4.
Table 2. Classification of pure cervical adenocarcinomas (Quoted from Young &
Clement, 2002).
Typical endocervical type
Variant Well-differentiated villoglandular papillary adenocarcinoma
Mucinous
Variants
(I) Adenoma malignum (minimal deviation adenocarcinoma)
(ii) Intestinal type (including signet-ring cell and colloid adenocarcinoma)
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Table 3. Classification of adenocarcinomas with a glandular and non-glandular
component (Quoted from Young & Clement, 2002).
Table 4. Benign glandular tumours (Quoted from Young & Clement, 2002).
Polyps
Adenomyoma I- Endocervical-type
II- Endometrioid a. Typical b. Atypical polypoid adenomyoma
Villous and villoglandular adenomas
Mullerian papilloma
1.7.1 Gross Appearance of Cervical Adenocarcinoma (Fig. 1).
There are no distinctive macroscopic appearances that reliably distinguish adeno¬
carcinoma from squamous or other carcinomas of the cervix. The presence of an
obvious mass typical of carcinoma clinically is always something to be borne in mind
in pathologic differential diagnosis. Some benign lesions, however, may be striking
grossly although they generally differ from carcinoma in usually being at least partly
cystic, whereas most cancers are solid. A final comment on gross features is that the
11
gross appearance of cervical adenocarcinoma is variable. Some early cancers are not
appreciable grossly and even deeply invasive tumours maybe somewhat deceptive on
gross examination. Grossly evident tumours range from polypoid to ulcerating to
those that diffusely thicken the cervical wall (Young & Clement, 2002).
(Fig .1) Endocervical adenocarcinoma (T) occupies the whole endocervix.
B=Body of uterus
1.7.2 Adenocarcinoma, Usual endocervical type
Usual endocervical adenocarcinoma accounts for at least 80% of cervical
adenocarcinomas. Most of them are moderately differentiated adenocarcinomas
characterized by glands of medium size. Cervical adenocarcinoma is often referred to
as mucinous adenocarcinoma but the most common form of endocervical adeno¬
carcinoma is not obviously mucinous, and yet it has a rather characteristic appearance
having cells with eosinophilic cytoplasm and brisk mitotic activity with frequent
apoptotic bodies (Tambouret et al., 2000; Young & Clement, 2002).
1.7.3 Variants of Adenocarcinoma, endocervical type
1.7.3.i Well differentiated villoglandular papillary adenocarcinoma (VGC)
Young and Scully first established villoglandular papillary adenocarcinoma (VGC) as
a distinct histological entity and a subtype of well differentiated adencarcinoma. The
superficial parts of the tumours often resemble villous adenomas formed of broad
papillae, with fibrovascular cores covered by a mildly atypical columnar epithelium,
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whereas deeper portions of the tumour are often formed of branching glands. Nuclear
pleomorphism and mitotic activity are mild or moderate, mucin is variable, and a
desmoplastic host response is often absent. These tumours may display a conventional
cribriform or glandular pattern confined to the deep stromal interface (Zaino, 2000).
1.7.3.ii Mucinous Adenocarcinoma
Three types of mucinous adenocarcinoma occur in the cervix, the most common of
which is the endocervical type, which resembles the cells lining the endocervical
glands. The neoplastic counterpart is formed of cells arranged in glands that may be
simple or branching, tubular or papillary, with basal or stratified nuclei, and pale
granular to vacuolated cytoplasm that stains for mucins. The intestinal type mimics
colonic epithelium and is characterized by glands that are lined by malignant-
appearing cells, some of which have their cytoplasm distended by a single large
vacuole of mucin, forming a goblet cell. Signet-ring cell carcinomas may be pure or
mixed with either of the other two mucinous types and contain single cells or solid
aggregates of polygonal cells with a nucleus displaced eccentrically by mucinous
vacuoles (Zaino, 2000).
1.7.3.iii Minimal Deviation Adenocarcinoma (MDA)
Minimal deviation adenocarcinoma (MDA) is a rare form of adenocarcinoma which
differentiates well, grows rapidly, spreads early , has poor prognosis and should be
treated as intensely as other primary adenocarcinomas of the endocervix (Zhang,
1989). Alternatively called adenoma malignum or extremely well-differentiated
adenocarcinoma, the term minimal deviation adenocarcinoma (MDA) reflects a bland
histological appearance (Landry et al., 2003). Areas of malignant cytology, vascular
invasion, or perineural invasion confirm the diagnosis. Stromal invasion deeper than
normal glands is common but not helpful in superficial biopsies. The small number of
cases of MDA and generally deep invasion at diagnosis make characterization of
behaviour somewhat unreliable, but the majority of women have had nodal spread and
ultimately died of tumour (Kaminski & Norris, 1983; Young & Scully, 1993).
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1.7.3.iv Intestinal-type adenocarcinoma, not otherwise specified, signet-ring cell
adenocarcinoma, and colloid adenocarcinoma
Rare adenocarcinomas of the cervix are lined predominantly by cells with an
intestinal appearance, including goblet cells that may be admixed with Paneth and
argentaffin cells. Signet-ring cells may be seen within otherwise typical cervical
adenocarcinomas and within adenosquamous carcinomas. Pure or almost pure signet-
ring cell carcinomas are rare. Microscopic examination shows cells with eccentric
nuclei and pale mucin-rich cytoplasm growing singly, in clusters and in nests or
columns. Colloid adenocarcinomas are even rarer but listed here for completeness
sake (Young & Clement, 2002).
1.7.3. v Endometrioid adenocarcinoma
Endometrioid adenocarcinomas of the cervix are defined as tumours composed of
cells that resemble those of typical adenocarcinomas of uterine corpus. The cells of
endometrioid adenocarcinomas tend to be stratified and have oval nuclei that are
arranged with their long axis perpendicular to the basement membrane of the gland.
As most adenocarcinomas of usual endocervical type, the cells of those tumours
contain little or no mucin and have less cytoplasm than do the cells of mucinous
adenocarcinomas. True endometrioid carcinomas of the cervix are rare. Some workers
have found that it accounts for 50% or more of their endocervical adenocarcinomas
(Zaino, 2002). Rare endometrioid adenocarcinomas of the cervix have arisen from
cervical endometriosis (Chang & Maddox, 1971). These tumours are diagnosable as
carcinoma on the basis of a distribution and architecture of glands incompatible with
any benign process and at least low-grade malignant cytologic features (Rahilly et al.,
1992; Young & Scully, 1993).
1.7.3.vi Clear cell adenocarcinoma
Histological examination of these tumours reveals three basic patterns: tubulocystic,
solid, and papillary. In the tubulocystic pattern, tubules and cysts of varying sizes are
lined by hobnail, flat, or clear cells. Rarely cells with abundant oxyphilic cytoplasm
may be present and occasionally are numerous. The cysts often contain mucin, and
intracytoplasmic mucin may be present in occasional cells, and signet-ring cells may
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even be present. The solid pattern is characterized by nests and sheets of cells
containing abundant, clear, glycogen-rich cytoplasm. The least common of the three
patterns, the papillary, is characterized by numerous papillae extending into the
tubules or cysts. The papillae vary from small and delicate with inconspicuous
fibrovascular cores, to larger papillae with more prominent fibrovascular cores that
are often extensively hyalinized. The stroma of nonpapillary tumours is also
occasionally prominently hyalinized (Young & Clement, 2002).
1.7.3 vii Serous papillary adenocarcinoma
Serous carcinoma is rare in the cervix and has recently been highlighted as a variant
of cervical adenocarcinoma. Its microscopic features is composed of papillae or
branching, gaping glands lined by cells with pleomorphic nuclei and often centrally
protruding apical cell cytoplasm, resulting in a scalloped configuration (Zaino, 2000).
In the largest series in the literature these tumours had a survival that did not differ
significantly from that of usual endocervical type adenocarcinoma. The diagnosis of
primary serous carcinoma of the cervix should be made only after spread from the
ovary, fallopian tube or endometrium has been excluded (Young & Clement, 2002).
1.7.3 viii Mesonephric adenocarcinoma
Mesonephric adenocarcinoma is one of the rarest subtypes of cervical adeno¬
carcinoma (Clement et al., 1995). Microscopic examination reveals a variety of
appearances, but a tubuloglandular pattern usually predominates. The tubules and
glands, which may be closely apposed, or separated by stroma, are usually small and
round but are occasionally larger and resemble endometrioid glands or are cystic. The
lumens may contain pink hyaline-like material. Rarely the tubuloglandular pattern
merges with solid sheets, slit-like spaces with a 'retiform' appearance, or serous-like
papillae. In occasional cases there is a prominent component of spindle cells (Ferry &
Scully, 1990).
1.7.3. ix Adenosquamous carcinoma
Adenosquamous carcinomas contain malignant glandular and squamous elements that
are recognizable without the use of special stains. The glandular component is usually
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of endocervical type but may be mucinous, including signet ring cell, or mixed
endocervical and mucinous, endometrioid or clear cell. Occasional tumours contain
relatively bland squamous morules (Dougherty & Cotten, 1994; Costa et al., 1994).
1.7.3. x Glassy cell carcinoma
Histological examination reveals sheets of large cells with abundant eosinophilic or
amphophilic, ground-glass or finely granular cytoplasm, prominent cell borders, large
nuclei with prominent nucleoli, a high mitotic rate, and often a stromal inflammatory
infiltrate composed predominantly of eosinophils and plasma cells. Rare foci of
squamous or glandular differentiation and intracellular mucin may be present (Cherry
and Glucksmann, 1961). Tumours with significant components of glassy cell
carcinoma and typical adenocarcinoma should be regarded as mixed carcinomas
(Liftman et al 1976).
1.7.3.xi Adenoid basal carcinoma
Histological examination reveals widely separated or occasionally closed packed
small, round, oval, or lobulated nests of uniform mostly basaloid cells with peripheral
palisading and no stromal reaction. The tumour cells usually have bland nuclei and
rarely more than an occasional mitotic figure except in some cases with squamous
differentiation in which the squamous cells can exhibit severely dysplastic features.
(Brainard & Hart, 1998; Young & Clement, 2002).
1.7.3. xii Adenoid cystic carcinoma
Histological examination shows nests of cells often with a focal cribriform pattern
resembling that seen in adenoid cystic carcinoma of the salivary glands, as well as
sheets, trabeculae, and cords (Ferry & Scully, 1988). The glandular lumens may
contain hyaline or mucinous material. There is usually at least focal palisading of cells
at the periphery of tumour nests. The neoplastic cells are larger than those of adenoid
basal carcinoma and have more pleomorphic nuclei. The mitotic rate is generally
high, and necrosis is typically present and may be extensive. An additional difference
from adenoid basal carcinoma is the presence of a stromal response, which may be
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myxoid, fibroblastic, or hyaline (Albores-Saavedra et al., 1992; Young & Clement,
2002).
1.7.3xiii Adenocarcinoma associated with a neuroendocrine tumour
Most cervical tumours of neuroendocrine type occur in pure form but occasionally
they contain a component of adenocarcinoma. The neuroendocrine component is most
often small cell carcinoma, but may be a large cell neuroendocrine carcinoma or
atypical or typical carcinoid tumour. The only issue is the distinction from pure
neuroendocrine tumours, an issue dependent on sampling (Young & Clement, 2002).
1.8 DIAGNOSIS OF CERVICAL ADENOCARCINOMAS
1.8.1 Cervical screening methods
1.8.1. i Introduction
The broadest and most successful application of clinical cytology has been in the
diagnosis of invasive carcinoma of the uterine cervix and precursor lesions through
the technique popularized by George Papanicolaou at Cornell University and
universally known as the Pap test. Today, it is widely used both as a screening test in
asymptomatic populations and in the follow-up of patients with cervical carcinomas
treated by either conservative surgery or irradiation (Rosai, 1998).
1.8.1.U Comparative study: conventional cervical and Liquid-based cytology
(ThinPrep)® Pap tests in a routine clinical setting
Although conventional Pap preparation (CP) has been useful in the detection of
precancerous lesions of the cervix, there are limitations associated with this method.
A variable false positive and false negative rate is associated with the conventional
Pap smear. In addition, the transfer of material from the smear-taking device to the
slide can be problematic because cells that remain adherent to the smear-taking device
can potentially be lost. Interpretation of the conventional Pap smear is often hampered
by the presence of blood or mucus obscuring the diagnostic cells. Another potential
problem in interpretation is the presence of air drying, which tends to cause
artefactual changes to the cells, thereby rendering accurate evaluation impossible.
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Inflammatory exudate is another possible cause of inaccuracy. Consequently, the CP
method results in a high unsatisfactory or suboptimal rate.
Due to the above difficulties, great efforts have been made to improve the accuracy of
cervical screening with the aim of improving sensitivity and specificity. The ThinPrep
(TP) test, a fluid-based method of liquid-based cytology (LBC), is currently being
promoted as an alternative methodology to replace the conventional direct PAP smear
in cervical cytology. Claims made in favour of LBC include improved sensitivity,
improved specificity and reduced numbers of inadequate smears. For this reason,
there are several studies to evaluate the Liquid-based cytology method (Grace et al.,
2002).
Moseley & Paget (2002) reported the dramatic improvement in specimen adequacy
with TP. With such an improvement in specimen adequacy the number of repeat
smears is dramatically reduced. This has the potential to reduce costs and also patient
anxiety associated with repeat testing. They also noted that, the time taken to screen a
TP was half (3-4 min) that of the conventional method. This obviously leads to
increased productivity with a reduction in the turnaround time for reporting cervical
cytology. The reason for this reduction in screening time is the improved quality of
the preparations, the absence of obscuring blood and mucus and the smaller size of the
screening area. Another advantage of the TP method of smear preparation is the
ability to make extra preparations from the residual material. This can be of value in
cases that are difficult to diagnose and also provides invaluable teaching material
(Grace et al., 2002).
1.8.2 Cervical biopsy and radiological imaging techniques
The diagnosis of carcinoma is made by pathologic examination of a tissue specimen.
A biopsy taken from the periphery of a tumour is more likely to contain morpholo¬
gically intact neoplastic cells that are best able to represent the tumour pathologically.
A biopsy specimen taken from the centre of a tumour mass may include necrotic
tumour debris; the result of hypoxia induced by the tumour's outgrowing its blood
supply. Therefore, to rely on these dead and distorted cells is to compromise the
accuracy of the histological profile (Amano et al., 1998). Lymph node status is not
addressed in the FIGO staging system for carcinoma of the cervix, but three
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radiologic imaging techniques are available to evaluate lymph node status: CT, MRI,
and lymph-angiography. Both CT and MRI have a place in detecting the spread of
cervical cancer. Patients with an abnormal Pap smear and no visible lesion require
colposcopy and biopsy (Subak et ah, 1995; Janus et al; 1989).
1.8.3 Cervical cone biopsy in diagnosis and management of glandular lesions
Although the diagnosis of invasive adenocarcinoma often can be made on small,
superficial cervical biopsies, it sometimes cannot be excluded even in cone biopsies,
particularly when AIS extends to involve the margin of excision. There is unresolved
controversy about the significance of margins in cone biopsies for AIS because the
lesion may be multifocal (Goldstein & Mani, 1998). Cervical cone biopsy was
recommended for diagnosis of VGC and MDA because VGC may be accompanied by
a conventional adenocarcinoma in their deep aspect, but superficial biopsies may not
even contain areas of unequivocal tissue invasion and MDA often cannot be
diagnosed confidently in superficial biopsies, and a request for additional tissue in
difficult cases may yield more obvious areas of stromal invasion or cytologic atypia
(Zaino, 2000).
1.8.4 Evaluation and Staging.
Successful therapy planning requires detailed evaluation of the patient's general
medical condition and the size and extent of the carcinoma. It is important to apply
the FIGO rules (table 5) for clinical staging of cervical adenocarcinoma (Bush, 1986;
Hirst, 1986).
Table, 5 showing Modified FIGO Staging (Shepperd, 1995).
Stage Description
0 Carcinoma in situ, intraepithelial carcinoma. Cases of stage 0
should not be included in any therapeutic statistics for invasive
carcinoma.
I The carcinoma is strictly confined to the cervix (extension to the
corpus should be disregarded).
IA Invasive cancer identified only microscopically. All gross
lesions, even with superficial invasion, are stage IB cancers.
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Invasion is limited to measured stromal invasion with a
maximum depth of 5 mm and a width no greater than 7 mm.
IA1 Measured invasion of stroma <3 mm in depth and <7 mm in
width.
IA2 Measured invasion of stroma >3 mm and <5 mm in depth and
<7 mm in width.
IB Clinical lesions confined to the cervix or preclinical lesions larger
than stage IA.
IB1 Clinical lesions <4 cm.
IB2 Clinical lesions >4 cm.
II The carcinoma extends beyond the cervix but has not extended
onto the pelvic wall. It involves the vagina but does not extend
as far as the lower third of the vagina.
IIA No obvious parametrial involvement.
IIB Obvious parametrial involvement.
III The carcinoma has extended onto the pelvic wall. On rectal
examination, there is no cancer-free space between the tumour
and the pelvic wall. The tumour involves the lower third of the
vagina. All cases with hydronephrosis or a nonfunctioning
kidney should be included unless they are known to result from
another cause.
IIIA No extension onto the pelvic wall but involvement of the lower
third of the vagina.
IIIB Extension onto the pelvic wall or hydronephrosis or
non-functioning kidney.
IV The carcinoma has extended beyond the true pelvis or has
clinically involved the mucosa of the bladder or rectum.
IVA Spread to adjacent organs.
IVB Spread to distant organs.
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1.9 Prognosis in cervical adenocarcinoma
Cervical adenocarcinoma behaves differently from squamous cell carcinoma. The
prognosis in cervical adenocarcinoma depends on the clinical stage, amount of tumour
(as determined by tumour volume), microscopic grade, and nodal status. In most
series, the overall prognosis has been less favourable than for the squamous cell
counterpart. There is not much difference among the various histological subtypes,
although the endometrioid variety is said to behave slightly better. The presence of
nodal metastases is an ominous prognostic sign. Increased serum levels of CA125 and
overexpression of c-erbB-2 and nm23-Hl proteins have also been found to represent
poor prognostic factors (Rosai, 1998).
1.10 Management of Cervical Adenocarcinoma
In patients with adenocarcinoma in situ, because of the risk of developing invasive
adenocarcinoma after fertility sparing surgery, hysterectomy is still the continuing
gold standard of the treatment of adenocarcinoma in situ. When margins are
compromised and future fertility desired, a second cone should be performed if the
subject accepts the risks associated with fertility sparing surgery. In the UK, there is a
trend towards more conservative treatment with LETZ for AIS. The fertility sparing
surgery such as cervical conization or LETZ may be adequate treatment for selected
women with early invasive glandular lesions. (Michael et al., 2001).
With the increasing evidence that the presence of glandular disease is associated with
a poorer outcome, extra modalities of treatment to standard care in the management of
such patients with established invasive adenocarcinoma have been added. The use of
neoadjuvant cytotoxic therapy and/or combined radiation/cytotoxic therapy remains to
be established, although such an approach seems attractive in view of the report of an




HUMAN PAPILLOMAVIRUSES (HPVs) AND CANCER
2.1 INTRODUCTION
Links between human papillomaviruses (HPVs) and cervical cancer were first
suspected almost 30 years ago. DNA of specific HPV types has since been found in
almost all cervical cancer biopsies. HPV oncogenes that are expressed in these cells
are involved in their transformation and immortalization, and are required for the
progression towards malignancy (zur Hausen, 2002).
The expression of specific viral genes (such as E6 and E7) was shown in cervical
cancer cell lines and cancer biopsies (Schwarz et al., 1985); a specific opening within
the viral ring molecule was shown for integrated genome copies; and the
immortalization property of viral DNA and the encoded viral oncogenes supported the
initial suspicions. An early epidemiological study pointed to a high rate of infection in
younger women and to a decreasing rate of infection with age, although persisting
infections still represent a high risk factor for cervical cancer development in older
women (Doeberitz et al., 1992; Doeberitz et al., 1994).
2.2 HPV PATHOGENESIS (LIFE CYCLE)
The papillomavirus life cycle requires the availability of epidermal or mucosal
epithelial cells that are still able to proliferate (basal layer cells). Following entry into
the suprabasal layers, 'late' viral gene expression is initiated; the circular viral genome
is then replicated and structural proteins form. In the upper layers of the epidermis or
mucosa, complete viral particles are assembled and released. E5, E6 and E7 are three
genes possess proliferation-stimulating activity. As HPV-infected lesions progress to
cervical cancer, the episomal viral DNA frequently becomes integrated into host-cell
DNA (Figure 6), and a substantial part of the genome, commonly including the E5
coding sequence, is deleted ( zur Hausen, 2002). The E6 and E7genes and their
proteins are consistently expressed in malignant tissue, and inhibiting their expression
blocks the malignant phenotype of cervical cancer cells. They are able to immortalize
various human cell types in tissue culture, but efficiency is increased when they are
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expressed together (Miinger et al., 1989; McDougall, 1994). Initial observations
revealed that E6 interacts with p53, and E7 interacts with RB to block the activity of
these tumour suppressors.
2.3 THE ORGANIZATION OF CIRCULAR HPV AND ITS INTEGRATION
INTO HOST-CELL DNA (Figure 2).
The human papillomavirus (HPV) genome contains between 6800 and 8000 base
pairs and is divided into eight open reading frames E6, E7, El, E2, E4, E5, and L2
and LI coding for 'early' (E) or 'late' (L) functions. In the course of cancer
development, the viral molecule frequently becomes integrated into host-cell DNA.
The ring molecule is most often opened within the E2 open reading frame, disrupting
the continuity of that gene. Part of E2 and open reading frames that are adjacent to E2,
E4, E5 and part of L2 are regularly deleted after integration (partial genes are
represented by an asterisk). Viral transcripts, which uniformly span the E6 and E7
region, and are often linked to flanking cellular sequences, are present and
transcription might be modulated (enhanced) by flanking host-cell promoters. LCR,
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(Fig.2) The organization of circular HPV DNA and its integration into host-cell
DNA (Quoted from zur Hausen, 2002).
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2.4 TYPES OF HPV AND GENITAL TRACT INFECTIONS
2.4.1 Types of HPY
There are at least 80 different types, which can be divided into those infecting
cutaneous surfaces and those infecting mucosal surfaces. Some types cause benign
warts and low-grade premalignant lesions and are not found in malignant tissues
which have been classified as"low risk" types. HPV type 6 and 11 (HPV-6, HPV-11)
are the most common isolates from these lesions (zur Hausen, 2002). There is another
group of viruses that are found in premalignant and malignant tissues which called"
high risk" types, and HPV-16 and -18 are commonly associated with these lesions.
2.4.2 HPV and Genital tract infection
HPV infection is the most common sexually transmitted disease, with more than 80%
of the population infected at some time in their life. However, there is evidence that
HPV can be transmitted from mother to neonate, probably during delivery. Laryngeal
warts in young children are thought to arise after such episodes of transmission
(Kashima et al., 1985; Fredericks et al., 1993; Austen et al., 1996). In addition, genital
infection is also possible after mother to neonate transmission ( Cason et ah, 1999),
but it is unclear whether such transmission leads to clinical disease later in life. The
immune system is important in the control of HPV infections. In proliferating cells
that are infected by HPV, there are two modes of control exist to protect them against
malignant transformation: one involves inhibition of viral oncoprotein function; the
other involves transcriptional control (zur Hausen, 2002).
2.5 HUMAN PAPILLOMA VIRUSES (HPVs) AND CERVICAL PATHOLOGY
2.5.1 The integration of HPV-16 and HPV-18 DNA in cervical carcinomas
It is generally accepted that HPV is causally associated with cervical carcinoma and
the WHO has declared that HPV-16 and HPV-18 are, indeed, carcinogens. The
integration of HPV DNA into host chromosomes plays an important role in the
progression to malignancy, but probably not sufficient for progression to invasive
cervical cancers. Up to 30% of cervical carcinomas contain episomal forms only of
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HPV-16. Das et al., 1993, therefore, suggest that HPV DNA integration may not be
necessary for malignant progression. However, one very important finding is that
100% of HPV-18 cervical carcinomas contain integrated forms only of HPV-18 DNA.
The physical state of HPV-18 DNA in cervical carcinomas using the combined
techniques of Southern hybridisation and PCR analysis studies demonstrated that
HPV-18 DNA in cervical carcinomas shows a specific integration pattern with respect
to the viral DNA, with a preference to retain a specific region of viral DNA. In
general, the regions of HPV-18 that are integrated are similar to HPV-16 with respect
to the LCR, E6, and E7 genes only. The total region of integrated viral DNA appears
to be much more conserved for HPV-18 than for HPV-16. This is particularly
noticeable within the LI and El regions (Corden et al., 1999).
2.5.2 Prevalence of HPVs in Cervical Adenocarcinoma
Prevalence of human papillomavirus (HPV) DNA in adenocarcinoma of the cervix is
as high as in squamous cell carcinoma of the cervix. Recent molecular biological
studies strongly suggested that HPV acts at least as a cocarcinogen in the female
genital organs (Riethdorf et al., 2000). EGD and MGH were lesions coexisting with
adenocarcinoma in situ. HPV DNA was not present in cases of microglandular
endocervical hyperplasia. Adenocarcinoma in situ may be the earliest event in HPV
infection of the endocervical cells to lead to the development of adenocarcinoma of
the cervix. None of the GAs was associated with low- or intermediate-risk HPV, and
only the GA (which was high grade) unassociated with a SILs contained a high-risk
virus type (Anciaux et al., 1997).
Type of HPV might influence the histological subtype of invasive adenocarcinoma, as
HPV type 16 predominated in the adenosquamous carcinomas while HPV type 18
was more frequently found in all other subtypes (Duggan et al, 1993). However, Bulk
et al, (2006) reported that HPV16, HPV18, and HPV45 display an increased
prevalence in cervical cancer compared to cytologically normal smears. HPV16
confers the greatest risk for SCC and HPVI8 for adenocarcinoma of the cervix. HPV
DNA was identified in >90% of in situ and invasive mucinous adenocarcinomas,
which encompass endocervical, intestinal, and endometrioid morphology and account
for 97% of all cervical adenocarcinomas. However, cases of MDA were negative for
HPV DNA (Ferguson et al., 1998; Skyldberg et al., 1999). Most of serous
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adenocarcinomas of the cervix were HPV DNA-positive while nonmucinous
adenocarcinomas were negative for HPV DNA, including mesonephric and clear cell
carcinomas (CCCs). However, Fujiwara et ah, 1995 have reported a highly variable
prevalence of HPV DNA in CCCs.
2.5.3 HPV and p53 Pleomorphism
HPV integration in the genome will lead to inactivation of the p53 pathway and the
Rb pathway. Recently it was shown that the presence of a common polymorphism
within the p53 protein, at position 72, can affect the susceptibility of p53 to E6
mediated degradation. Thus, the p53Arg polymorphic variant is more susceptible to
the effects of HPV E6 than the p53Pro (Storey et al., 1998). Interestingly, this
pleomorphism lies within the poly-proline region of p53 which has also been recently
shown to be involved in the induction of p53 mediated apoptosis. This is particularly
important from a therapeutic point of view, since this will determine whether the
appropriate signals are already present within these cell lines to activate p53 function
(Wentzensen et al., 2002).
2.5.4 HPV Detection and Typing
2.5.4. i Introduction
The absence of an episomal HPV genome in the majority of glandular tumours, as
opposed to squamous tumours, may result in a significant underestimation of HPV
DNA prevalence in adenocarcinomas (Pirog et al., 2000). Glandular epithelium does
not support productive viral infection and HPV DNA in endocervical neoplasms
(notably HPV 18), is usually present in the integrated form. Therefore, detection of
HPV DNA in adenocarcinomas requires a sensitive detection assay. Further, as the
successful amplification of HPV DNA in a PCR assay depends on the presence of
intact DNA target sequences, two additional factors may reduce the efficiency of HPV
detection: 1) DNA fragmentation as a result of formalin fixation and storage in
paraffin; and 2) loss of portions of the viral genome during integration. (Park et al.,
1997; Pirog et al., 2000).
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2.5.4.U Techniques ofHPVdetection
Methods of light microscopy, electron microscopy, immunohistochemistry and
molecular biology can be used to detect HPV in cervical biopsies. Molecular biology
is now commonly used. Southern blot, Northern blot, Dot (Spot) blot, Filter In Situ,
and In Situ hybridization are applied for HPV detection and typing. Recently PCR has
been developed to amplify DNA sequences shared by many of the 20 or so different
types of genital HPVs. However, no 'gold standard 'has yet been established (Jacobs
et al., 1995; Gravitt et al., 2000). Currently, an HPV DNA detection system, Hybrid
Capture 2 (Digene Corporation, Gaithersburg, Maryland, US) is approved by the Food
and Drug Administration for use in patient care. This assay uses signal amplification
technology with RNA multiprobe cocktails to distinguish between high-risk and low-
risk HPV types, but does not identify the specific HPV DNA type detected.
2.5.4.iii Cytological and Histological detection ofHPV
The morphologic hallmark of HPV infection of the cervical squamous epithelium is
koilocytosis. The koilocyte is a superficial or intermediate mature squamous cell
characterized by a sharply outlined perinuclear vacuolation, dense and irregular
staining peripheral cytoplasm, and an enlarged nucleus with an undulating (raisin- or
prune-like) nuclear membrane and a rope-like chromatin pattern. Binucleation and
multinucleation can occur (Rosai, 1998; Giovagnoli et al., 1996).
2.5.5 HPV Testing and Cancer Screening
Cervical carcinomas are unfortunate complications of longstanding infection with
high-risk types of human papillomavirus (hrHPV) (Walboomers et al., 1999). The
presence of high-risk HPV (hrHPV) markers needs careful clinical investigation and
repeated testing for HPV persistence, which is a significant risk factor for the
development of proliferative lesions and their progression. Testing for hrHPV types
combined with cervical cytology becomes increasingly attractive as data accumulate
that a combined test increases the efficacy of cervical screening programmes and
triage policies for women with both equivocal and normal cervical smears (Cuzick et
al., 2003; Khan etal., 2005).
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2.5.6 Cervical Cancer Prevention
With respect to cancer prevention, in addition to enforcing specific standards of
hygiene, cervical screening has reduced the incidence of cervical cancer significantly
(Peto et al., 2004) and although a clinical success story, there is evidence to suggest it
could be improved by incorporation of adjunctive HPV testing. Although less specific
than cytology (especially in young sexually active women), HPV testing is more
sensitive for the detection of underlying cervical abnormalities, indeed, HPV testing
has been introduced (in combination with cytology) in the US, for women over 30 in
primary screening (Sallow et ah, 2002). In addition, the UK pilot studies (due to
report later this year) were designed to assess the utility of using HPV testing for the
triage of women with low grade abnormalities to colposcopy (www.cancer-
screening.nhs.uk). There is also good evidence to suggest that HPV testing (in the
context of a negative result) could be used as a "test-of cure" of treatment for women
with high-grade cervical disease, with the potential to reduce the intensity of post
treatment follow-up (Zielinski et ah, 2004). Further improvements in the diagnostic
accuracy of cytology based screening, such as HPV testing, could be particularly
prescient for the reduction of adenocarcinoma as it and its precursor stage are
reportedly more likely to be "missed" than squamous cell cytological abnormalities
(Brink et ah, 2005).
Moreover, two prophylactic HPV vaccines are currently in Phase 3 trials both of
which are designed to target HPV 16 and 18 infections. Initial results from these
trials would suggest that the vaccines are highly immunogenic, well tolerated and
induce seroconversion in more than 99% of vaccinees. They therefore constitute a






For over a century, tissue has been preserved in formalin and embedded in paraffin for
sectioning before microscopic examination. This method has become the standard
method of histopathologic analysis (Wright, 1985). In 1998, Kononen and colleagues
in the lab of Ollie Kallioniemi invented a mechanism for examining several
histological sections at one time by arraying them in paraffin block. These tissue
microarrays are assembled by taking core needle "biopsies" of pre-existing paraffin-
embedded tissues and re-embedding them in an arrayed "master" block. In this way,
tissue from hundreds of specimens can be represented on a single paraffin block that
can be analyzed using a variety of techniques, including immunohistochemistry and in
situ fluorescence hybridization (FISH) (Kononen et al., 1998; Bubendorf et ah, 1999;
Moch et ah, 1999; Schraml et ah, 1999; Mucci et ah, 2000; Perrone et ah, 2000).
Compared with conventional techniques, tissue microarray (TMA) technology has
several advantages. It enables the study of an entire cohort of cases by analyzing just
one (or a few) master slide(s) in contrast to traditional techniques, which require the
processing and staining of hundreds of slides. In addition, microarray analysis allows
that all specimens are processed at one time using identical conditions. Furthermore, it
markedly reduces the amount of archival tissue required for a particular study, thus
preserving ample remaining tissue for other research or diagnostic needs (Mills et ah,
1995; Camp et ah, 2000). Moreover, tissue microarray (TMA) technology allows
rapid visualization of molecular targets in thousands of tissue specimens at a time,
either at the DNA, RNA or protein level. The technique facilitates rapid translation of
molecular discoveries to clinical applications. Besides, it paves the way of the
standardization of inspection and automation of analysis (Dan et ah, 2004). TMAs are
ideally suitable for genomics-based diagnostic and drug target discovery by revealing
the cellular localization, prevalence and clinical significance of candidate genes. The
speed of molecular analyses is increased by more than 100-fold, precious tissues are
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not destroyed and a very large number of molecular targets can be analyzed from
consecutive TMA sections.(Kallioniemi et al, 2001).
The main problem of tissue microarrays is that they reduce the amount of tissue
analyzed from a whole tissue section to a core, 0.6 mm in diameter that may not be
representative of the protein expression patterns of the entire tumour because of tissue
heterogeneity. Thus, it is important to determine how many tissue disks are required
to adequately represent the expression of a particular antigen by a tumour and to
determine antigen survival because this new technique has the potential to examine
large cohorts of patients with long-term follow-up. Specifically, in determining
whether archival tissues retain their antigenicity despite decades of storage as paraffin
blocks. There is some evidence to suggest that such tissues remain antigenically intact
(Shibata et al., 1988; Ibrahim et al., 1997). On the other hand, although paraffin
should protect the tissue from oxidation or other damage, there is evidence that once
tissues are sectioned they are subject to rapid loss of antigenicity (Jacobs et al., 1996;
Shin et al., 1997). This question is also revisited because maximal sectioning of
microarrays requires many array sections to be cut at one time, even if they are not
analyzed within the same day or week (Camp et al., 2000).
Finally, tissue microarrays are a population-level screening tool to rapidly analyze
frequencies of expression of biomarkers in cell populations, tissues or patients using
large sample sets. They are not designed to characterize in detail every "corner" of a
particular tumour mass. For this purpose, careful dissection of the tumour and
consecutive sectioning throughout the tumour is needed (Nocito et al, 2001).
3.2 TMA CONSTRUCTION
3.2.1 Microarray using paraffin-embedded tissues
Although a device is needed to manufacture TMAs, the preparatory work that
involved in making TMAs is traditional pathology work and is very similar to what is
needed for traditional studies involving 'large' tissue sections. The major difference
may lie in the number of tissues involved, which is typically an order of magnitude
higher in TMA studies than in traditional projects. First, a list of potentially suited
tissues needs to be generated. Then all sections of these specimens are collected from
the archive and reviewed by a pathologist in order to select optimal donor blocks. A
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morphologically representative area of interest within the donor block is identified
under the microscope using an H&E stained section (Fador & De Marzo 2005).
Different colours are recommended for marking different areas on one section.
Subsequently, the selected blocks are collected from the archive. These blocks and
their corresponding marked slides must then be brought together and sorted in the
order in which they should appear on the TMA. Meanwhile, the outline of the TMA
needs to be defined and a file should be generated that contains the identification
numbers of the tissues together with their locations and the coordinates to be selected
on the arrayer. A tissue arraying device could be employed after this preparatory work
has been done. The only tissue arraying system that is commercially available is
identical to the prototype machine used in the early development of TMA technology
(Beecher Instruments, Silver Springs, MD, USA). Using this manually operated
device, excellent TMAs can be produced in the hands of a talented and experienced
person (Bubendorf et al., 2001).
Initial large-core biopsies of over 3 mm in diameter were minimized to 0.6 mm in
diameter (Hoos & Cordon-Cardo, 2001). Punched tissue blocks remain fully
interpretable for all morphological and molecular analyses if a reasonable number of
punches are selected. Since the entire thickness of the donor block tissue is
represented in each of the cylindrical tissues of a TMA block, tissue arrays can
generate between 100 and 500 sections (Fador & De Marzo 2005).
3.2.2 Tissue heterogeneity (Validation Strategies)
The main concern linked to TMA technology is to what extent tumour heterogeneity
would affect the validity of the TMA approach. The 0.6-mm biopsies of tumour
specimens on an array may not be representative of the whole tumour specimen
because of tissue heterogeneity is the main concern regarding the tissue microarray
technique. However, it claimed that, 2-fold redundancy can lead to greater than 97%
concordance between the two methods and that the addition of more cores increases
concordance to 99.5% with 5 cores per specimen (Camp et al., 2000).
Some immuno-phenotypes can be very complex, and often clinicopathological studies
require the application of cut-off values as used for full-section analysis of many
markers (Drobnjak et al., 1994; Hoos et al., 2001a). Therefore, it is crucial to evaluate
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the number of cores required in conjunction with phenotype complexity. However,
tumour heterogeneity can lead to lower concordance rates if more complex phenotypes
are analyzed and that some cases may need to be excluded from the analysis if two
cores with contradictory readings provide inconclusive data. The addition of a third
core can improve concordance rates and prevent the exclusion of such cases because it
allows a majority decision (2 > 1) (Cote et al., 1998; Hoos et al., 2001b).
It is unavoidable that some alterations are not detected if the analysis of potentially
heterogeneous tumours is restricted to samples measuring 0.6 mm in diameter.
However, to understand the apparent lack of a major influence of tissue heterogeneity
on the results of TMA analyses, it is important to realize that the tissue array approach
has been designed to survey tumour populations and not to examine individual
tumours. The inability to detect all alterations on a TMA is not only due to true
heterogeneity, but also to technical problems often preventing reliable analysis in
some areas of a fixed tumour. Therefore, comparison between TMA analysis and
conventional analysis need to be carried out with other tissues and other markers
(Hoos & Cordon-Cardo, 2001; Hoos et al, 2001b). .
3.2.3 Technical considerations for array construction
It is crucial to consider technical problems during construction of a tissue microarray
carrying paraffin-embedded tissues so that it can be a source for multiple high-quality
sections representing as many arrayed specimens as possible. The main problem is
that the arrayed samples have been pre-fixed and embedded in paraffin which could
affect the quality of the studies performed on these samples by introducing RNA
modifications and damage (Fejzo & Slamon 2001). Tissue loss during sectioning and
staining is a common problem of the tissue array technique (Schraml et al., 1999;
Mucci et al., 2000; Richter et al., 2000). In addition, staining artefacts at the tissue
borders are a well-known phenomenon in immunohistochemistry. Both occur most
frequently in the periphery of the tissue microarray.
The orientation of the specimens on the array is crucial because confusion about their
localization can threaten the evaluation of the experiment. For keeping the orientation
of rows simple, researchers used different normal tissues to allow the identification of
every row based on morphology.
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The loss rate of assessable cases, resulting from tissue loss during cutting and transfer
of array sections and vigorous staining procedures or because of inconclusive data,
can be a significant factor of array-based analysis. Previously reported rates of tissue
damage range from 10% to more than 30% (Bubendorf et al., 1999; Schraml et ah,
1999; Mucci et ah, 2000; Richter et ah, 2000; Hoos et ah, 2001b). Loss of arrayed
cases can be minimized without compromising the efficiency of the array technology
by using three cores per tumour specimen, as indicated above. In addition, usage of
0.6-mm core diameters and 0.2- to 0.3-mm spacing between the cores.
It is advisable to array uniformly long tissue cores for each specimen to get as many
high-quality sections from one multi-tissue block as possible. To avoid problems with
micro-movement of cores in the punched holes of the multi-tissue block, cores should
be inserted all the way to the bottom of the holes and completed tissue array blocks
should be heated at 37° C for 30 minutes to make tissue cores and surrounding
paraffin stick together tightly (Hoos & Cordon-Cardo, 2001).
3.3 TISSUE MICROARRAYS STAINING AND ANALYSIS
TMAs are suited for all analyses that can be done in situ such as
immunohistochemistry, fluorescence in situ hybridization (FISH), and RNA in situ
hybridization (RNA-ISH). In general, the same protocols can be used as for large
sections. The most significant difference compared with traditional large section
studies lies in the unprecedented level of standardization that can be achieved within
one TMA experiment. All the slides of one TMA study are usually incubated within
one jar, ensuring absolutely identical concentrations and temperatures of all reagents
(Fador & De Marzo 2005). Moreover, the age of a slide (time between sectioning and
use), section thickness, and the exposure times for all steps are also exactly identical
in these studies, where all the tissues of one study are located on the same TMA slide.
This is a significant difference compared with traditional studies, where a slight
variability in some minor experimental parameters (such as slide age or section
thickness) is perceived as tolerable. It must be expected that tissues will be
heterogeneous in their preservation of proteins and nucleic acids if hundreds of
biopsies were all treated individually at the time that they were removed, fixed in
buffered formalin, and subsequently paraffin-embedded. This is best illustrated in the
outcome of FISH analyses. (Bubendorf et al., 2001).
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3.4 APPLICATIONS OF TMAs
TMAs are vital to study tumour biology because it makes it possible to compare
different diagnostic or predictive markers or kits with one another on consecutive
TMA sections. TMAs are also ideally suited for optimization and quality control
purposes. Dozens of different staining or hybridization conditions can be tested (such
as pre-treatments or tissues, probe/antibody labeling, detection, etc.) in replicate
experiments to achieve optimal performance of the assay. Appropriate positive and
negative control tissues can be inserted into each TMA block as internal controls, and
it is possible to measure variability of molecular detection schemes and determine
which specific step in the detection process causes the most variability. All these
issues will be critical to determine each new molecular marker to be introduced for
diagnostic purposes (Nocito et ah, 2001). Virtually all tissues are suitable to be placed
into a TMA. Therefore, the range of TMA application is as broad as the imagination
of the users of this technology. Typical TMAs that have been constructed include
multi-tumour, progression, and prognostic arrays.
Arrays of multi-tumour are composed of samples from multiple tumour types and
utilized to screen different tumour types for molecular alterations of interest (Nocito
et ah, 2001). Progression TMAs can be used to study molecular alterations in different
stages of tumour progression within a given organ. For example, in prostate cancer
progression, TMA was constructed containing 371 prostate specimens, consisting of
32 specimens of normal prostate or benign prostatic hyperplasia, 64 incidental
carcinomas (stage pTl), 159 organ-confined carcinomas (pT2), 62 distant metastases
and 54 recurrent tumours diagnosed after androgen deprivation treatment had failed.
Molecular profiling of such tumour progression arrays revealed sets of genetic
alterations and gene expression patterns that are characteristic of a specific stage of
cancer progression (Nocito et ah, 2001). Patient outcome TMAs contain tumour
samples from patients for whom clinical follow-up data are available, such as data on
tumour recurrence, therapy response and time to metastasis or patient survival. These
types of TMAs are most sensitive to the effects of sampling, which needs to be
comprehensive enough to capture the clinically meaningful features of tumour
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aggressiveness. Analyses of known prognostic parameters (previously discovered and
validated using conventional sections) almost invariably can be reproduced in TMA
studies (Moch et al., 1999; Mucci et al, 2000).
It will be easy to determine the nature of inter-laboratory discrepancies once such
studies are executed on TMAs. Exchanging unstained slides between laboratories that
have reported conflicting data would rapidly allow researchers to see whether
experimental differences caused the problem. Exchanging stained sections (either in
real or as images) would easily clarify whether different modes of interpretation
contributed to the confusion. Even differences in tissue processing could be unmasked
as a reason for discrepancies if matched series of tumours from different laboratories
were placed on one joint TMA (Bubendorf et al., 2001).
TMAs could be useful for educational purposes. While the interpretation of large
sections always reflects an attempt to integrate the observations in multiple different
regions of a tissue section, the reading of TMAs is much easier and therefore more
reproducible. In TMAs, morphological classifications and interpretations of immuno-
staining are based on the findings within one small, highly defined tissue area.
Therefore, the criteria for diagnostic decision-making can easily be applied and
learned on TMAs. Examples for analyses that could be trained on TMAs include the
histological grading of urinary bladder tumours and the interpretation of HER-2
immunostaining in breast cancers. In both cases, a trainee could read a TMA slide and
then be allowed to verify his diagnostic ability by comparing his/her results with
those of a recognized expert in the field and generating a survival curve based on
his/her own data and comparing it with the survival curve based on the expert's
opinion (Bubendorf et al., 2001).
TMAs make it possible to anonymize completely large sets of tissue samples with
abundant clinical information, even for internal use. The only requirement to generate
such absolutely anonymous tissue collections is to destroy the original biopsy/patient
identifiers from the data file attached to a TMA once a TMA block is constructed. As
soon as the survival information and pathology information are linked to a TMA
coordinate, there is no need to retain information on which patient sample has been
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put on which array position. Destruction of this information will make it impossible to
trace biological information back to a patient (Bubendorf et ah, 2001).
CHAPTER 4
IMMUNOHISTOCHEMISTRY
Recently there are a large number of articles investigating the use of immuno-
histochemistry in diagnostic gynaecological pathology. Although the value of
immunohistochemical markers as prognostic indicators in various tumours is very
important in surgical pathology, at present, there are few established markers of
prognostic significance (McCluggage, 2002).
4.1 IMMUNOHISTOCHEMICAL STUDIES USEFUL IN DISTINCTION
BETWEEN ENDOCERVICAL AND ENDOMETRIAL ADENOCARCINOMA.
A preoperative distinction between an endometrial and endocervical tumour is
important since primary surgical treatment may differ. When there is doubt,
immunohistochemical studies may assist. Previous studies have separately addressed
the value of vimentin, CEA and ER staining ( Dabbs et al., 1996; Castrillon et al.,
2002) and a recent study combined these three antibodies (McCluggage et al.,
2002).This study concluded that immunostaining with vimentin, CEA and ER was of
value in the preoperative distinction between a primary endometrial and endocervical
adeno-carcinoma. Endometrioid type endometrial adenocarcinomas are characteristic-
cally ER and vimentin-positive but negative with CEA (with the exception that
endometrioid adenocarcinomas with squamous differentiation often exhibit strong
positivity with CEA). In contrast, primary cervical adenocarcinomas of endocervical
type are characteristically CEA-positive (with the exception that mesonephric
adenocarcinomas often exhibit CEA-negative) and vimentin and ER-negative.
However, this study did not address the immunophenotype of primary cervical
endometrioid adenocarcinomas. Immunostaining for human papillomavirus (HPV)
has also been found to be of value in the distinction between a primary endometrial
and endocervical adenocarcinoma (McCluggage et al., 2001; McCluggage, 2002;
McCluggage, 2003).
Recently it has been reported that pl6 may also be of some value in distinguishing
between an endocervical and an endometrial adenocarcinoma. Strong diffuse
positivity involving 100% of cells is the rule in primary endocervical adenocarcinoma,
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whereas endometrial adenocarcinoma usually exhibits a lesser degree of staining.
However, occasional endometrial adenocarcinomas will exhibit diffuse positivity and
there is often strong staining of benign squamous elements for pi6. It is necessary to
do further studies to refine the diagnostic use of pi6 immunostaining in this situation
and to ascertain whether those endometrial adenocarcinomas that exhibit diffuse
positivity are associated with high risk HPV types (McCluggage, 2003).
4.2 IMMUNOHISTOCHEMICAL TECHIQUES USEFUL IN DISTINCTION
OF MALIGNANT AND PREMALIGNANT CERVICAL LESIONS FROM
BENIGN MIMICS.
A wide variety of benign endocervical glandular lesions may be confused with CGIN
and even invasive cervical adenocarcinoma, especially the mucinous variant of MDA.
Many of these benign mimics are rare and in everyday practice the lesions most likely
to be confused with CGIN are tubo-endometrial metaplasia (TEM) and endometriosis.
A close morphological examination usually allows a confident distinction between
CGIN and benign mimics. However, in doubtful cases, MIB-1 staining may be useful.
Other antibodies may also be of value. Bcl2 is usually positive in cases of TEM but
generally negative in CGIN. In addition pi 6 may be of use in the distinction between
CGIN and benign mimics. Cases of CGIN almost invariably show strong diffuse
positivity for pi6, while most benign mimics are negative or show focal positivity.
However, some cases of TEM may be focally positive for pi6. A combination of
MIB-1, pl6 and Bcl2 staining may be of considerable value in the separation of CGIN
from TEM and MGH. TEM has been shown to stain positively with vimentin and it
has been suggested that this is a useful means of distinguishing TEM from CGIN.
Immunohistochemical staining with monoclonal carcinoembryonic antigen (CEA)
may assist in the distinction of neoplastic endocervical glandular lesions from benign
mimics (McCluggage, 2002). However, caution should be exercised since adeno¬
carcinomas are occasionally negative or only focally positive for CEA (Speers et al.,
1983; Steeper & Wick, 1986). Mesonephric adenocarcinomas are typically CEA-
negative. Accordingly, a negative stain for CEA should be cautiously interpreted but
intense positive staining throughout the cytoplasm is unlikely in a benign lesion and
strongly favours carcinoma. Negative CEA staining is also seen with the other
pseudo-neoplastic glandular lesions considered here but experience with CEA staining
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of many of them is limited and a diagnosis should not be rendered solely on the basis
of immunohistochemical staining results. Normal endocervical glands and those of
pseudoneoplastic lesions may exhibit a glycocalyceal pattern of CEA staining that
contrasts with the diffuse cytoplasmic staining typically seen in cervical
adenocarcinomas (Jones et ah, 1991). Moreover, normal endocervical glands may
show luminal CEA positivity and MGH may exhibit cytoplasmic positivity, usually
confined to areas of immature squamous metaplasia or reserve cell hyperplasia. A
combination of CEA, MIB-1 and p53 staining was found to be useful in
discriminating benign and malignant endocervical glandular lesions, although p53
expression was found in some cases of MGH. Immunohistochemical expression of
CD44 has also been investigated in endocervical glandular lesions. It was concluded
that CD44 v5 immunoreactivity may be a useful diagnostic marker of endocervical
neoplasia (McCluggage, 2002; McCluggage, 2003).
4.3 IMMUNOHISTOCHEMICAL STUDIES USEFUL IN DIAGNOSIS OF
CERVICAL MESONEPHRIC LESIONS
Both cervical mesonephric hyperplasia and adenocarcinoma may cause diagnostic
difficulties, the former in the separation from other benign mimics and from adeno¬
carcinoma (especially MDA) and the latter in the recognition of this as a special
subtype of cervical adenocarcinoma. CD 10 staining in cervical mesonephric remnants
and adenocarcinomas has been investigated in a recent immunohistochemical study.
In this study, consistent positive staining of cervical mesonephric lesions for CD 10
with a characteristic luminal staining pattern was found. In the cervix, CD 10 positivity
of benign glandular elements appears to be relatively specific for mesonephric
derivatives, with little or no staining of normal endocervical glands or of other benign
mimics, although some ordinary endocervical adenocarcinomas may be focally
positive ( McCluggage, 2003).
4.4 IMMUNOHISTOCHEMICAL STUDIES USEFUL IN DIAGNOSIS OF
MDA
Recently, it shown that gastric mucins are present in adenoma malignum and that
HIK1083, a monoclonal antibody against gastric gland mucous cell mucin, is useful
for the diagnosis of this uncommon neoplasm (Utsugi et al., 1999; Ishii et al., 2001).
Normal endocervical glands are consistently negative although very small foci of
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positivity may be found in ordinary endocervical adenocarcinomas. Less well-
differentiated areas in adenoma malignum are usually negative. Thus HIK1083
staining can discriminate between benign endocervical glands and the well-
differentiated glands of adenoma malignum. This can be extremely helpful since CEA
staining may not always be diagnostic.
The recently described benign endocervical glandular lesion termed Tobular
endocervical glandular hyperplasia', which may mimic adenoma malignum, is now
also thought to have a pyloric gland phenotype on the basis of histochemical staining
characteristics and immunohistochemistry with antibodies against pyloric gland-type
mucins such as M-GG MC-1 (Mikami et al., 2001; McCluggage, 2002).
Histochemical stains may also be useful in the diagnosis of cervical adenoma
malignum. A combined Alcian blue-periodic acid Schiff (PAS) stain may be useful
because normal endocervical glands, as a result of their high content of acid and
neutral mucins, stain a purple/violet colour. In contrast, the glands of cervical
adenoma malignum (and conventional adenocarcinomas) stain red using this
preparation because of the almost exclusive presence of neutral mucin. In doubtful
cases, a combined Alcian blue-PAS stain may be useful in distinguishing normal
endocervical glands from the glands of adenoma malignum (Hayashi et al, 2000).




Cytokeratins are constituents of the intermediate filaments of epithelial cells which
are expressed in various combinations depending on the epithelial type and the degree
of differentiation (Zemer et al., 1998). Studying the CK phenotype of the tumours has
a practical importance for differential diagnostic purposes (epithelial vs. nonepithelial
tumours, adenocarcinomas vs. squamous and transitional cell tumours), as well as for
typing of adenocarcinomas in a search for unknown primary tumours from
metastases. Furthermore, studies indicating different CK expressions according to
tumour differentiation have been published (Tot, 2000).
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4.5.1.U Keratin expression in human tissues and neoplasms
Keratin filaments constitute type I and type II intermediate filaments (IFs), with at
least 20 subtypes named keratin 1-20. Since certain keratin subtypes are only
expressed in some normal human tissues but not others, and vice versa, various tissues
have been subclassified according to the pattern of keratin staining. Simple epithelia
generally express the simple epithelial keratins 7, 18, 19, and 20, while complex
epithelia express complex epithelial keratins 5/6, 10, 14, and 15. When an epithelium
undergoes malignant transformation, its keratin profile usually remains constant.
Therefore, since keratin expression varies so greatly among different epithelia, they
have been widely used in the fingerprinting of various carcinomas (Chu & Weiss,
2002).
4.5.1.M Antibodies to keratins
In the early days of immunohistochemistry, most anti-keratin antibodies used in
surgical pathology were not reactive to a specific keratin; rather, they were mixed
monoclonal antibodies or polyclonal antibodies that reacted to several keratins.
Currently, high-quality anti-keratin monoclonal antibodies to all of the 20 keratins are
commercially available from many biomedical reagent vendors. However, one should
be aware that some of the anti-keratin antibodies still used by many pathologists today
are reactive to several keratins, and many immunohistochemical studies published in
literature have used these antibodies (Chu & Weiss, 2002).
4.5. l.iv Keratins in carcinomas
4.5.1. iva Generalpatterns
Virtually all carcinomas, regardless of their tissue origin, are immunoreactive to
keratin antibodies. However, keratin expression patterns in carcinomas from stratified
epithelia and from simplex epithelia are different. Among anti-keratin antibodies,
monoclonal antibodies to K7, K20, K14 and K5/6 have the highest discriminative
value among different types of carcinomas. In general, carcinomas of simple epithelial
origin are positive for K7 and/or K20 and negative for K14 and K5/6; whereas
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carcinomas of stratified epithelial origin are positive for K14 and K5/6, and negative
for K7 and/or K20.
4.5.1. ivb keratin 7 (K7)
The expression of K7 in epithelial neoplasms is restricted to a subgroup of
adenocarcinomas of glandular epithelial origin (Ramaekers et al., 1990; Wang et ah,
1995). The vast majority of cases of adenocarcinoma of the lung, ovary, uterus, breast,
pancreas, salivary gland and thyroid tumours, cholangiocarcinoma, and transitional
cell carcinoma are positive for K7. In contrast, only a small percentage of cases of
colorectal adenocarcinoma and gastric adenocarcinoma are K7+. Two-thirds of cases
of malignant mesothelioma are positive for K7, and about 20-40% cases of neuro¬
endocrine neoplasms, including small cell carcinoma of the lung, neuroendocrine
carcinomas from a variety of organs, and carcinoid tumour, are positive for K7. It is
worthwhile to mention that in kidney, papillary, collecting duct and chromophobe
renal carcinomas are frequently positive for K7, whereas conventional renal
carcinomas are not. Squamous cell carcinomas of the skin are usually negative for K7;
however, squamous cell carcinomas arising from non-cornified squamous epithelia, in
particular the uterine cervix, are often positive for K7 (Fuchs et ah, 1981; Chu et ah,
2000).
4.5.1 ivc keratin20 (K20)
K20 expression is restricted to a few organ systems. Over 90% of cases of colon
carcinoma, 86% cases of Merkel cell tumour of skin, 68% cases of transitional cell
carcinoma, 56% cases of gastric carcinoma, and 52% of cases of pancreatic
adenocarcinoma are K20+. The CK20+ staining pattern in Merkel cell carcinoma is
cytoplasmic dot-like, which is different from the diffuse cytoplasmic staining seen in
cases of CK20+ gastric and colorectal carcinoma.. Since the vast majority of cases of
ovarian mucinous tumours actually represent metastases from gastrointestinal tract
primaries, they are frequently positive for K20; however, it is believed that the true
K20+ rate in primary ovarian mucinous carcinomas is low. In addition, unlike their
gastrointestinal counterparts, ovarian mucinous tumours are usually positive for K7
(Chu & Weiss, 2002).
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4.5.1.ivd The keratin expression pattern ofcervical adenocarcinoma
In cervical adenocarcinoma, the keratin expression pattern is considerably more
complex than expected from the results obtained with adenocarcinomas arising in
other tissues (Moll et al., 1992). Like other gynaecological adenocarcinomas, cervical
adenocarcinoma contains K7, K8, K18 and K19; but it is also frequently positive for
K17 and K14 while cervical and vaginal squamous carcinomas are frequently positive
for K7, K8 and K18 (Chu et al., 2000). Furthermore, sporadic expression of K4, K5,
K10 and K13 may be seen. None of these above keratins is present in the normal
columnar cells lining the endocervical canal. Because of this, it has been speculated
that cervical adenocarcinoma does not usually arise from columnar cells, but instead
derives from reserve cells. Squamous cell carcinoma in situ may thus make the
transition to an adenocarcinoma. It may be difficult to distinguish histologically
between a primary cervical adenocarcinoma and a metastatic adenocarcinoma arising
from the bowel, endometrium, mesothelium, or ovary. This dilemma may be
addressed by determining the keratin phenotype of these adenocarcinomas. Colonic
adenocarcinomas have a simple keratin expression pattern consisting of K8, K18, K19
and K20, whereas cervical adenocarcinoma contains K7, K17, and frequently K14,
and usually lacks K20. Absence of K5/6 in cervical adenocarcinoma can help
distinguish this neoplasm from malignant mesothelioma. In discriminating between a
primary cervical adenocarcinoma and a metastatic endometrial/ovarian serous or a
mucinous carcinoma, the absence of K14 and K17 in the latter may be a useful
differential diagnostic tool. Although arising from the same epithelium, cervical
dysplasia and invasive carcinoma have different keratin profiles in comparison with
normal cervical non-keratinizing epithelia. Normal cervical epithelium expresses K10,
but not K7, K8, K17 and K18. In contrast, cervical dysplasia (cervical intraepithelial
neoplasia (CIN)) or cervical squamous cell carcinoma tends to express K7, K17 and
K18, but not K8 and K10 (Smedts et al., 1993). Using a combination of K10 and K17,
it is possible to separate cervical squamous cell carcinoma from benign conditions
with a sensitiveity of 100% and specificity of 93% (Maddox et al., 1999; Chu &
Weiss, 2002).
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4.5.2 Carcinoembryonic antigen (CEA)
Cytoplasmic carcinoembryonic antigen (CEA) positivity assists in the distinction of
benign and malignant glandular lesions of the cervix, but some cases remain
problematic. At the University of Kentucky Medical Centre, van Nagell et al., (1978)
found that, levels of carcinoembryonic antigen were elevated (greater than 2.5 ng/ml)
in 48% of cervical cancer patients, and varied directly with stage of disease and
histological differentiation of the tumour. Plasma CEA levels were more commonly
elevated in patients with endocervical adenocarcinoma than in those with squamous
cell carcinoma, but were not related to vascular invasion in the specimen or regional
lymph nodal morphology. A progressive rise of plasma CEA preceded the clinical
diagnosis of recurrence by 1 to 23 months. Patients with progressively rising plasma
CEA levels following therapy for cervical cancer should be extensively evaluated to
rule out the presence of occult recurrence.
A study by Cina et al (1997) reported that the combination of CEA positivity and a
moderate-to-high proliferative index was limited to cases of invasive adenocarcinoma,
adenoma malignum, and adeno-carcinoma in situ, as compared with benign glandular
lesions (p=0.005). A high Ki-67 proliferative index and/or CEA positivity were
features of malignant lesions rather than benign mimickers; there were no false
positives or false negatives. Similarly, only malignant neoplasms shared a
combination of p53 overexpression and CEA positivity (p=0.043). Strong staining of
more than 10% of the glandular epithelial nuclei was interpreted as positive for p53
protein overexpression. CEA positivity was determined by either diffuse or focal
cytoplasmic staining of columnar epithelial cells equalling glycocalyceal staining in
intensity. The combination of cytoplasmic CEA positivity in glandular cells and a
moderate-to-high MIB-1 (Ki-67) proliferative index is diagnostic of malignancy in
endocervical lesions. With the exception of florid microglandular hyperplasia, p53
expression is only seen in neoplastic lesions of the endocervix.
The differential diagnosis of endocervical and endometrial adenocarcinomas can be
improved by the demonstration of CEA in tissue by means of immunoperoxidase
staining (as already discussed). Also, the extent of the immunoperoxidase localization
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of CEA did not seem to correlate with the degree of differentiation in either kind of
cancer. Among the positive cases, CEA staining was located over whole cytoplasm in
18 (80%) of 22 positive endocervical adenocarcinomas and on apical surface in 24
(75%) of 32 positive endometrial adenocarcinomas. The pattern of CEA distribution
in endocervical adenocarcinoma of endometrioid type was not similar to that observed
for primary endometrial adenocarcinoma (Toki et ah, 1985).
4.5.3 Oestrogen receptor (ER) and progesterone receptor (PgR)
4.5.3A Introduction
Biochemical and immunohistochemical studies have identified ER and PgR in the
endocervical columnar epithelium and the normal endocervix appears to be the target
tissue of steroid hormones because the quantity and quality of endocervical mucus
fluctuates in response to hormonal changes during the menstrual cycle (Gaton et ah,
1982).
4.5.3.U ER and PgR Immunocytochemistry
In all cases, normal endocervical cells and fibroblast-like stromal cells of the cervix
stained positively for ER and PgR. The staining pattern in the tumour cells was
similar to that observed in the normal endocervical cells and was restricted to the
nucleus. However, the intensity and distribution of ER and PgR staining in the tumour
tissue was more heterogeneous than that observed in the normal tissues. ER and PgR
staining in individual tumour cases would often vary from strongly positive to
completely negative. In the tumours, staining for both ER and PgR was frequently
observed in the nuclei of nonneoplastic stromal cells surrounding the tumour cells.
Mucinous adenocarcinomas of the endocervical type and endometrioid subtypes are
the two histologic subtypes most commonly associated with ER and PgR positivity.
There is a strong relationship between histologic grade and ER and PgR positivity. ER
positivity was somewhat reduced in poorly differentiated (Grade 3) tumours
compared with well differentiated and moderately differentiated (Grade 1 and 2)
tumours (p=0.07). In contrast, no reduction in PgR positivity was observed with
increasing tumour grade. However, other study reported no significant difference was
observed between tumours that were Stage I and those that were Stage II or higher
with respect to ER and PgR positivity. Similarly, no statistically significant
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differences in ER and PgR status were observed with age and racial/ethnic group
(Fujiwara et al., 1997).
4.5.3.M ER and PgR Status as a Clinical Prognosticator
In overall survival or disease free survival, no statistically significant differences were
observed between PgR positive and PgR negative cases. Similarly, no statistically
significant difference was observed between patients with ER positive and ER
negative tumours. Although the current data suggested that women with ER positive
tumours may have longer disease free survival than women with ER negative tumours
(p=0.06), this finding must be interpreted with caution because it did not reach
statistical significance (p=0.06) (Fujiwara et al., 1997).
4.5.4 PTEN
PTEN (phosphatase and tensin homolog deleted on chromosome ten) is a tumour
suppressor gene which appears to negatively control the phosphoinositide 3-kinase
signaling pathway for regulation of cell survival and cell proliferation by
dephosphorylating phosphatidylinositol 3, 4, 5-triphosphate (Myers et al., 1998). The
loss of PTEN function results in an increased concentration of PIP-3 and this in turn
leads to Akt hyperactivation. This suggests that the tumour-suppressor function of
PTEN is exerted through the negative regulation of the PI3-kinase/Akt cell survival
pathway (Furnari et al., 1998; Stambolic et al., 1998). The protein phosphatase
activity of PTEN is not considered to be as important as its lipid phosphatase activity
for tumour suppression. However, PTEN function as protein phosphatase has been
implicated in the inhibition of cell migration and invasion via dephosphorylation of
focal adhesion kinas [FAK], a molecule critical in the regulation of integrin signalling
(Tamura et al., 1998; Tamura et al., 1999) and also in the inhibition of cell cycle
progression (Hlobilkova et al., 2000).
To date, 110 germline PTEN mutations have been reported in patients affected with
rare multiple hamartoma syndromes (Eng & Peacocke, 1998). PTEN has also been
found to be defective in a large number of sporadic human tumours of breast, prostate,
brain and endometrium (Li et al., 1997; Steck et al., 1997; Kong et al., 1997). PTEN is
a good candidate for involvement in the pathogenesis of sporadic colon cancer.
However, to date, few somatic PTEN mutations or deletions have been identified in
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sporadic colon cancers (Frayling et al., 1997; Wang et al., 1998; Taniyama et al.,
2001). Somatic PTEN mutations are more particularly involved in two types of human
cancers: endometrial carcinomas (Kawanishi et al., 1997) and glioblastomas (Rasheed
et al., 1997; James et al., 1999). In most cases, these somatic mutations result in
protein inactivation and, as with germline mutations, recurrent somatic mutations are
found in CpG dinucleotides. A mutagenesis by insertion-deletion in repetitive
elements is however specifically observed in endometrial carcinomas (Bonneau &
Longy, 2000).
Being one of the initial genetic changes seen in endometrial carcinogenesis, the PTEN
gene acts as a gatekeeper for this process (Ali, 2000). In normal endometria, isolated
PTEN negative glands may well be the earliest detectable phases of endometrial
tumourigenesis yet seen, but the clinical relevance of such small lesions remains to be
determined (Mutter & Lin, 2000; Mutter et al., 2001). It is anticipated that similarly
high rates of initiation will be seen in other tissues because comparable biomarkers for
neoplastic initiation become available in other tissue sites. Lesions have now fulfilled
most of those postulates predicted for clinically relevant precancerous disease. Loss of
PTEN function occurs quite frequently within the endometrial regenerative pool, at
such a high rate that they can be considered part of background"normal" genetic
events. These mutant clones remain indistinguishable from non-mutant glands in
normal cycling and anovulatory endometrium. Involution or expansion of mutant
clones due to non-genetic factors is one possible mechanism whereby the ambient
hormonal state may modify the risk of endometrial cancer (Mutter, 2002).
Interestingly, the PTEN gene appears to be hormonally regulated, with greatest
physiological endometrial gland expression in an oestrogen rich environment (Mutter
et al., 2000). Thus, the diminished PTEN tumour suppressor function effects are
probably accentuated under the very circumstances known to increase endometrial
cancer risk: protracted oestrogen exposure unopposed by progestins (Curry, 1990;
Parazzini et al., 1991). Mutant glands then acquire additional genetic damage and
subsequently become recognisable as focal lesions by their crowded architecture and
altered cytology (Mutter, 2002).
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4.5.5 MIB-1 (Proliferation Marker)
As well as being of use in certain situations in the interpretation of cervical squamous
lesions, MIB-1 and other proliferation markers may also be of value in the diagnosis
of preinvasive cervical glandular lesions (McCluggage et al., 1997; Ogawa et al.,
1999). In the distinction between high-grade CGIN and TEM or MGH, MIB-1
staining is of value. Generally in benign lesions only scattered nuclei are positive,
whereas in high- grade CGIN many nuclei are usually positive. One study found that a
MIB-1 labelling index of >30% was highly predictive of a malignant or premalignant
endocervical glandular lesion (Ogawa et al., 1999). However, in this study cases of
low-grade CGIN were not included and it might be expected that there would be some
overlap in the MIB-1 labelling indices between low-grade CGIN and TEM. In
addition, cases of atypical TEM have been described (sometimes in association with
high-grade CGIN of tubal type with cilia) and these might be expected to have a
higher proliferation index than typical TEM (McCluggage, 2002). Another recent
study found that MIB-1 staining <10% always reflected a benign process whereas a
MIB-1 index of >50% was always associated with a neoplastic process. It should be
noted that MIB-1 staining is also of value in cervical squamous lesions, especially in
the distinction of atrophy or immature squamous metaplasia from CIN III (Young &
Clement, 2002). However, there is no significant differences in MIB-1 labelling index
existed between the adenocarcinoma and AIS groups (McCluggage et al., 1995).
In addition to these, there were statistically significant differences in HPV 16/18, p53
and MIB-1 expressions between malignant endocervical glandular lesions and EGD,
but no significant difference in p53 and MIB-1 expressions in relation to HPV 16/18
expression. In malignant endocervical glandular lesions, HPV 16/18 infection may be
a major causative factor, but not be related to p53 and MIB-1 expressions (Yoon et
al., 2001).
4.5.6 The Suppressor Gene p53
Alterations of the p53 tumour suppressor gene are correlated with a critical step in the
development of many human cancers. The tumour suppressor gene functions include
regulation of the cell cycle and the cellular response to DNA damage, initiation of
DNA repair and replication, induction of apoptosis and promotion of cell
differentiation. Inactivation of p53 may result from a number of events including
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mutation of the p53 gene, binding of p53 to cellular or viral proteins and cytoplasm
sequestration of the protein. In cervical carcinoma, loss of p53 function can occur
through its interaction with the E6 protein of oncogenic HPV types. In addition, DNA
of these HPV types is often found integrated into cellular DNA. This integration can
result in deletion or mutation of some viral genes. The clinical significance of p53
changes has been evaluated elsewhere for a wide variety of human cancers, including
cervical cancer. Although cervical low-grade neoplasia can progress to cervical
cancer, few molecular studies have indicated p53 mutation at this stage of the lesion
(Oliveira et al., 2002).
It was claimed by McCluggage et al., (1995) that p53 protein expression is frequent in
endocervical adenocarcinoma and suggests that mutation of the p53 gene may be
important in the evolution of some cases of endocervical adenocarcinoma. Scattered
p53-positive cells may be seen in endocervical adenocarcinoma in situ and in non¬
neoplastic endocervical glandular lesions, the significance of which is uncertain. Bcl-
2 protein expression is seen in a proportion of endocervical adenocarcinomas and may
play a role in the evolution of these tumours through inhibition of apoptosis.
Widespread positivity for bcl-2 protein is seen in most cases of tubo-endometrial
metaplasia, suggesting that this type of metaplastic epithelium may represent an
unusually stable population of cells.
Skyldberg et al, (1999) reported that the HPV-positive tumours predominantly
showed a tetraploid DNA distribution pattern, whereas HPV-negative tumours more
frequently showed highly scattered aneuploid DNA profiles. Both HPV-positive and
HPV-negative cases displayed high proliferative activity, as indicated by high Ki-67
and cyclin A immunoreactivity. Tumour suppressor gene analysis detected low p53
expression and high p21/WAFl expression in HPV-positive patients and high p53
expression without simultaneously increased p21/WAFl (indicative of mutated p53)
in HPV-negative cases in the groups of women older than 59 years of age. Moreover,
Storey et al, (1998) claimed that, nuclear accumulation of p53 was found to be
associated with the presence of HPV. There was no significant difference in parietal
infiltration, lymph node involvement and prognosis between HPV+p53+ patients and
HPV-p53- patients. Tumour aggressiveness is likely to be enhanced by factors other
than HPV infection and p53 overexpression
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AIMS OF THE WORK
The objectives of this study were to (1) use tissue microarray technique as a new tool
for histopathological studying of archival paraffin-embedded cervical adenocarcin¬
omas cases; (2) use tissue microarray technology to evaluate the immunoprofile of a
large set of cervical adenocarcinomas with an extended panel of antibodies,
comparing the profile of AIS with invasive subtypes of cervical adenocarcinomas; (3)
compare the tissue microarray technique with whole tissue staining in regard to
quality of staining, reproducibility, and the impact of tissue heterogeneity, (4) study
the morphological and histological structure of cervical adenocarcinomas archival
donor blocks; (5) evaluate the diagnostic and prognostic value of different antibodies
which are commonly used in immunohistochemistry of cervical lesions; (6) assess the
prevalence of HPV 16 and 18 infection in various cervical adenocarcinomas cases
using PCR methods and evaluate its relation to other parameters of cervical
adenocarcinomas; (7) evaluate the correlation between HPV 16 and 18 and the




Morphological and Histopathological study
1.1 Tissue Samples
A computerized tumour registry search was conducted for all patients diagnosed with
invasive cervical adenocarcinoma at the University of Edinburgh, Pathology
Department from 1991 to 2001. In addition, twenty cases of adenocarcinoma in situ
were used as a sample to compare with invasive cases. Nonprimary cervical
adenocarcinomas were excluded. Ethical approval for this study was granted by the
local research ethics committee. Surgical cervical specimens were obtained from the
archival collections. A total of 273 samples (paraffin-embedded blocks) were obtained
from 177 biopsies composed of 16 normal cervical biopsies, 139 different patients
with endocervical adenocarcinomas, and 22 patients with second biopsies.Pathology
reports and cervical smear history reports were reviewed. Cases with sufficient
residual tissue in the archival tissue blocks were selected to ensure an adequate
sample for haematoxylin and eosin sections, TMA construction, immunohisto-
chemical analysis and HPV detection. The final set of study cases included samples of
glandular tissues including normal endocervical mucosa (16) which were taken from
patients suffering from different non-cervical pathologies, adenocarcinoma in situ
(20), invasive adeno-carcinoma (119) and 22 cases with second biopsies.
3-M-m serial sections from the routinely processed formalin-fixed, paraffin-embedded
tissue blocks were prepared. Before deparaffinizing the sections, they were baked
overnight at 60°C and stained with haematoxylin and eosin method to study the
morphological and histopathological features of the cervical cases.
1.2 Haematoxylin and eosin method
Fresh 3-H-m sections were cut from each paraffin-embedded block and transferred to
glass slides (Dako ChemMate capillary gap microscope slides, 75 mm, Dako A/S,
Glostrup, Denmark). Following deparaffinization in xylene(2 times, 5 minutes each
time) and rehydration through descending graded ethanol, 100%, 95% and 70% (2
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minutes each time), the sections were washed well with tap water for 2 minutes.
Staining was performed by placing the sections into haematoxylin (to stain the nuclei
of the cells) for 5 minutes and washing in tap water until colour changes from red to
blue. The sections were treated with acid alcohol for 5 seconds and placed into tap
water until sections again go blue. Then the sections were stained with eosin (to stain
the cytoplasm of the cells) for 30 seconds and washed in tap water. After dehydration
of the sections through ascending graded ethanol, 70%, 95%, and 100%, (5 seconds
each time), the sections were cleared well with xylene. Finally, sections were mounted
in DPX by placing one drop of DPX on to a coverslip and placing the slide on top of
this covering the section. Then sections were left to dry overnight.
1.3 Reviewing of the Haematoxylin and eosin-stained slides and collection of
data
All haematoxylin and eosin-stained slides were reviewed and diagnostic groups were
assigned and graded according to standard histological criteria. Histopathologic
sections were available for normal endocervical mucosa, all invasive cases, adeno¬
carcinoma in situ cases with smooth peripheral contour and cases of early invasion if
there are small buds of malignant glandular cells protruding into the stroma from
glands with adenocarcinoma in situ, if the otherwise smooth peripheral contour of
adenocarcinoma in situ was absent, or if malignant glands extended below the level of
adjacent benign glands or adenocarcinoma in situ. The presence of an associated
squamous intraepithelial lesion was recorded. Clinicopathological parameters were
obtained from the pathology reports.
Each specimen was associated with a large number of data items. Therefore, database
was designed using Microsoft Access to hold the large amount of data that generated
from each specimen. Data was verified and entered in the database.
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CHAPTER 2
Tissue Microarray (TMA) construction
2.1 Tissue Samples
A fresh 3-Mrn section was stained with haematoxylin-eosin from each of 273 samples
(blocks) obtained from 177 biopsies composed of 16 normal cervical biopsies, 139
different patients with endocervical adenocarcinomas, and 22 patients with second
biopsies. All sections available were reviewed histologically, and areas of
morphologically representative, nonnecrotic sites in the tumour were marked with
coloured indelible marker on the glass slides of H&E stained sections. In our study,
the area of invasive adenocarcinoma was marked by black circle; the area of
adenocarcinoma in situ was marked by blue circle while the area of normal
endocervical glands within the tumour was marked by red one. From each
corresponding paraffin block, two paired tissue cores (0.6 mm in diameter) were
sampled from each marked area in the "donor" block and mounted into two
"recipient" paraffin blocks, one pair in each paraffin block, by the use of a custom-
made instrument (Beecher Instruments, Silver Springs, MD). In the ensuing paraffin
array block, the tissue cylinders were aligned, and marked for identification according
to a chart (Figure 3).
The final set of tissue samples consisted of 667 tissue cylinders in 6 TMA blocks
which included samples of normal endocervical mucosa (32 cores) in one TMA block,
normal endocervical glands from the tumours tissue (125), adenocarcinoma in situ (59
cores) in duplicate TMA blocks, and invasive adenocarcinoma (196 cores) in
duplicate TMA blocks.
The "recipient" paraffin blocks (TMA blocks) were baked at 56°C for 10 minutes
before sectioning and 3-pm paraffin sections were then made by standard technique.
After that, TMAs sections were stained with haematoxylin and eosin method and
different antibodies for immunohistochimstry. Finally, H&E -stained TMA sections
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were compared with some of whole sections to investigate whether TMAs are
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Fig. 3 diagram ofTMA organization chart which used in this study. Tissue samples
were distributed and located in TMA chart using (X: Y) relationship.
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Fig 4b TMA H&E slide
55
2.2 Tissue Microarray (TMA) Technique (written by M. Herriot)
1. Prepare blank recipient (array) paraffin blocks. These should be 5-10mm
deep. A suitable mould is the large Tissue-Tek 1. Ensure that the wax is
free from holes or other irregularities. The array identifier code may be
marked at this stage.
2. At least one block of control tissue and two for the tumour samples
(adjacent cores to allow for within-tumour variation) should be prepared.
The areas for blocking should be circled on the corresponding slides
3. Clamp all recipient blocks into holders, ensuring that they are all in the
same position. With the screws facing you, place the block with the
number-end on the left, in the rear left corner of the holder and tighten the
screws.
4. Place the first block on the Manual Tissue Arrayer (TMA-1) on the magnet
and firmly against the back and side rails. Align the (0, 0) position. The
standard grid for this laboratory consists of 2 sections of 10 x 15 at 1mm
intervals therefore the (0,0) position should be 5mm from the bottom and
9mm from the left side. The micrometers should be zeroed at this position.
5. With the plunger raised, punch a hole at (0,0) using the fine bore (red)
needle, twist the needle then raise from the block. Use the plunger to expel
the wax core.
6. Move the larger (blue) needle into position and check that it is correctly
aligned. Place the donor block bridge on the stage and select a suitable
marker tissue (normally liver stained with crystal violet). Punch the block
and remove the stage. Bring the needle gently down until it is just touching
the array block above the hole. Carefully expel the core into the hole. The
core should end up just below the surface of the block.
7. When assembling the tumour arrays, it is convenient to swap blocks after
each core is inserted. This ensures that adjacent tumour samples are in the
same positions in each array.
8. Move the stage to (1, 1) and punch the next hole using the red needle.
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9. Use the blue needle to punch the first test tissue matching the block with
the selected area on the slide and expel into the position.
10. Mark the template with the identifying number or score the position off
and record the position and identity in a separate book.
11. Move the stage to (2,1) and continue.
12. After (10, 15), move the stage to (11,0) and insert the second marker tissue
(usually acid fuchsin stained lung). These markers ensure that however the
tissue sections are floated; the array can still be orientated.
13. Move the stage to (12, 1) and continue with the next section.
14. Once the arrays are constructed, remove the blocks from their holders and
place in a 56°C incubator for 10 minutes. This softens the paraffin. Gently
press down on the surface of the array with a glass slide and allow to cool.
15. The array blocks are now ready to cut. Face-up carefully in order to obtain
a cross-section of as many samples as possible - 90% + is acceptable. A
common problem is that of samples curling-up. If this happens, repeat the
softening of the paraffin at 56°C and press with the glass slide. The array





A 3-P-im TMAs sections (as mentioned previously in chapter 2) and some of the whole
sections (as mentioned in chapter 1) were used to study and to compare between them
and to evaluate the heterogeneity within the tumours. These sections were stained for
the following antigens, carcinoembryonic antigen (CEA), Cytokeratin7 (CK7),
Cytokeratin20 (CK20), oestrogen receptors (ER), progesterone receptors (PgR), MIB-
1 proliferation marker, and p53 suppressor gene. These antigens were chosen to
represent known positive (CK7), expected negative (CK20), steroid receptors (ER and
PgR) as examples of potentially heterogeneous expression- to compare staining in
whole sections with those in TMA; CEA and p53 to investigate their expression in a
large series; and phosphatase and tensin homolog deleted on chromosome ten (PTEN)
antigen to evaluate it in differential diagnosis between primary endocervical
adenocarcinoma and primary endometrial adenocarcinoma. Pathology reports and
cervical smear history reports were reviewed.
3.2 Immunohistochemical Staining
Fresh S-Pm sections were cut from each Microarrays and the original paraffin-
embedded block and transferred to glass slides (BDH Superfrost plus microscope
slides, 75mm, BDH Laboratory Supplies). Following deparaffmization in xylene (2
times, 5 minutes each time) and rehydration through descending graded ethanol ,
100%, 95%, and 70% (2 minutes each time), the sections were washed well with tap
water for 2 minutes. Antigen retrieval was performed by immersing tissue sections to
be used for CEA, CK20, MIB-1 and p53 antibodies in EDTA (pH 8) and heating them
for 15 minutes in a microwave at 750 W, while the sections which will be used for
CK7, PTEN, and Progesterone receptors, antigen retrieval was performed by
immersing in citrate buffer pH 6 with pressure cooking for 6 minutes at lm bar. The
sections were washed well in water then loaded onto Shandon Sequenza staining
apparatus. Endogenous peroxidase was then blocked by treatment with 1% hydrogen
peroxide for 5 minutes followed by washing in distilled water and then PBS. Using
58
Dako Envision System, the tissue sections were stained with the following
monoclonal primary antibodies for 30 minutes: carcinoembryonic antigen (CEA)
(clone 11-7, DakoCytomation, Denmark A/S), incubated at 1:300 dilution; CK20
(clone Ks20.8, DakoCytomation, Denmark A/S), incubated at 1:350 dilution, Ki 67
(clone MIB-1, DakoCytomation, Denmark A/S) incubated at 1:100 dilution; p53
(clone DO-3, DakoCytomation, Denmark A/S) incubated at 1:50 dilution. CK7 (clone
OV-TL 12/30, DakoCytomation, Denmark A/S), incubated at 1:10 dilution; PTEN
(clone 28H6, NovoCastra Laboratories Ltd, UK) incubated at 1:100 dilution and
progesterone receptor (clone PgR 636, DakoCytomation, Denmark A/S), incubated at
1:20 dilution.
For each tissue block, negative controls contained samples in which the primary
antibody was omitted and positive control tissues of known positivity to these
antibodies were performed. The positive tissue control for CK7, PgR and P53 was
breast carcinoma, for CK20 and CEA was colonic carcinoma and PTEN and MIB-1
was tonsil. The sections were washed well in PBS (2 times, 5 minutes each time). The
tissue sections were incubated with Dako EnVision/HRP rabbit/mouse polymer for 30
minutes, and then washed well in PBS (2 times, 5 minutes each time). After that, the
sections were incubated at room temperature with 3,3'- diaminobenzidine (DAB)
solution for 5 minutes and washed in tap water. Finally, the sections were
counterstained with haematoxylin, washed in tap water, then in STWS, dehydrated in
ascending graded ethanols, 70%, 95%, and 100%, (5 seconds each time), cleared well
with xylene and mounted by DPX.
For oestrogen receptors (ER) staining, PowerVision Poly-HRP Flistostaining kit
(Biotin-ffee, anti-mouse/rabbit) was used from ImmunoVision Technologies Co.
Negative and positive controls were also performed, the positive tissue control for ER
was breast carcinoma. Fresh 3-Hm sections were cut, deparaffinized in xylene, and
rehydrated through descending graded ethanol (as mentioned above). The sections
were washed well with tap water for 2 minutes. Antigen retrieval was performed by
immersing tissue in EDTA/NaOH (pH 8) with pressure cooking for 6 minutes. The
sections were washed well in water then loaded onto Shandon Sequenza staining
apparatus. Endogenous peroxidase was then blocked by treatment with 1% hydrogen
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peroxide for 5 minutes followed by washing in distilled water and then PBS. The
tissue sections were incubated in ER (clone 6F11, NovoCastra Laboratories Ltd, UK)
diluted 1:150 in Pre-antibody Blocking Solution for 1 hour. A negative control that
consisted of omission of the primary antibody and a positive control from tissue for
which was known its positivity to ER antibody were performed. The positive tissue
control for ER was breast carcinoma. The sections were washed well in PBS (2 times,
5 minutes each time). The tissue sections were incubated with Post-antibody Blocking
(Polymer penetration enhancer) for 20 minutes, and then washed well in PBS (2
times, 5 minutes each time). After that, the sections were incubated with Poly-HRP
anti-mouse/rabbit IgG for 30 minutes and washed well in PBS (2 times. After that, the
sections were incubated with DAB solution for 5 minutes and washed in tap water.
Finally, the sections were counterstained with haematoxylin, washed in tap water, and
"blue" in STWS, dehydrated in ascending graded ethanols, 70%, 95%, and 100%, (5
seconds each time), cleared well with xylene and mounted by DPX.
3.3 Evaluation of Tissue Staining
To determine how many cores are required to adequately represent a cervical
adenocarcinoma histologically, each H&E stained TMA core was analysed separately
and in relation to its original whole section. It was decided that in order for an
immunohistochemical result to be considered reliable, a minimum of two TMA cores
from the tumour should show concordant staining patterns. If divergent staining
patterns were obtained, results from third or subsequent cores were assessed, and the
case was considered to show positive staining if a minimum of two cores showed
specific staining.
In the evaluation of staining, cores were scored if at least 10% of the core area
contained tumour and each core was analyzed separately and graded as either positive
or negative. Staining was considered positive when the tumour cells showed staining
in at least 2 valuable tissue microarrays. Also, the staining reaction was compared
between the cores and some of the whole sections. The staining reaction of invasive
and preinvasive cases was compared with that of normal tissue with respect with the
intensity and distribution of PTEN expression. All microscopy was performed with a
Zeiss microscope (KPI lOx eyepiece with a high-power field HPF) (*40).
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Chapter 4
DETECTION AND TYPING OF HPVs DNA
4.1 Clinical Specimens
As mentioned in materials and methods in section 1.1
4.2 DNA extraction from paraffin blocks
Three 10-pm sections of formalin-fixed, paraffin-embedded tissue were collected into
tubes after cutting into the block. The microtome blade was changed after each case.
Tissue samples were incubated with lysis buffer containing (1 mg/ml) proteinase K
(400ul/sample) for 18 hours at 55°C and boiled for 20mins to denature the DNA and
destroy the proteinase K. Then lOul was used from each sample immediately for
detection and typing of HPVs DNA 16 and 18 using the PCR methods (Levi et al.,
1991).
4.3 Polymerase Chain Reaction (PCR) Methods.
4.3.1 Primer design
The sequences of type specific primers which designed from E6 and E7 ORFs and
Used for PCR methods (table 6) came from publications (Hwang, 1999).
Table 6. Type specific primers
Type specific primers
HPV 16 (F) 5" -TGTCAAAAGCCACTGTGTCC-3"
(R) 5' -GAGCTGTCATTTAATTGCTC-3"
HPV 18 (F) 5' -TGCCAGAAACCGTTGAATCC-3"
(R) 5"-TCTGAGTCGCTTAATTGCTC-3 '




PCR reactions were performed using sterile 0.5 ml RNAse / DNAse-free tubes and
each PCR reaction was made up to a final volume of 50pl.A typical 50pl PCR
reaction contained lOOmM-KCL, 20Mm Tris-HCL pH 8.0, 2.0mM MgC12, 2.5 mM
of dNTP's, 1.5 units of Taq polymerase (Invitrogen, UK), and 25 pmol of each primer.
40 ul from the mastermix was added to each tube and overlayed with 50ul of paraffin
oil. 10 ul of sample was added to each tube. To avoid false positives, a negative
control tube that consisted of omission of the DNA sample and a positive control tube
(HeLa for HPV-18 and SiHa for HPV-16) were performed. Once the PCR was set up,
the tubes were carried to run through the PCR program.
4.3.3 PCR Program.
The following program was run on an Omn-E™ thermal cycler with tube temperature
control (Hybaid). The mixtures were denatured initially for 90 seconds at 94°C, for 1
cycle, then 40 cycles, at 55°C for lmin, 72°C for lmin, and 94°C for lmin. Finally,
they were cycled at 72°C for lOmin, for 1 cycle. Once the appropriate number of
cycles had been completed or the program had finished, PCR samples were analysed
by agarose gel electrophoresis.
4.3.4 Agarose gel electrophoresis
PCR samples were run on 1% agarose (Sigma) gels. Agarose gels were manufactured
by mixing 2g of agarose with 100 mis lx Tris/boric acid/EDTA (TBE) buffer in a
glass conical flask and heating in a microwave until all the agarose had dissolved.
After heating the agarose solution was allowed to cool at room temperature and 5ul of
5mg/ml ethidium bromide was added and left on the bench until agarose cooled to
60°C. Once the agarose had cooled enough to comfortably hand hold, but was still
liquid, it was poured into the a gel tray and the relevant number of wells were created
by inserting combs, ensuring no air-bubbles were present. Once solid, the agarose gel
(and tray) was transferred into the gel tank which was filled with TBE so that the gel
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was completely submerged in the buffer. Firstly, 5 ul Kilobase DNA marker
(Invitrogen, UK) loaded onto the gel, then lOul PCR of each sample was mixed with
3ul loading dye and loaded onto the gel. Gel electrophoresis was run at 75V for 60
minutes depending on how far it was necessary to run the samples. Once the gel had
run far enough, the power was disconnected and the gel tray was removed from the
gel tank. DNA bands were visualised by UV trans-illumination.
4.3.5 Gel Visualisation
Gels were visualised by UV trans-illumination. Images were saved to floppy disk and
were printed using the Enhanced Analysis System (EASY, Scotlab, Coatbridge,
Lanarkshire, Scotland). This program allows semi-quantitative analysis of PCR
products. It designates the brightest band on the gel a value of 1000 (background = 0)
and thus can designate all the other bands a value between 0 and 1000 depending on
their intensity. Therefore this program allows the intensity of PCR bands (which is
proportional to the amount of PCR product) to be semi-quantitatively assessed
following a range of different treatments and conditions.
4.3.6 Restriction digestion of genomic DNA
To test and confirm the subtypes of HPVs DNA-16 and -18, all positive samples were
collected and processed through restriction digests which consisted of, 3ul restriction
enzyme buffer, 14ul sterile distilled water, lOul PCR product, and 3ul restriction
enzyme Ava II (10 units/ml) (Table 7).The contents of mixture was gently mixed but
thoroughly mixed and incubated at 37°C overnight. lOul of product was run on a 2%
agarose gel with 5ul (5mg/ml) of ethidium bromide/100ml gel and visualised by UV
trans-illumination (as mentioned previously).





Table 7. Restriction enzyme fragment sizes of PCR products (Hwang, 1999).
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4.3.7 Optimisation the HPV PCR analysis
To optimise the HPV PCR analysis, all HPV-negative adenocarcinomas were
subjected to a second HPV test using specific primers from the E6 and E7 genes of
HPV 16 and 18 for the PCR reaction. Thereafter, PCR products, indicating infection
with HPV 16 or 18, were identified on agarose gels
4.4 Laser Capture Microdissection (LCM)
4.4.1 Tissue Samples
All HPVs positive cases which composed of blocks from 87 different patients and
detected by previous PCR methods were collected and pathology reports were
reviewed. Special LCM processing schedule was followed to avoid contamination.
The water bath was cleaned using RNAse solutions, rinsed thoroughly with distilled
water and was filled with distilled water. All instruments used were cleaned with
100% EtOH (brushes, forceps, and pencil). A new blade was used for each block and
100% EtOH was used to wipe each blade while sectioning. Gloves were worn at all
times while sectioning. A 9-Hrn section was cut from each paraffin-embedded block
and transferred to glass slides (Dako ChemMate capillary gap microscope slides, 75
mm, Dako A/S, Glostrup, Denmark).
4.4.2 Staining of Paraffin Sections
Fresh 9-Mmr sections were cut from each paraffin-embedded block and transferred to
glass slides (Dako ChemMate capillary gap microscope slides, 75 mm, Dako A/S,
Glostrup, Denmark). Following deparaffinization in xylene (2 times, 5 minutes each
time) and rehydration through descending graded ethanol, 100%, 95%, and 70% (2
minutes each time), the sections were washed well with tap water for 2 minutes.
Staining was performed by placing the sections into haematoxylin (to stain the nuclei
of the cells) for 5 minutes and washing in tap water until colour changes from red to
blue. The sections were treated with acid alcohol for 5 seconds and placed into tap
water until sections again go blue.Then the sections were stained with eosin(to stain
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the cytoplasm of the cells) for 30 seconds and washed in tap water. After dehydration
of the sections through ascending graded ethanol, 70%, 95%, and 100%, (5 seconds
each time), the sections were cleared well with xylene (2 times, 5 minutes each time)
which is very important for the efficiency of the LCM . Finally, the tissue sections
were left to dry completely (2-4 minutes) and stored in an airtight box containing
silica gel.
4.4.3 DNA Extraction Protocol of LCM tissue
After micro dissection (roughly 500-1,000 cells) from the most presentable area of the
whole tissue sections of the tumour, the cap was inserted into an Eppendorf tube
containing digestion buffer (25 pi buffer containing O.lmg/ml Proteinase K, 10 mM
Tris-HCL (pH 8.0), 1 mM EDTA, and 1% Tween-20). The tube was placed upside
down so that the digestion buffer contacted the tissue on the cap in a shaking oven at
37°C. The incubation was continued overnight at 37°C for 16 hours. Next day the tube
was centrifuged for 5 minutes at high speed and the cap was removed. The reaction
was heated to 99°C for 10 minutes to inactivate the proteinase K. It can then be used
directly as template for PCR (usually small volumes PCR reactions to decrease the
amount of DNA used; e.g. total PCR volume - 25 pi and DNA template-5/xl). The
tissue samples were tested for presence of HPV DNA by Polymerase Chain Reaction
(PCR) Methods.
4.4.4 Polymerase Chain Reaction (PCR) Methods.
PCR reactions were performed using sterile 0.5 ml RNAse / DNAse-free tubes and
each PCR reaction was made up to a final volume of 25 pi. A typical PCR reaction
contained 4ul sterile DDW, 4ul dNTP's (200mM), 2.5ul Buffer (lOOmM-KCL, 20Mm
Tris-HCL pH 8.0), 1 pM of each primer, 1.25ul DMSO, lul MgCl 2 (50 mM), and
0.125ul of Taq polymerase. Then, 15 ul from these mastermix was added to each tube
and overlayed with 25ul of paraffin oil. 5 ul of LCM sample was added to each tube.
A negative control tube was performed that consisted of omission of the DNA sample
and a positive control tube from HELA. Once the PCR was settled up, the tubes were
carried to run through the PCR programme. All other steps of PCR method were
undertaken same as mentioned previously.
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Statistics
The age-group distribution, stromal response, stage of cancer, and grade in the
different types of adenocarcinoma groups were compared using the Kruskal-Wallis
test. The independence of the type of adenocarcinoma and the immunohistochemistry
results, TZ results, CIN/CGIN results, HPV results, pattern of invasion, LVSI, local
spread and lymph node spread was examined using the Chi-square test. The age-group
distribution and stromal response in the adenocarcinoma-in-situ and invasive
adenocarcinoma groups were compared using the Wilcoxon rank-sum test. The
independence of type of adenocarcinoma (adenocarcinoma-in-situ or invasive
adenocarcinoma) and immunohistochemistry results, and TZ result was examined
using Fisher's exact test. The independence of type of adenocarcinoma
(adenocarcinoma-in-situ or invasive adenocarcinoma) and CIN/CGIN results, and
HPV results was examined using the Chi-square test. All significance tests were exact
tests carried out using StatXact-4 package. Professional statistical assistance was
provided by the Medical Statistical Unit, University of Edinburgh. Throughout this




Morphological and Histopathological study
1.1 Clinicopathological Characteristics
The 139 patients with cervical adenocarcinomas ,excluding results from second
sample for 22 patients with two samples, used in this study, consisted of 20 patients
with adenocarcinoma-in-situ and 119 with invasive adenocarcinoma. Sixteen of 119
patients with invasive adenocarcinoma had early invasive adenocarcinoma which met
criteria for FIGO stage IAj carcinoma of the cervix. The types of invasive adeno¬
carcinoma are presented in the following table.
Table summaries the subtypes of invasive adenocarcinoma included in this study
Type of Invasive Adenocarcinoma Number
Adenocarcinoma NOS, 50
Villoglandular papillary adenocarcinoma, 23
Adenosquamous carcinoma, 22
Minimal deviation adenocarcinoma 8
Other types of adenocarcinoma.
The other types of adenocarcinoma were;
• Microglandular adenocarcinoma,
• Endometroid adenocarcinoma,
• Clear cell carcinoma
• Intestinal type adenocarcinoma
• Signet -ring cell adenocarcinoma








The specimen types were; 64 LETZ, 34 punch or wedge biopsy, 17 Wertheim's
hysterectomy, 8 cone biopsy, 6 cervical polyp, 5 cervical curettings, 4 simple
hysterectomy and 1 endometrial biopsy.
Ages of the patients at time of sample ranged from 23 to 89 years old. 58 (42%)
patients were <= 39 years old, 42 (30%) were 40 - 50 years old, and 39 (28%) were
>=51 years old.
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There was one patient with unavailable data. In the other 138 patients CIN was absent
in 89 and present (CIN1 or CIN2 or CIN3) in 49 patients, while CGIN was not
identified in 45 (33%) and present (low or high grade) in 93 patients. So both CIN &
CGIN were absent for 33, CIN only was present for 12, CGIN only was present for
56, and both CIN & CGIN were present for 37 patients.
In the 119 patients with invasive adenocarcinoma, the pattern of invasion was
confluent in 22 (18%), diffuse in 1 (1%), infiltrative in 77 (65%), and pushing in 19
(16%). A stromal response was absent in 28 (20%) patients, mild in 47 (34%)
patients, moderate in 39 (28%) patients, and intense in 25 (18%) patients. The focality
could not be determined for 76 (64%) of the 119 patients with invasive adeno¬
carcinoma. For the 43 patients where the focality was determined 6 had one focus, 4
had two foci, 4 had three foci, and 29 had more than three foci.
Staging of all of the tumours was taken from the pathology reports. The FIGO stage
of cancer was Ial for 16 (13%), Ia2 for 11 (9%) and lb or greater for the remaining of
the 119 patients with invasive adenocarcinoma.
Of the 119 patients with invasive adenocarcinoma there were 54 (45%) patients with
grade 1 (well differentiated) cancer, 36 (30%) with grade 2 (moderately
differentiated) cancer, and 29 (24%) with grade 3 (poorly differentiated) cancer.
For the 22 patients with two samples, there was no significant difference between the
two samples regarding the morphological and histopathological features.
1.2 Adenocarcinoma in situ
Twenty of 139 patients showed with adenocarcinoma in situ without invasion. These
were defined by showing nuclear stratification and loss of polarity, nuclear atypia and
hyperchromasia, macronucleoli, loss of intracytoplasmic mucin, atypical mitoses,
apoptotic bodies, goblet cells, and abrupt transition to normal. Not all of these findings
usually present in every individual case. There was often an abrupt transition from
normal glands to glands involved by AIS and this abrupt transition may be seen within
individual glands. Both the surface epithelium and the underlying crypts may be
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involved. There was common occurrence of apoptotic bodies and mitotic figures in
AIS; however their occurrence was not prominent in every case (Fig. 5).
Large masses of densely packed architecturally complex glands with papillary growth
process, and cribriform areas were observed in the AIS cases which strongly
suggested invasion. There was a gradual thinning of the glandular epithelium until the
basement membrane was destroyed and stromal invasion started. This appearance was
called "elastic band sign" (Fig. 18)'
All subtypes of AIS were seen including endocervical, intestinal, endometroid, and
mixed adenosquamous types. The endocervical type retained a basic resemblance to
the normal endocervix, with at least focally vacuolated, often granular, pale,
basophilic to eosinophilic cytoplasm. The intestinal type displayed distention of apical
cytoplasm by a large mass of mucin, resembling intestinal goblet cells. The
endometrioid type was characterized by cells with densely eosinophilic cytoplasm
containing no apparent mucin in routinely stained sections, resembling hyperplastic
glands of the endometrium. The mixed adenosquamous type was characterized by
cells of cervical glands with AIS and squamous epithelium with CIN3 (Fig.6). There
were some endocervical glands which showed total replacement by CIN3. The
transformation zone (TZ) of the all patients with recorded TZ (13 from 13 patients)
had adenocarcinoma in situ was involved by the AIS (100%) (Fig.7).
The age group of adenocarcinoma in situ is younger than those with invasive
adenocarcinoma presented in table 8. Patients with adenocarcinoma in situ were
younger than those with invasive adenocarcinoma and, there was significant statistical
difference between AIS and invasive adenocarcinoma with respect to age group (p =
0.006). Fourteen of 20 patients who had adenocarcinoma in situ were <=39 years old
(70%), four patients were 40-50 years old (20%), and two patients were >= 51 years
old (10%).
The association of CIN with or CGIN together with invasive adenocarcinoma is
presented in table 9 (p =0.009). Most of the patients (42%) with invasive adeno¬
carcinoma associated with CGIN (Fig.6).
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Table 8 Age Group in AIS and invasive adenocarcinoma.
Age-group Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
<=39 years old 14 70 44 37
40-50 years old 4 20 38 32
>=51 years old 2 10 37 31
Total 20 100 119 100
Table 8 showing comparison between adenocarcinoma in situ and invasive adeno¬
carcinoma with respect to age group using Wilcoxon rank-sum test(p= 0.006)
Table 9 CIN and CGIN in invasive adenocarcinoma.
CIN and CGIN Invasive adenocarcinoma
N %
Both absent 33 28
CIN only 9 8
CGIN only 49 42
CIN + CGIN 27 23
Total 118 100
Table 9 showing comparison between adenocarcinoma in situ and invasive
adenocarcinoma with respect to CIN and CGIN association using Chi-square test (p=
0.009). There was 1 patient with squamoid metaplasia recorded who has not been
classified regarding absence/presence of CIN and CGIN (1 invasive adenocarcinoma).
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1.3 Invasive endocervical adenocarcinoma
There were 119 patients with invasive cervical adenocarcinomas, excluding results
from second sample for 22 patients with two samples, used in this study. They are
presented in section 1.1.The clinicopathological characteristics of all subtypes of
endocervical adenocarcinomas including the others types of adenocarcinomas in
comparison to AIS were presented in tables 11-18.
1.3.1 Adenocarcinoma NOS, usual endocervical type, (Fig. 8).
Fifty of 119 patients with invasive adenocarcinoma had adenocarcinoma NOS, usual
endocervical type. Their age group was mainly among <=39 years old (44% of the
patients). Most of them, 56% of the patients, had histopathologic grade 1 well
differentiated. Most of the patients presented with frankly invasive tumours (58% of
the patients).Tumours were characterized by glands of medium size. The arrangement
of the glands was highly variable, some being widely spaced, others forming closely
packed aggregates with cells often have eosinophilic cytoplasm and atypical nuclei
.Occasionally, there were villous papillae presented on the surface. The tumours were
associated with CGIN in 52% of the patients. The main pattern of invasion of those
tumours was infiltrative (74% of the patients) and their focality could not be
determined in 52% of the patients.Stromal response was mild (54% of the patients).
Four patients (8%) presented with lymphovascular invasion.
1.3.2 Adenosquamous carcinoma (Fig.9).
Twenty two of 119 patients with invasive adenocarcinoma had adenosquamous
carcinoma. Their age group was mainly among >=51 years old (36% of the patients).
Most of them, 45 % of the patients, had histopathologic grade 3 poorly differentiated.
Most of the patients presented with frankly invasive tumours (82% of the patients).
Adenosquamous tumours had malignant glandular and squamous elements that were
recognizable without the use of special stains. The glandular component in
adenosquamous carcinomas was usually of endocervical type but mucinous, including
signet ring cell, or mixed endocervical and mucinous, endometrioid or clear cell were
occasionally observed. The tumours were mainly associated with CIN and CGIN
(41% of the patients). The main pattern of invasion of those tumours was infiltrative
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(86% of the patients) and their focality could not be determined in 95% of the
patients. Stromal response of them was moderate (45% of the patients). Two patients
(9%) presented with lymphovascular invasion.
1.3.3 Villoglandular papillary adenocarcinoma (VGC) (Fig. 10).
Twenty three of 119 patients with invasive adenocarcinoma had villoglandular
papillary adenocarcinoma (VGC). Their age group was mainly among <=39 years old
(48% of the patients). Most of them, 52 % of the patients, had histopathologic grade 1
well differentiated. Most of the patients presented with frankly invasive tumours (78
% of the patients).Most of VGC had a major surface papillary component. The
papillae were tall and thin and had a fibrovascular stroma, focally infiltrated by
lymphocytes and plasma cells. The deep portions of the neoplasms contained
elongated and branching glands. The papillae and glands were lined by slightly
columnar cells, but there was no cellular tufting or budding. The nuclei were round,
oval, or elongated, showed mild to moderate atypia, and contained scanty mitotic
figures. The lining epithelium usually was of endometrioid type. However,
endocervical mucinous and intestinal-type epithelium were occasionally presented
focally. In addition, exophytic tumour was observed in some cases. The tumours were
mainly associated with CGIN only (57% of the patients). The main pattern of invasion
of those tumours was pushing (65 % of the patients) and their focality could not be
determined in 48 % of the patients. The main stromal response of them was mild
(52% of the patients). No patients presented with lymphovascular invasion. The
spread pattern of those tumours was 100% confined to the cervix, no lymph node
spread, and no distant spread.
1.3.4 Minimal deviation adenocarcinoma (Fig.l 1).
Eight of 119 patients with invasive adenocarcinoma had minimal deviation adeno¬
carcinoma. Their age group was mainly among 40-50 years old (50% of the patients).
All of them, 100% of the patients, had histopathologic grade 1 well differentiated.
Most of the patients presented with frankly invasive tumours (88% of the patients).
They were characterized by glands lined by columnar cells with mucinous apical
cytoplasm and basal nuclei of generally bland cytology. These glands were variable in
shape and size, often with large size with branching, cystic dilation, or papillary
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enfolding of the epithelium. The presence of mitotic figures and a desmoplastic host
response was usually rare. Stromal invasion deeper than normal glands was common
but cribriform or back-to-back arrangement of neoplastic glands was not seen. There
were 2 tumours associated with CGIN only, 2 with CIN only, 1 with CGIN and CIN,
and the remaining 3 with CGIN and CIN were absent. The main pattern of invasion of
all tumours was infiltrative (100% of the patients) and their focality was determined
as >3 foci in 63 % of the patients. The main stromal response of them was absent
(88% of the patients). No patients presented with lymphovascular invasion. The
spread pattern of those tumours was 88% confined to the cervix, 13% invaded the
parametrium, no lymph node spread, and no distant spread.
1.3.5 Other types of adenocarcinoma.
1.3.5.i Microglandular carcinoma (MGC) (Fig. 12).
Five of 119 patients with invasive adenocarcinoma had microglandular carcinoma
(MGC), three of them had histopathologic grade 2 moderately differentiated and two
had histopathologic grade 3 poorly differentiated. The tumours were composed of
small glands closely packed to each other with very little or no stroma between them.
These glands lined with one layer of malignant cells which had oval atypical nuclei
that were arranged with their long axis perpendicular to the basement membrane of
the glands and. All of those tumours had areas of microglandular hyperplasia.
1.3.5.ii Endometrioid adenocarcinoma (Fig. 13).
Four of 119 patients with invasive adenocarcinoma had endometrioid adeno¬
carcinoma, three of them had histopathologic grade 1 well differentiated and one had
histopathologic grade 2 moderately differentiated .The tumours were showed glands
lined with malignant cells that resemble those of typical adenocarcinomas of uterine
corpus. The cells usually were stratified and had oval atypical nuclei that were
arranged with their long axis perpendicular to the basement membrane of the gland.
The cells of those tumours had little or no mucin with little amount of cytoplasm.
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1.3.5.iii Clear cell carcinoma (CCC) (Fig. 14).
Three of 119 patients with invasive adenocarcinoma had clear cell carcinoma (CCC).
All of tumours, 100% of the patients, had histopathologic grade 3 poorly differentia¬
ted. All tumours revealed tubulocystic pattern. In these tubulocystic patterns, tubules
and cysts of varying sizes were lined by hobnail, flat, or clear cells. Rarely cells with
abundant oxyphilic cytoplasm were seen and occasionally were numerous.
Intracytoplasmic mucin was presented in occasional cells, and a signet-ring cell was
also observed.
1.3.5.iv Intestinal-type adenocarcinoma (Fig. 15).
Two of 119 patients with invasive adenocarcinoma had intestinal-type adenocar¬
cinoma. The tumours had histopathologic grade 2 moderately differentiated. The
tumours composed of glands lined by malignant-appearing cells, some of which had
their cytoplasm distended by a single large vacuole of mucin, forming a goblet cell.
1.3.5.V Signet-ring cell adenocarcinoma (Fig. 16).
One of 119 patients with invasive adenocarcinoma had signet-ring cell adenocar¬
cinoma. The tumour had histopathologic grade 3 poorly differentiated. The tumour
composed of glands lined by malignant-appearing cells with eccentric nuclei and pale
mucin-rich cytoplasm growing singly, in clusters, in nests or columns or in solid
aggregates of polygonal cells with a nucleus displaced eccentrically by mucinous
vacuoles giving appearance of signet-ring.
1.3.5.vi Adenoid basal carcinoma .
One of 119 patients with invasive adenocarcinoma had adenoid basal carcinoma. The
tumour had histopathologic grade 3 poorly differentiated. The tumour showed closed
packed small, round, oval, or lobulated nests of uniform mostly basaloid cells with
peripheral palisading and no stromal reaction. Lumens were formed in the centres of
the nests. The tumour cells usually had bland nuclei and increased mitotic figures.
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1.3.5.vii Glassy adenocarcinoma (Fig.17).
One of 119 patients with invasive adenocarcinoma had glassy adenocarcinoma. The
tumour had histopathologic grade 3 poorly differentiated. The tumour showed sheets
of large cells with abundant eosinophilic or amphophilic, ground-glass or finely
granular cytoplasm, prominent cell borders, large nuclei with prominent nucleoli, a
high mitotic rate, and a stromal inflammatory infiltrate.
1.4 Cervical Smear History
Cervical smear history reports of the all cervical adenocarcinomas (139 patients) exc¬
luding results from second sample for 22 patients with two samples, are presented in
table 10. 71/119 patients presented with abnormal Papanicolaou smears only. The
smear results were mainly adenocarcinoma (37/119). Most of patients 92/119 had
colposcopic evaluation before initial treatment.
Table 10 Cervical Smear History
Symptoms N Smear result N
Abnormal smear only 71 Adenocarcinoma 37
Unknown 23 No smear result 28
Abnormal smear +PCT 7 Glandular 20
Abnormal smear +CAC 12 Severe 22
PCBA 12 Negative 16
CAC only 4 ?Invasive 7
CAC+Bleeding 4 Moderate 5
Bleeding only 3 Borderline 2
Abnormal smear+bleeding 3 Inadequate 1
Total 139 Total 139
Table 10. Cervical smear history reports of all cervical adenocarcinomas. PCT=
previous colposcopic treatment, CAC= clinically abnormal cervix, PCBA= Previous
















































































































































































































































































































































































































































































































































































































































































































































































































































































































1.5 Early invasive adenocarcinoma (Microinvasive adenocarcinoma)
1.5.1 Clinicopathological Characteristics
Sixteen of 119 patients with invasive adenocarcinoma had early invasive
adenocarcinoma, excluding results from 22 patients with two samples, and met
criteria for FIGO stage IAj carcinoma of the cervix. Eight patients (50%) with early
invasive adenocarcinoma were <= 39 years old, 5 (31%) were 40 - 50 years old, and 3
(19%) were >= 51 years old. The type of carcinoma was adenocarcinoma NOS in 14
patients and adenosquamous carcinoma in 2 patients with early invasive
adenocarcinoma. All tumours were histopathologic grade 1 well differentiated. The
tumours showed three patterns of early invasive adenocarcinoma: small glandular
budding arising from HCGIN, infiltrating the stroma with an associated inflammatory
reaction, confluent glands in a complex pattern with little or no intervening stroma,
and intraluminal tufting resulting in a papillary pattern. Usually, the early invasive
adenocarcinoma was recognized by loss of the normal smooth peripheral glandular
outlines, prominent cribriform and/or solid areas, and the architectural complexity of
endocervical glands including deep invagination. There was a gradual thinning of the
glandular epithelium until the basement membrane destroyed and stromal invasion
started, and with respect to its appearance we called "elastic band sign" (Fig. 18)
which was also noticed in the AIS cases strongly suggest of early invasive
adenocarcinoma.
CIN only was present in 8 (50%) patients, and both CIN and CGIN were present in
the other 8 (50%) patients. The main pattern of invasion of those tumours was
infiltrative in 15 of the patients (94%) and was confluent in one patient (6%). The
focality could not be determined for 2 of the 16 patients with early invasive
adenocarcinoma. For the other 14 patients where the focality was determined 3 had
one focus, 2 had two foci, 2 had three foci, and 7 had more than three foci. A stromal
response was mild in 12 (75%), moderate in 3 (19%), and intense inl (6%) patient
with early invasive carcinoma. No patients were presented with lymphovascular
invasion.
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1.5.2 Cervical Smear History
Cervical smear history reports of all early invasive adenocarcinomas are presented in
table 19. Ten patients presented with abnormal Papanicolaou smears only, two with
abnormal Papanicolaou smears and clinically abnormal cervix and two were
unknown. 11 patients had colposcopic evaluation before initial treatment.
Table 19 Cervical Smear History








4 Severe dyskaryosis 3
Moderate dyskaryosis 2
Unknown 2 No smear result 2
Negative 1
Total 16 Total 16
Table 19. Cervical smear reports history of all early invasive adenocarcinomas.
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Figure 5 (A) A characteristically sharp comparison between normal endocervical epithelium
fright) and adenocarcinoma in situ (AIS) (left)(H&E,x400). (B) AIS showing stratified hyper-
chromatic nuclei, mitotic figures (circle) and easily identifiable apoptotic bodies toward the
)asement membrane( H&E,x400).
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Figure 6 (A) Association of adenocarcinoma in situ (AIS) (left) with squamous carcinoma in
situ (CIN3)(right)(H&E,x200). (B) A higher power of the same lesion(H&E,x400).
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Figure 7 (A) Well-differentiated villoglandular papillary endocervical adenocarcinoma
(VGC) at the squamous columnar junction with normal stratified squamous epithelium
(H&E, x200). (B) Same findings in other lesion (H&E,x400).
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Figure 8 (A) A well differentiated adenocarcinomas of usual endocervical type show¬
ing a widely separated glands lined with malignant cells with eosinophilic cytoplasm
(H&E,x200). (B) A higher power of the same lesion ( H&E ,x400).
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Figure 9 (A) Poorly differentiated adenosquamous carcinoma showing squamous elem¬
ent (right) and glandular element (left). Both the individual cells of squamous and gla¬





Figure 10(A) Well differentiated Villoglandular papillary adenocarcinoma (VGC)
formed of broad, long,branching papillae ,with fibrovascular cores covered by a
mildly atypical columnar epithelium(H&E x200). (B) A higher power of the same
lesion(H&E x400).
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Figure 11 (A) Well differentiated minimal deviation endocervical adenocarcinoma showing
essentially normal gland structure with minimal deviation of cell structure from normal.
Note, elongated glands whivh extend deep into the cervical stromawith no stromal reaction
(H&E,x 100) .(B) A higher power of the same lesion (H&E,x400).
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Figure 12 (A) A poorly differentiated endocervical adenocarcinoma , Microglandular carcinoma,
showing a confluent glandular invasion pattern with cribriform pattern(H&E,xlOO). (B) A higher
lower of the same lesion(H&E,x200).Note, a single layer of atypical oval nuclei surrounding each
glandular lumen with very little amount of stroma inbetween.
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Figure 13 (A) Well-differentiated endometrioid adenocarcinoma showing, typical glandular
morphology lined with atypical columnar cells (H&E, xlOO). (B) High power view of the
same lesion (H&E, x200).
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Figurel4(A) A poorly differentiated clear cell adenocarcinoma showing tubules lined
by malignant cells with intracytoplasmic mucin and signet-ring cells.(H&E,x400).
(B) A poorly differentiated clear cell adenocarcinoma showing cells with abundant
oxyphilic cytoplasm and hobnail, flat, or clear cells(H&E,x400).
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1. 4m i
Figure 15(A) Endocervical adenocarcinoma, intestinal type, showing atypical columnar
cells with numerous flask shaped goblet cells and intraluminal extracellular mucin
(H&E,x200). (B) A higher power of the same lesion(H&E,x400).
97
Figure jg (A) A poorly differentiated endocervical adenocarcinoma, signet-ring cell type,
showing a solid area of the tumour formed of signet-ring-like cells with intracellular mucin
(H&E,x200). (B) A higher power of the same lesion(H&E,x400).
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Figurel7(A) A poorly differentiated glassy cell carcinoma,form of adenosquamous
carcinoma,showing sheets of large cells with abundant eosinophilic, ground-glass
or finely granular cytoplasm, prominent cell borders, large nuclei with prominent
nucleoli, and a stromal inflammatory response (H&E, x200) .(B) A higher power of
same lesion (H&E,x400).
Figure 18(A) Malignant endocervical glands showing gradual thinning of the endocervical
columnar epithelium until basement membrane destroyed and stromal invasion started
(elastic band ).Note, the gradual sequence of the process 1,2,then 3. (H&E,x200). (B) A high¬
er power of the same lesion(H&E,x400).
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Chapter 2
Validation of Tissue Microarray Technology
2.1 Tissue microarray technology as a new tool for cervical adeno¬
carcinoma study
The recent development of tissue microarray technology has potentiated large-scale
retrospective cohort studies using archival formalin-fixed, paraffin-embedded tissues.
A major obstacle to broad acceptance of microarrays is that they reduce the amount of
tissue analyzed from a whole tissue section to a disk, 0.6 mm in diameter (Fig. 19-24)
that may not be representative. One of the aims of this study was to evaluate whether
tissue microarray technology is adequately representative of the histopathology of
cervical adenocarcinomas using H&E stain, and of the expression of eight common
antigens in cervical adenocarcinomas. The staining of 2 paired TMA cores and the
whole tissue sections from which they were derived were examined and compared to
each other.
With respect to how many cores are required to adequately represent a cervical
adenocarcinoma histologically, each core was analyzed separately and in relation to
its original whole section. We found that histological subtype and degree of
differentiation were accurately represented in all cases when two duplicate cores were
examined, and it was possible to determine histological subtype and degree of
differentiation from examination of the TMA core alone, but this always needed to be
confirmed by reference to the original section (Fig. 25-32). This is not surprising since
the areas are being specifically chosen and this process was performed by a
gynaecological pathologist. In cases of adenocarcinoma-in-situ, early invasive
adenocarcinoma and well differentiated adenocarcinoma; it was often not possible
from the TMA cores to determine whether the lesion was invasive or in situ. This is
not surprising, as the histological criteria for diagnosis of invasive disease are often
focal. Other important histological features that rely on extensive tissue sampling,
such as lymphovascular space invasion, can not be diagnosed reliably in TMA cores.
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With respect to antigen expression, we found that two paired TMA cores gave
comparable results to analysis of a whole tissue section in more than 97% of cases
(Figures 40-60). Microarrays and the original block from which they were derived
were stained for carcinoembryonic antigen (CEA), Cytokeratin7 (CK7),
Cytokeratin20 (CK20), oestrogen receptor (ER), progesterone receptor (PgR), MIB-1
proliferation marker, and p53 suppressor gene antigens. These antigens were chosen,
in part because they are potentially useful in diagnostic specimens of cervical
adenocarcinoma. However, phosphatase and tensin homolog deleted on chromosome
ten (PTEN) was chosen to evaluate it in differential diagnosis between primary
endocervical adenocarcinoma and primary endometrial adenocarcinoma. Analysis of
those antigens revealed that the average staining of the microarray cores agreed with
the whole-section analysis. However, in small number of these cases, one TMA core
was discordant with the average staining pattern of the whole section but the other
TMA core was concordant. In such cases, analysis of two paired cores was necessary.
Ifpositive staining was identified in a minimum of two cores, the case was considered
positive. Thus, analysis of two paired TMA cores provided staining results that were
consistent with the original whole section in about 97% of cases (Table 20).
Therefore, generally, the average staining pattern agreed with the whole section in
each.






Positive Cases Negative Cases
N % N %
CK7 3 136 132 97% 4 3%
CK20 5 134 4 3% 130 97%
CEA 3 136 92 68% 44 32%
ER 2 137 64 47% 73 53%
PgR 4 135 50 37% 85 63%
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MIB1 5 134 119 89% 15 11%
PTEN 2 137 121 88% 16 12%
P53 4 135 37 27% 98 73%
Table 20 showing immunohistochmical results of eight antigens for 139 patients with
cervical adenocarcinomas using TMAs. Number of positive, negative, available and
not available cases in each antigen.
For the expression of different antigens in cervical adenocarcinoma, each core was
analyzed separately and graded as either positive or negative. The average chance of
correctly calling each case was calculated. In the majority of cases, staining was
uniform across all the cores and consequently the chance of adequately representing
the tumour in each core was 100% to match that of the whole sections from which it
came. The results of this analysis demonstrated that, despite the variability of antigen
expression between cores, analysis of a single readable core would match the staining
pattern of an entire section more than 97% of the time. Analysis of two paired TMA
cores achieved greater than 97% representation.
2.2 Immunohistochemical Results of Cervical Adenocarcinomas
Using TMA Technology
2.2.1 General Immunohistochemical profile
There were 139 patients with cervical adenocarcinomas, excluding results from
second sample for 22 patients with two samples, used in this study. They consisted of
20 patients with adenocarcinoma-in-situ and 119 with invasive adenocarcinoma. The
types of invasive adenocarcinoma are presented in chapter 1 (1.1). Excluding results
from second sample for 22 patients with two samples, immunohistochemical results
for 139 patients with cervical adenocarcinomas using tissue microarray are
summarised in table 22.
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After reviewing and comparing the immunohistochemical results of the first sample
with that of the second sample of the same patient, it was found that, for the 22
patients with two samples, there was no significant difference between the two
samples with respect to immunohistochemical staining. These were therefore
excluded from the analysis.
After comparing the immunohistochemical staining of normal cervical tissues which
were taken from patients suffering from different non-neoplastic cervical pathologies
with that of the normal cervical glands samples which were identified and taken from
cervical adenocarcinomas cases, it was found that there was no significant difference
between the two groups with respect to immunohistochemical staining.
2.2.2 Cytokeratin7 (CK7)
Immunohistochemical staining for CK7 was confined to cytoplasm only. Cytoplasm
of the malignant endocervical cells was stained diffusely. Generally, the staining
reaction of the endocervical cells was of strong intensity. There were 3 patients where
CK7 result was not available. In the other 136 patients the result was negative for 4
(3%) and positive for 132 (97%). In normal endocervical glands, there was diffuse
delicate membrane staining, but much of the cytoplasm was unstained. This is in
contrast to cells of AIS and invasive adenocarcinoma, where there was diffuse strong
cytoplasmic staining. Endocervical stromal cells were negative with CK7 and there
was no positivity in all kinds of stromal cells .There was diffuse cytoplasmic staining
ofpositive controls in all cases but no staining of negative controls.
2.2.2i Adenocarcinoma in situ
All cases of adenocarcinoma in situ (eighteen of 139 patients) (100%), excluding 2
patients where CK7 result was not available, were positive with CK7. CK7 results of
adenocarcinoma in situ in comparison to those of invasive adenocarcinoma are
presented in table 21.
2.2.2U Invasive adenocarcinoma
Excluding one patient from 119 patients with invasive adenocarcinoma where CK7
result was not available, 114 of 118 patients (97%) with invasive cervical adeno¬
carcinoma were positive with CK7 and the other 4 patients (3%) were negative. CK7
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results of all subtypes of invasive adenocarcinoma in comparison to each other and in
comparison to adenocarcinoma in situ were presented in table 29.
2.2.2iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. There was 1 patient where CK7 result was not
available. In the other 15 patients, the result was negative for 1 (7%) and positive for
14 (93%).
2.2.3 Cytokeratin 20 (CK20)
The pattern of immunohistochemical staining for CK20 was cytoplasmic only. The
cytoplasm of the malignant endocervical cells was stained diffusely. Generally, the
staining reaction of the endocervical cells was of very weak intensity. When present,
there were 5 patients where CK20 result was not available. In the other 134 patients
the result was negative for 130 (97%) and positive for 4 (3%). Normal endocervical
glands were negative with COO and there was no positivity in all cells. Endocervical
stromal cells were negative with COO and there was no positivity in all kinds of
stromal cells. There was diffuse cytoplasmic staining of positive controls in all cases
but no staining of negative controls.
2.2.3i Adenocarcinoma in situ
All cases of pure adenocarcinoma in situ (eighteen of 139 patients) (100%), excluding
2 patients where COO result was not available, were negative with COO. COO
results of adenocarcinoma in situ in comparison to those of invasive adenocarcinoma
were presented in table 22.
2.2.3ii Invasive adenocarcinoma
Excluding 3 patients from 119 patients with invasive adenocarcinoma where COO
result was not available, 112 of 116 patients (97%) with invasive cervical
adenocarcinoma were negative with COO and the other 4 patients (3%) were
positive. COO results of all subtypes of invasive adenocarcinoma in comparison to
each other and in comparison to adenocarcinoma in situ are presented in table 30.
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2.2.3iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive
adenocarcinoma, excluding results from 22 patients with two samples, met criteria for
FIGO stage IAi carcinoma of the cervix. There was 1 patient where CK20 result was
not available. In the other 15 patients the result was negative for 14 (93%) and
positive for 1 (7%).
2.2.4 Carcinoembryonic antigen (CEA)
Immunohistochemical staining for CEA was cytoplasmic. The cytoplasm of the
malignant endocervical cells was stained diffusely. However, in some cases, there was
diffuse delicate luminal staining with CEA but this positivity was considered as
negative if there was no cytoplasm staining. Generally, the staining reaction of the
endocervical cells was of strong intensity. There were 3 patients where CEA result
was not available. In the other 136 patients the result was negative for 44 (32%) and
positive for 92 (68%). Normal endocervical glands were negative with CEA and there
was no positivity in all cells .Endocervical stromal cells were negative with CEA and
there was no positivity in all kinds of stromal cells .There was diffuse cytoplasmic
staining of positive controls in all cases but no staining of negative controls.
2.2.4i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where CEA result
was not available, 13 of 18 patients (72%) with adenocarcinoma in situ were positive
with CEA and the other 5 patients (28%) were negative. CEA results of
adenocarcinoma in situ in comparison to those of invasive adenocarcinoma are
presented in table 23.
2.2.4ii Invasive adenocarcinoma
Excluding one patient from 119 patients with invasive adenocarcinoma where CEA
COO result was not available, 79 of 118 patients (67%) with invasive cervical
adenocarcinoma were positive with CEA and the other 39 patients (33%) were
negative (table 21). CEA results of all subtypes of invasive adenocarcinoma in
comparison to adenocarcinoma in situ are presented in table 31.
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2.2.4iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. The CEA result was negative for 5 (31%) and
positive for 11 (69%) patients.
2.2.5 Oestrogen receptors (ER)
Immunohistochemical staining for ER was nuclear only. The nuclei of the malignant
endocervical cells were stained diffusely either as fine or as coarse granular dots.
Generally, the staining reaction of the malignant endocervical cells was of strong
intensity. There were 2 patients where ER result was not available. In the other 137
patients the result was negative for 73 (53%) and positive for 64 (47%). In all cases,
normal endocervical cells and normal stromal cells of the cervix stained weakly
positive for ER. The staining pattern in the tumour cells was stronger than that
observed in the normal endocervical cells and was restricted to the nucleus. In
addition, the intensity and distribution of ER staining in the tumour tissue were more
heterogeneous than that observed in the normal tissues. There was strong nuclear
staining ofpositive controls in all cases but no staining of negative controls.
2.2.5i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where ER result
was not available, 13 of 18 patients (72%) with adenocarcinoma in situ were negative
with ER and the other 5 patients (28%) were positive. ER results of adenocarcinoma
in situ in comparison to those of invasive adenocarcinoma were presented in table 24.
2.2.5 ii Invasive adenocarcinoma
59 of 119 patients (50%) with invasive cervical adenocarcinoma were positive with
ER and the other 60 patients (50%) were negative. ER results of all subtypes of
invasive adenocarcinoma in comparison to each other and in comparison to
adenocarcinoma in situ are presented in table 32.
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2.2.5iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage LA-i carcinoma of the cervix. The ER result was negative for 7 (44%) and
positive for 9 (56%) patients.
2.2.6 Progesterone receptors (PgR)
Immunohistochemical staining for PgR was nuclear, except for the cytoplasm of
goblet cells in intestinal-type adenocarcinoma, signet-ring cells in signet-ring-type
adenocarcinoma, and normal endocervical glands from abnormal tissues, which
stained diffusely. The nuclei of the malignant endocervical cells were stained
diffusely with PgR either as fine or as coarse granular dots. Generally, the staining
reaction of the malignant endocervical cells was of strong intensity. There were 4
patients where PgR result was not available. In the other 135 patients the result was
negative for 85 (63%) and positive for 50 (37%). In all cases, normal endocervical
cells and normal stromal cells of the cervix stained weakly positive for PgR.The
staining pattern in the tumour cells was stronger than that observed in the normal
endocervical cells and was restricted to the nucleus. In addition, the intensity and
distribution of PgR staining in the tumour tissue were more heterogeneous than that
observed in the normal tissues.There was strong nuclear staining of positive controls
in all cases but no staining ofnegative controls.
2.2.6i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where PgR result
was not available, 11 of 18 patients (61%) with adenocarcinoma in situ were negative
with PgR and the other 7 patients (39%) were positive. PgR results of adeno¬
carcinoma in situ in comparison to those of invasive adenocarcinoma were presented
in table 25.
2.2.6ii Invasive adenocarcinoma
Excluding 2 patients from 119 patients with invasive adenocarcinoma where PgR
result was not available, 74 of 119 patients (63%) with invasive cervical
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adenocarcinoma were negative with PgR and the other 43 patients (37%) were
positive. PgR results of all subtypes of invasive adenocarcinoma in comparison to
each other and in comparison to adenocarcinoma in situ were presented in table 33.
2.2.6iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. The PgR result was negative for 9 (56%) and
positive for 7 (44%) patients.
2.2.7 MIB1 proliferation marker
Immunohistochemical staining for MIB1 was nuclear only. The nuclei of the
malignant endocervical cells were stained diffusely either as fine or as coarse granular
dots. Generally, the staining reaction of the malignant endocervical cells was of strong
intensity. There were 5 patients where MIB1 result was not available. In the other 134
patients the result was negative for 15 (11%) and positive for 119 (89%). Normal
endocervical glands were negative with MIB1. In all cases, normal endocervical
stromal cells were negative with MIB1 and there was no positivity in all kinds of
stromal cells. There was marked heterogeneity with respect to the intensity and the
distribution of MIB1 staining pattern between and within tumours in the same section.
There was strong nuclear staining of positive controls in all cases but no staining of
negative controls.
2.2.7i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where MIB1 result
was not available, 17 of 18 patients (94%) with adenocarcinoma in situ were positive
with MIB1 and only one patient (6%) was negative. MIB1 results of adenocarcinoma
in situ in comparison to those of invasive adenocarcinoma were presented in table 26.
2.2.7ii Invasive adenocarcinoma
Excluding 3 patients from 119 patients with invasive adenocarcinoma where MIB1
result was not available, 102 of 119 patients (88%) with invasive cervical
adenocarcinoma were positive with MIB1 and the other 14 patients (12%) were
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negative MIB1 results of all subtypes of invasive adenocarcinoma in comparison to
each other and in comparison to adenocarcinoma in situ were presented in table 34.
2.2.7iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. The MIB1 result was negative for 4 (25%) and
positive for 12 (75%) patients
2.2.8 Phosphatase and tensin homolog deleted on chromosome ten
(PTEN)
Immunohistochemical staining for PTEN was nuclear only. The nuclei of the
malignant endocervical cells were stained diffusely either as fine or as coarse granular
dots. Generally, the staining reaction of the malignant endocervical cells was of strong
intensity. There were 2 patients where PTEN result was not available. In the other 137
patients the result was negative for 16 (12%) and positive for 121 (88%). In all cases,
normal endocervical cells and normal stromal cells of the cervix stained weakly
positive for PTEN. The staining pattern in the tumour cells was stronger than that
observed in the normal endocervical cells and was restricted to the nucleus. In
addition, the intensity and distribution of PTEN staining in the tumour tissue were
more heterogeneous than that observed in the normal tissues. There was marked
heterogeneity with respect to the intensity and the distribution of PTEN staining
pattern between and within tumours in the same section .There was strong nuclear
staining ofpositive controls in all cases but no staining of negative controls.
2.2.8i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where PTEA result
was not available, 16 of 18 patients (89%) with adenocarcinoma in situ were positive
with PTEN and the other 2 patients (11%) were negative. PTEN results of
adenocarcinoma in situ in comparison to those of invasive adenocarcinoma were
presented in table 27.
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2.2.8U Invasive adenocarcinoma
105 of 119 patients (88%) with invasive cervical adenocarcinoma were positive with
PTEN and the other 14 patients (12%) were negative PTEN results of all subtypes of
invasive adenocarcinoma in comparison to each other and in comparison to
adenocarcinoma in situ were presented in table 35.
2.2.8iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. The PTEN result was negative for 2 (13%) and
positive for 14 (88%) patients
2.2.9 p53 suppressor gene
Immunohistochemical staining for p53 was nuclear only. The nuclei of the malignant
endocervical cells were stained diffusely either as fine or as coarse granular dots.
Generally, the staining reaction of the malignant endocervical cells was of strong
intensity. There were 4 patients where p53 result was not available. In the other 135
patients the result was negative for 98 (73%) and positive for 37 (27%). In all cases,
normal endocervical cells and normal stromal cells of the cervix stained negative for
p53. There was marked heterogeneity with respect to the intensity and the distribution
of p53 staining pattern between and within tumours in the same section. There was
strong nuclear staining of positive controls in all cases but no staining of negative
controls. P53 overexpression is usually associated with frankly invasive cases. Using
the Fisher's Exact test, there was a significant statistical difference of p53 expression
between AIS and villoglandular papillary adenocarcinoma (p=0.014). However, there
were no significant statistical differences of p53 expression between AIS and the
other different subtypes of invasive adenocarcinoma (table 36).
2.2.9i Adenocarcinoma in situ
Excluding 2 patients from 20 patients with adenocarcinoma in situ where p53 result
was not available, 15 of 18 patients (83%) with adenocarcinoma in situ were negative
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with p53 and the other 3 patients (17%) were positive. p53 results of adenocarcinoma
in situ in comparison to those of invasive adenocarcinoma were presented in table 28.
2.2.9ii Invasive adenocarcinoma
Excluding 2 patients from 119 patients with invasive adenocarcinoma where p53
result was not available, 83 of 119 patients (71%) with invasive cervical
adenocarcinoma were negative with p53 and the other 34 patients (29%) were
positive. p53 results of all subtypes of invasive adenocarcinoma in comparison to each
other and in comparison to adenocarcinoma in situ were presented in table 36.
2.2.9iii Early invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive adeno¬
carcinoma, excluding results from 22 patients with two samples, met criteria for FIGO
stage IAi carcinoma of the cervix. The p53 result was negative for 13 (81%) and
positive for 3 (19%) patients.
Table 21. CK7 expression in AIS and invasive adenocarcinoma
CK7
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
Negative 0 0 4 3
Positive 18 100 114 97
Total 18 100 118 100
Table 21 showing no difference between adenocarcinoma in situ and invasive adeno¬
carcinoma with respect to CK7 using Fisher's exact test (p= 1.00). There were 3
patients where CK7 result was not available (2 adenocarcinoma-in-situ, 1 invasive
adenocarcinoma).
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Table 22. CK20 expression in AIS and invasive adenocarcinoma
CK20
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
Negative 18 100 112 97
Positive 0 0 4 3
Total 18 100 116 100
Table 22 showing no difference between adenocarcinoma in situ and invasive adeno¬
carcinoma with respect to CK20 using Fisher's exact test (p=1.00). There were 5
patients where CK20 result was not available (2 adenocarcinoma-in-situ, 3 invasive
adenocarcinoma.
Table 23. CEA expression in AIS and invasive adenocarcinoma
CEA
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
Negative 5 28 39 33
Positive 13 72 79 67
Total 18 100 118 100
Table 23 showing no significant c ifference between adenocarcinoma in situ anc
invasive adenocarcinoma with respect to CEA using Fisher's exact test (p= 0.79).
There were 3 patients where CEA result was not available (2 adenocarcinoma-in-situ,
1 invasive adenocarcinoma).
Table 24. ER expression in AIS and invasive adenocarcinoma
Adenocarcinoma in situ Invasive
ER
adenocarcinoma
N % N %
Negative 13 72 60 50
Positive 5 28 59 50 '
Total 18 100 119 100
Table 24 showing comparison between adenocarcinoma in situ and invasive adeno¬
carcinoma with respect to ER using Fisher's exact test (p=0.13). There were 2 patients
where ER result was not available (2 adenocarcinoma-in-situ).
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Table 25 PgR expression in AIS and invasive adenocarcinoma
PgR
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
Negative 11 61 74 63
Positive 7 39 43 37
Total 18 100 117 100
Table 25 showing no difference between adenocarcinoma in situ and invasive
adenocarcinoma with respect to PgR using Fisher's exact test (p=1.00). There were 4
patients where PgR result was not available (2 adenocarcinoma-in-situ, 2 invasive
adenocarcinoma).
Table 26. MIB-1 expression in AIS and invasive adenocarcinoma
Adenocarcinoma in situ Invasive
MIB1
adenocarcinoma
N % N %
Negative 1 6 14 12
Positive 17 94 102 88
Total 18 100 116 100
Table 26 showing comparison between adenocarcinoma in situ and invasive adenoc¬
arcinoma with respect to MIB1 using Fisher's exact test (p=0.69). There were 5
patients where MIB1 result was not available (2 adenocarcinoma-in-situ, 3 invasive
adenocarcinoma)
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Table 27. PTEN expression in AIS and invasive adenocarcinoma
PTEN
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
Negative 2 11 14 12
Positive 16 89 105 88
Total 18 100 119 100
Table 27 showing no difference between adenocarcinoma in situ and invasive
adenocarcinoma with respect to PTEN using Fisher's exact test (p=l .00).There were 2
patients where PTEN result was not available(2 adenocarcinoma-in-situ).
Table 28. p53 expression in AIS and invasive adenocarcinoma
Adenocarcinoma in situ Invasive
p53
adenocarcinoma
N % N %
Negative 15 83 83 71
Positive 3 17 34 29
Total 18 100 117 100
Table 28 showing no significant difference between adenocarcinoma in situ and
invasive adenocarcinoma with respect to p53 using Fisher's exact test (p=0.40). There
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Figyre 19 showing A- TMA paraffin block
B- TMA slide stained with H&E
11^ TBIHI
Figure 20 (A) Two H&E-stained tissue-microarray cores biopsies specimens from
liver (above) which used as a slide marker and from normal endocervical tissue
(below) (H&E, xlOO). (B) H&E-stained tissue-microarray core biopsy specimen
showing normal endovervical glands (H&E, xlOO).
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Figure 21 Sequence of H&E-stained tissue-microarray core biopsy sampling
from normal endocervical tissue. (A) Before sampling (H&E, x200).(B) After
tissue core was removed (H&E, x200).(C) The core (H&E, xlOO).
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Figure 22 Sequence of H&E-stained tissue-microarray core biopsy sampling from
endocervical tissue with adenocarcinoma in situ (AIS).(A) Before sampling (H&E,




Figure 23 Sequence of H&E-stained tissue-microarray core biopsy sampling from
endocervical tissue with invasive adenocarcinoma .(A)Before sampling (H&E, x200).
(B) After tissue core was removed (H&E, x200).(C) The core (H&E, x 100).
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Figure 25 (A) H&E-stained tissue-microarray core biopsy specimen from moderate
differentiated endocervical adenocarcinoma, usual type (H&E,xlOO).(B)A higher
power of the the above core showing The glands are lined by cells with atypical nuclei
and deeply eosinophilic cytoplasm (H&E, x400).
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Figure 26 (A) H&E-stained tissue-microarray core biopsy specimen from adenosquamous
carcinoma (H&E, xlOO).(B) A higher power of the the above core showing cohesion
between both the individual cells of squamous(left) and glandular elements(right)
which have malignant features (H&E, x400).
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Figure 27 (A) H&E-stained tissue-microarray core biopsy specimen from well
differentiated villoglandular papillary adenocarcinoma (VGC) (H&E,xlOO).
(B)A higher power of the the above core showing a broad papillae, with
fibrovascular cores covered by a mildly atypical columnar epithelium (H&E, x400).
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Figure 28 (A) H&E-stained tissue-microarray core biopsy specimen from endocervical
adenocarcinoma, Microglandular carcinoma,(H&E,xl00). (B) A higher power of the
above core showing a single layer of atypical oval nuclei surrounding each glandular
lumen with very little amount of stroma inbetween (H&E,x400). Note,no stratification
of lining epithelium of the glands. 133
A
Figure 29 (A) H&E-stained tissue-microarray core biopsy specimen from poorly
differentiated clear cell carcinoma (H&E, xlOO). (B)A higher power of the the above
core showing a sheets of large cells with large nuclei with prominent nucleoli, and




Figure 30 (A) H&E-stained tissue-microarray core biopsy specimen from poorly
differentiated endocervical adenocarcinoma, signet-ring cell type, (H&E, xlOO).
(B) A higher power of the the above core showing a solid area of the tumour formed
of signet-ring-like cells with intracellular mucin (H&E,x400).
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IIS
Figure 31 (A) H&E-stained tissue-microarray core biopsy specimen from adenoid
basal carcinoma (H&E,x200). (B)A higher power of the the above core showing a





Figure 32 (A) H&E-stained tissue-microarray core biopsy specimen from poorly
differentiated glassy cell carcinoma (H&E, xlOO). (B)A higher power of the above
core showing a sheets of large cells with abundant eosinophilic, ground-glass or
finely granular cytoplasm, prominent cell borders, large nuclei with prominent
nucleoli, with numerous mitotic figures(circles) (H&E, x400).
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Figure 33 Three CK7-stained tissue-microarray cores biopsies specimens. (A) Normal endo-
cervical glands exhibit no staining (xlOO).(B) AIS exhibits strong positive cytoplasmic staining
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Figure 34 Three tissue-microarray cores biopsies specimens exhibit no staining with CK20.
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Figure 35 Three progesterone receptors (PgR) -stained tissue-microarray cores biopsies
specimens. (A) Normal endocervical glands exhibit normal weak positive nuclear staining
(xlOO).(B) AIS exhibits strong positive nuclear staining (xlOO).(C) Invasive adenocarcino¬



















































Figure 38 Invasive adenocarcinoma(A)The whole tissue section ,after tissue core
was removed , exhibits positive nuclear staining with PTEN (x200).(B)The tissue-
toicroarray core biopsy specimen exhibits the same positive reaction with PTEN
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Figure 40 (A) CK7-stained tissue-microarray core biopsy specimen from adenocar¬
cinoma in situ exhibits positive staining of the cytoplasm with CK7 (H&E,xl00).(B)
A higher power of the above core (H&E, x400).
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CEA
Figure 41 (A) CEA-stained tissue-microarray core biopsy specimen from adenoc¬
arcinoma in situ exhibits no cytoplasmic staining with CEA (H&E, xlOO).(B) A hi¬
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Figure 42 (A) ER-stained tissue-microarray core biopsy specimen from adenocar¬
cinoma in situ exhibits no nuclear staining with ER (H&E, xlOO).(B) A higher po¬
wer of the above core (H&E, x400).
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A
Figure 43 (A) ER-stained tissue-microarray core biopsy specimen from endocervical
adenocarcinoma, usual type, exhibits positive nuclear staining with ER (H&E, xlOO).
(B) A higher power of the above core (H&E, x400). Note stromal cells are positive.
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A
Figure 44 (A) CK7-stained tissue-microarray core biopsy specimen from poorly
differentiated adenosquamous carcinoma exhibits positive staining of the cytoplasm
with CK7 (H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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Figure 45 (A) PTEN-stained tissue-microarray core biopsy specimen from poorly
differentiated adenosquamous carcinoma exhibits positive nuclear staining with
PTEN (H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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Figure 46 (A) CK7-stained tissue-microarray core biopsy specimen from well
differentiated villoglandular papillary adenocarcinoma (VGC) xhibits positive
staining of the cytoplasm with CK7 (H&E, xlOO).(B) A higher power of the
above core (H&E, x400).
A
Figure 47 (A) ER-stained tissue-microarray core biopsy specimen from well
differentiated villoglandular papillary adenocarcinoma (VGC) exhibits positive




Figure 48 (A) PgR-stained tissue-microarray core biopsy specimen from well
differentiated villoglandular papillary adenocarcinoma (VGC) exhibits positive
nuclear staining with PgR (H&E, xlOO).(B) A higher power of the above core
(H&E, x400).
A
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Figure 49 (A) PTEN-stained tissue-microarray core biopsy specimen from well differ¬
entiated minimal deviation endocervical adenocarcinoma (MDA) exhibits positive nuc¬
lear staining with PTEN (H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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Figure 50 (A) MIB-1-stained tissue-microarray core biopsy specimen from endocervical
adenocarcinoma, Microglandular carcinoma, exhibits positive nuclear staining with
MIB-1 (H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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CK7
Figure 51 (A) CK7-stained tissue-microarray core biopsy specimen from poorly diffe¬
rentiated clear cell carcinoma exhibits positive staining of the cytoplasm with CK7
(H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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Figure 52 (A) CK7-stained tissue-microarray core biopsy specimen from endocervical
adenocarcinoma, intestinal type , exhibits positive staining of the cytoplasm with CK7
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Figure 53 (A) PTEN-stained tissue-microarray core biopsy specimen from endocervical
adenocarcinoma , intestinal type, exhibits positive nuclear staining with PTEN (H&E,
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Figure 54 (A) CK20-stained tissue-microarray core biopsy specimen from poorly
differentiated endocervical adenocarcinoma, signet-ring cell type, exhibits no cyt¬
oplasmic staining with CK20 (H&E, xlOO). (B) A higher power of the above core
(H&E, x400). 159
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Figure 55 (A)PTEN-stained tissue-microarray core biopsy specimen from poorly
differentiated endocervical adenocarcinoma , signet-ring cell type, exhibits no
nuclear staining with PTEN (H&E, xlOO). (B) A higher power of the above core
(H&E, x400). Note, stromal cells are positive.
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Figure 56 (A) p53-stained tissue-microarray core biopsy specimen from poorly differ¬
entiated endocervical adenocarcinoma, signet-ring cell type, exhibits no nuclear stai¬
ning with p53 (H&E, xlOO).(B) A higher power of the above core (H&E, x200).
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Figure 57 (A) CK7-stained tissue-microarray core biopsy specimen from adenoid
basal carcinoma exhibits positive staining of the cytoplasm with CK7 (H&E, xlOO).
(B) A higher power of the above core (H&E, x400).
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Figure 58 (A) CEA-stained tissue-microarray core biopsy specimen from adenoid
basal carcinoma exhibits positive cytoplasmic staining with CEA (H&E, xlOO).(B)
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Figure 59 (A)CK20-stained tissue-microarray core biopsy specimen from poorly
differentiated glassy cell carcinoma exhibits no cytoplasmic staining with CK20
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Figure 60 (A) PTEN-stained tissue-microarray core biopsy specimen from poorly
differentiated glassy cell carcinoma exhibits positive nuclear staining with PTEN
(H&E, xlOO).(B) A higher power of the above core (H&E, x400).
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Chapter 3
Human papilloma viruses 16 and 18 in cervical adenocarcinoma
3.1 HPV Detection and Typing
A total of 257 paraffin-embedded, formalin-fixed tissues of 139 different patients with
cervical adenocarcinomas, excluding results from second sample for 22 patients with
two samples, and 16 normal cervical biopsies were used in this study. The 139
patients with cervical adenocarcinomas consisted of 20 patients with adenocarcinoma-
in-situ and 119 with invasive adenocarcinoma. The types of invasive adenocarcinoma
are presented in the following table.
Table summaries types of invasive adenocarcinoma included in this study
Type of Invasive Adenocarcinoma Number
Adenocarcinoma NOS, 50
Villoglandular papillary adenocarcinoma, 23
Adenosquamous carcinoma, 22
Minimal deviation adenocarcinoma 8
Other types of adenocarcinoma.
The other types of adenocarcinoma were;
• Microglandular adenocarcinoma,
• Endometroid adenocarcinoma,
• Clear cell carcinoma
• Intestinal type adenocarcinoma
• Signet -ring cell adenocarcinoma








HPV DNA was detected by PCR test using type specific primers from the E6 gene
and E7 gene of HPV type 16 and HPV type 18. Out of a total of 257 cervical biopsies
from 139 women with various cervical adenocarcinomas lesions, HPV DNA was
identified in 87 cases (62.6%) in which, HPV16 was positive for 65 (47%) patients
(Figure 63) and HPV18 was positive for 41 (29%) patients (Figure 64). Genotyping
by RFLP and PCR revealed that, HPV type 16 was the most frequent type of infection
comprising 46 cases (33%), followed by HPV type 18 in 22 cases (16%), and HPV
typel6 and HPV type 18 in 19 cases (14%). There were 52 (38%) of 139 of patients
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with various cervical adenocarcinomas lesions with HPV typel6 and HPV type 18
both negative. HPV typing in all cases of 16 normal cervical biopsies revealed
negative with both HPV typel6 and HPV type 18.
After reviewing and comparing the HPV infection results of the first sample with that
of the second sample of the same patient, we found that, for the 22 patients with two
samples, there was no significant difference between the two samples with respect to
HPV infection. There were therefore excluded from further analysis.
Regarding results of LCM method from the most presentable area of the whole tissue
tumour section, sampling for 87 patients with positive HPV in their paraffin
embedded blocks, HPV type 16 was the most frequent type of infection comprising 21
cases, followed by HPV typel6 and HPV type 18 in 3 cases. HPV type 18 in 1 case.
There were 62 patients from 87 with HPV type 16 and HPV type 18 both negative
(Fig. 61 & 62).
3.2 Adenocarcinoma in situ
In the 20 in situ adenocarcinomas patients, there were 7/20 (35%) with HPV 16 only
positive, 5/20 (25%) with HPV 18 only positive, 3/20 (15%) with both HPV 16 and
HPV 18 positive, and the remaining 5/20 (25%) with both HPV 16 and HPV 18
negative. There was no significant difference between adenocarcinoma in situ and
invasive adenocarcinoma with respect to HPV16 and HPVI8 infection using Chi-
square test (p=0.53) was presented in table 37 .
3.3 Invasive Adenocarcinoma
In the 119 invasive adenocarcinomas patients, there were 39/119(33%) with HPV 16
only positive, 17/119 (14%) with HPV 18 only positive, 16/119 (13%) with both HPV
16 and HPV 18 positive, and the remaining 47/119 (39%) with both HPV 16 and HPV
18 negative. The prevalence of HPV varied with different histological subtypes but
there was no significant difference between all subtypes of invasive adenocarcinoma
in comparison to each other and in comparison to AIS with respect to prevalence of
HPVI6 and HPV18 infection using Chi-square test (p= 0.12) was summarised in table
38.
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3.4 Early invasive adenocarcinoma
In the 16 early invasive adenocarcinomas patients, there were 5/16 (31%) with
HPV16 only positive, 3 (19%) with HPV18 only positive and 2/16 (13%) with
HPV16 and HPV18 both positive, and 6/16 (38%) patients with HPV16 & HPV18
both negative. In general, early invasive adenocarcinomas patients revealed HPV16
was negative for 9 (56%) and positive for 7 (44%) patients, and HPV18 was negative
for 11 (69%) and positive for 5 (31%) patients.
Table 37. HPV 16 and 18 infection in AIS and subtypes of invasive adenocarcinoma.
HPV 16 and HPV 18
Adenocarcinoma in situ Invasive
adenocarcinoma
N % N %
HPV16 -ve and HPV18 -ve 5 25 47 39
HPV16 +ve and HPV18 -ve 7 35 39 33
HPV16 -ve and HPV18 +ve 5 25 17 14
HPV16 +ve and HPV18 +ve 3 15 16 13
Total 20 100 119 100
Table 37 showing no significant difference between adenocarcinoma in situ and




































































































































































































































Figure 63. HPV type 16 in Cervical Adenocarcinoma
Figure 63 showing determination and confirmation of HPV type 16 by RFLP
pattern and PCR using specific primers. Sample was taken from the
whole tissue section of cervical adenocarcinoma. Using this method,
an HPV- 16 specific pattern is evident as 157 nt and 81 nt fragment
and its total length is 238bp on a 2% agarose gel.
Lane M: Kilobase DNA Marker
Lane 1 : PCR products of HPV 16 extracted from paraffin section (Uncut)
Lane 2 : A Fa II fragments of lane 1 (Cut)
Lane 3 : Positive control SiHa (Uncut)
Lane 4 : AVa II fragments of lane 3 (Cut)
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Figure 64. HPV type 18 in Cervical Adenocarcinoma
300bp
200bp
Figure 64 showing determination and confirmation of HPV type 18 by RFLP
pattern and PCR using specific primers. Sample was taken from the
whole tissue section of cervical adenocarcinoma. Using this method,
An HPV-18 specific pattern is evident as 172 nt and 96nt fragments
and its total length is 268bp on a 2% agarose gel.
Lane M : Kilobase DNA Marker
Lane 1 : Positive control HeLa (Uncut)
Lane 2 : A Va II fragments of lane 1 (Cut)
Lane 3 : PCR products of HPV 18 extracted from paraffin section (Uncut)




Morphological and Histopathological study
1.1 Invasive endocervical adenocarcinoma
There is evidence that there is a real increase in the incidence of malignant and
premalignant endocervical glandular lesions of the cervix which are therefore
assuming increasing importance in diagnostic surgical pathology (McCluggage,
2003). There is also a relative increase mainly due to efficient cervical cytological
screening for preinvasive squamous cell carcinoma. Figures for the proportion of
invasive adenocarcinomas of cervix range from 6% in the 1950s to 26% in the 1990s
in different studies (Nieminen et al, 1995; Rutledge et al 1975; Kjorstad 1977;
Shingleton et al 1995). This increased incidence may be only apparent and attributable
to better diagnosis with mass screening programmes (Leminen et al 1990; Hopkins et
al 1988), or real, particularly in women under age of 35 (Horowitz et al 1988; Angel
et al 1992). HPV infection, particularly HPV 18, is the most widely recognised
aetiological factor (Brand et al 1988). Focus has also been put on other factors
affecting the incidence of cervical adenocarcinoma including oral contraceptives,
diabetes, obesity and pauciparity (Schwartz et al 1986; Brinton et al 1993), although
these factors can not fully explain the observed incidence pattern for invasive
adenocarcinoma (Zheng et al 1996), and the pathogenic mechanism remains unclear.
In this series 139 patients with cervical adenocarcinomas were studied, consisted of
20 patients with adenocarcinoma-in-situ and 119 with invasive adenocarcinoma.
Sixteen of 119 patients with invasive adenocarcinoma had early invasive
adenocarcinoma which met criteria for FIGO stage IAi carcinoma of the cervix. This
mix of cases was a result of a computerized tumour registry search which conducted
for all patients diagnosed with invasive cervical adenocarcinoma at the University of
Edinburgh, Pathology Department from 1991 to 2001. In addition, twenty cases of
adenocarcinoma in situ were used as a sample to compare with invasive cases.
Unlike squamous cell carcinoma, frequently diagnosed after an abnormal cervical
smear, adenocarcinoma presents in a variety of different ways. The identification of
early invasion in cervical glandular lesions may not always be possible and in 10-15%
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of cases the pathologist may be uncertain. CGIN and even invasive cervical
adenocarcinoma can be confused with a wide variety of benign endocervical glandular
lesions particularly the mucinous variant of minimal deviation adenocarcinoma
(McCluggage et al, 2003).
The annual growth rate of cervical adenocarcinoma in young women aged 25-49
years in both England and Scotland was about 10% for cohorts born between 1935
and 1955 (Vizcaino et al 1998). In the present study, ages of the patients at time of
sample ranged from 23 to 89 years old. 58 (42%) patients were <=39 years old, 42
(30%) were 40 - 50 years old, and 39 (28%) were >= 51 years old. While the outcome
of our patients was not studied, the effect of age as a prognostic factor is widely
debated. For some authors, age influences overall survival (Kilgore et al 1988), but in
other series (Angel et al 1992; Hopkins et al 1991) no effect has been found.
Clinical stage usually determines the prognosis of cervical adenocarcinoma. However
it is equally well known that the clinical course of patients within the same stage of
disease may differ considerably (Graflund et al, 2002). In our series, based on
pathology reports, It was found the FIGO stage of cancer was Ial for 16 (13%), Ia2
for 11 (9%) and lb or greater for the remaining of the 119 patients with invasive
adenocarcinoma. However Graflund et al, 2002 found stage I lesions in 63.8% of
cases, stage II in 13.4% and stage III-IV in 12.8%. Mixed forms with an epidermoid
component occur in 13% (Tamimi et al 1982) to 40% (Fu et al 1982) and many
authors have been unable to demonstrate poorer prognosis (Leminen et al 1990;
Korhonen 1984; Harrison et al 1993).
In the current series, with respect to histological grading of the tumours, it was found
of the 119 patients with invasive adenocarcinoma there were 54 (45%) patients with
grade 1 (well differentiated) cancer, 36 (30%) with grade 2 (moderately
differentiated) cancer, and 29 (24%) with grade 3 (poorly differentiated) cancer. Many
investigators have reported that poorly differentiated adenocarcinoma showed a poor
prognosis (Eifel et al 1990; Berek et al 1985), whereas others have found histological
differentiation to be of little prognostic value (Leminen et al, 1990; Milsom et al
1983). However Kilgore and Helm,(1990) include it among prognosis factors to
define risk groups. Other factors influencing survival have been explored, such as
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lymph-vascular invasion (Siago et al, 1986; Matthews et al, 1993).and stromal
invasion of the cervix (Hopkins et al, 1991; McLellan et al 1994; Berek et al 1985;
Kilgore and Helm, 1990). In our study a stromal response was absent in 28 (20%)
patients, mild in 47 (34%) patients, moderate in 39 (28%) patients, and intense in 25
(18%) patients. The focality could not be determined for 76 (64%) of the 119 patients
with invasive adenocarcinoma. For the 43 patients where the focality was determined
6 had one focus, 4 had two foci, 4 had three foci, and 29 had more than three foci.
Moreover lymph-vascular invasion were reported in 9 cases of 119 of invasive
adenocarcinomas.
Conclusion
In view of the increasing incidence of adenocarcinoma of the cervix in young women,
separate monitoring of incidence and mortality for adenocarcinoma of the cervix
remains necessary. Further studies on the causes of cervical adenocarcinomas are
required to elucidate the reasons behind this increase.
1.2 Early Invasive Adenocarcinoma (Microinvasive Adenocarcinoma)
Patients with microinvasive adenocarcinoma who meet criteria for FIGO stage IAi
cervical carcinoma have disease limited to the cervix, and excellent prognoses. Many
investigators reported clinical outcomes of patients with microinvasive cervical
adenocarcinoma, but none have rigorously defined lesions that might be managed
conservatively (Kaku et al 1997; Ostor et al 1997; Kaspar et al 1993). In this study, it
was found that 16 of 119 patients with invasive adenocarcinoma had early invasive
adenocarcinoma and met criteria for FIGO stage IAi carcinoma of the cervix. Kaku et
al (1997) reviewed 30 cases of microinvasive cervical adenocarcinoma and among 21
with less than 3 mm invasion in their study, none had evidence of disease beyond the
cervix, and none developed recurrent disease. In a clinicopathologic study of 77
women with microinvasive cervical adenocarcinoma, Ostor et al (1997) found disease
confined to the cervix and no recurrences among 43 patients with up to 3 mm
invasion. Kaspar et al (1993) reported two recurrences among 36 patients with less
than 3 mm invasion, yet both were considered stage IB] because of tumour width
exceeding 7 mm.
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In this study, based on the pathology reports, it was found that all FIGO stage la
tumours were histopathologic grade 1 well differentiated. The tumours showed three
patterns of early invasive adenocarcinoma: small glandular budding arising from
HCGIN, infiltrating the stroma with an associated inflammatory reaction, confluent
glands in a complex pattern with little or no intervening stroma, and intraluminal
tufting resulting in a papillary pattern. Usually, the early invasive adenocarcinoma
was recognized by loss of the normal smooth peripheral glandular outlines, prominent
cribriform and/or solid areas, and the architectural complexity of endocervical glands
including deep invagination. Similar results were reported by Mulvany & Ostor,
(1997), Ostor et al (1997), and Rollason et al, (1989). Moreover, it was noticed that
there was a gradual thinning of the glandular epithelium until the basement membrane
destroyed and stromal invasion started, and an appearance which was called "elastic
band sign" which was also noticed in the H-CGIN cases strongly suggestive of
impending early invasive adenocarcinoma. However, there is very little information
on the incidence of microinvasive adenocarcinoma and its relation to H-CGIN
(Kurian & Al-Nafussi 1999).
Lymph-vascular space invasion and grade 3 carcinomas have been reported in less
than 10% of patients with microinvasive adenocarcinoma, yet both are independent
risk factors for recurrence in squamous cell cervical carcinoma (Kaku et al 1997;
Ostor et al 1997; Delgado 1990). None of the patients in our study had these
histopathologic findings. However, we found that the main pattern of invasion of
those tumours was infiltrative in 15 of the patients (94%) and was confluent in one
patient (6%). For the 14 patients patients with early invasive adenocarcinoma where
the focality was determined 3 had one focus, 2 had two foci, 2 had three foci, and 7
had more than three foci. A stromal response was mild in 12 (75%), moderate in 3
(19%), and intense in 1 (6%) patient with early invasive carcinoma. However,
Schorge et al, 1999 were not able to stratify the data to evaluate specifically the
importance of multifocal disease or invasion beyond 2 mm, as a result of the small
number of patients in this preliminary study.
Eight patients (50%) with early invasive adenocarcinoma in our study were <=39
years old, tumours in 10 of patients were located at the transformation zone and CGIN
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was present in 8 (50%) patients. Similar results were reported by Schorge et al, 1999
who found that invasive lesions arose predominantly from the endocervical surface, at
or within 5 mm of the squamocolumnar junction, regardless of whether lesions were
unifocal or multifocal. Topographic studies suggest that the vast majority of
microinvasive and adenocarcinoma in situ lesions are located at the transformation
zone, with contiguous involvement of the endocervical canal for a variable distance
(Bertrand et al 1987; Nicklin et al; 1991).
Conclusion
The results of this study suggest that, the vast majority of microinvasive and
adenocarcinoma in situ lesions are located at the transformation zone. Stromal
response and an appearance we called "elastic band sign" which was noticed in the H-
CGIN cases are strongly suggestive of early invasive adenocarcinoma.
1.3 ADENOCARCINOMA IN SITU (AIS) (High grade CGIN)
Many studies supported the view that H-CGIN is a precursor of invasive
adenocarcinoma (Boon et al, 1981; Gloor & Ruzicka 1982; Kurian and Al-Nafussi,
1999). The proportion of adenocarcinomas of the cervix in the United States has
increased from approximately 11% to 23% over a 23-year period, probably reflecting
both a decrease in squamous carcinomas and an increase in adenocarcinomas (Plaxe
et al 1999). Cervical cancer screening programs have been effective in decreasing
both the incidence and mortality from squamous carcinoma, but although
adenocarcinoma mortality rates have declined, incidence rates have not (Nieminen et
al 1995). This may reflect the difficulty in detecting adenocarcinoma in situ, but also
suggests that invasive adenocarcinoma is being detected at an earlier stage. The
diagnosis of AIS is often problematic. Endocervical abnormalities such as dysplasia,
tubal metaplasia, cervical endometriosis, and pathological or histological changes due
to previous biopsy, cervicitis, and use of OCs have been misdiagnosed as AIS
(Valente & Hanjani 1986; Yeh et al; 1991; Pacey et al 1988; Lee, 1988), and others
have reported on the difficulty of distinguishing AIS from microinvasive lesions
(Kudo et al 1991) and even invasive disease (Fu et al 1987). In our study, twenty of
139 patients showed adenocarcinoma in situ without invasion. These were defined by
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showing nuclear stratification and loss of polarity, nuclear atypia and hyperchromasia,
macronucleoli, loss of intracytoplasmic mucin, atypical mitoses, apoptotic bodies,
goblet cells, and abrupt transition to normal but without invasion of stroma. Not all of
these findings usually present in every individual case. There was often an abrupt
transition from normal glands to glands involved by AIS and this abrupt transition
may be seen within individual glands. Both the surface epithelium and the underlying
crypts may be involved. In all patients with adenocarcinoma in situ (13 from 13
patients), the transformation zone (TZ) was involved by the AIS (100%). Similar
results were reported by Lee et al, (2000); Teshima et al, (1985); Oster et al, (1984)
and Noda et al, (1983) who observed that most cases of invasive adenocarcinoma
evolve from an adenocarcinoma in situ precursor located within or just proximal to
the transformation zone.
In this series, large masses of densely packed architecturally complex glands with
papillary growth process and cribriform areas were observed in the AIS cases which
strongly suggested invasion. There was a gradual thinning of the glandular epithelium
until the basement membrane was destroyed and stromal invasion started. There is a
window of approximately 5 years between clinically detectable adenocarcinoma in
situ and early invasive adenocarcinoma, indicative of an opportunity for screening and
detection before invasion (Lee et al, 2000; Boon et al 1981). However, the detection
of adenocarcinoma in situ has been challenging for a number of reasons.
Papanicolaou smears may be less sensitive than they are for squamous precursors
because adenocarcinoma in situ may mimic endometrial cells or reactive endocervical
cells (Lee et al, 1997). Also, benign conditions such as tubal metaplasia (Novtny et al
1992; Wells et al 1986) and cervical endometriosis (Pacey et al 1988) may
cytologically mimic adenocarcinoma in situ. Colposcopic evaluation and sampling are
said to be more difficult because of the location of adenocarcinoma in situ within the
endocervical canal (Christopherson et al 1979).
In this study, we found the age group of AIS is younger than those with invasive
adenocarcinoma. Patients with adenocarcinoma in situ were younger than those with
invasive adenocarcinoma (p=0.006). Fourteen of 20 patients who had adenocarcinoma
in situ were <=39 years old (70%), four patients were 40-50 years old (20%), and two
patients were >= 51 years old (10%). Kurian and Al-Nafussi, (1999) reported the
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mean age of women progressively increased from 39 years for L-CGIN, to 43 years
for both H-CGIN and microinvasive adenocarcinoma, and 48 years for
adenocarcinoma, a span of approximately 10 years. The difference in mean age,
however, between H-CGIN and frankly invasive disease was only five years. This
concurs with previous studies showing CGIN preceding invasive adenocarcinoma by
an interval ranging from two to eight years (Boon et al 1981; Boddington et al, 1976;
Kashimura et al, 1990). Other studies have shown that women with H-CGIN are 10 to
20 years younger than those with invasive adenocarcinoma (Brown &Wells 1986;
Boon et al 1981; Gloor & Ruzicka 1982).
Conclusion
The results of this study support the view that AIS is usually located at TZ and
recorded in patients younger than those with invasive adenocarcinoma.
1.4 Cervical Smear
The cytological features of glandular neoplasia have been refined (Anderson, 1995;
Biscotti et al 1997; Bousfield et al, 1980). Incidence rates and registrations of
adenocarcinoma and squamous cell carcinoma in the population served by a single
NHS Health Authority are reported during a 12-year period, which covers the
introduction of comprehensive cervical screening (Herbert et al, 2001). Although
there was a significant fall in the incidence of squamous cell carcinoma, from 14.0 to
7.2 per 100.000 women years, there was no consistent rise or fall in that of
adenocarcinoma. The relative proportion of adenocarcinoma increased from 17% to
30%. It is well recognized that screening as currently performed is less effective in
preventing adenocarcinoma than squamous cell carcinoma (Mitchell et al 1995;
Herbert et al 2001). In this study, according to cervical smear history reports of the
139 patients with cervical adenocarcinomas, it was found that 71/119 patients had
abnormal Papanicolaou smears. The largest category of smear results was mainly
adenocarcinoma (37/119) and the remaining are presented in table 13. Most patients
92/119 had colposcopic evaluation before initial treatment. Clinical symptoms such as
bleeding were reported in a few cases. However, Luesley et al 1987 reported that 71%
of their cases had at least one cervical smear suggesting glandular abnormality in the
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preceding 12 months. Widrich et al (1996) reported that 19 of 45 cases of
adenocarcinoma in situ (42%) had glandular abnormality on smear test, while Casper
et al 1997 reported that only 23% of low grade CGIN was screen detected. Our
findings support the importance of cervical screening programme to detect tumours
early, and confirm the importance of colposcopy in management in most cases.
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Chapter 2
Validation of Tissue Microarray Technology
2.1 Tissue microarray technology as a new tool for cervical adenocarcinoma
study
Archival formalin-fixed, paraffin-embedded tissues of cervical adenocarcinoma are
the most widely used tumour material in the search for novel prognostic markers to
analyze using tissue microarray technology. In this study we investigated whether the
tissue microarray technique could be used to preserve valuable tumour material. We
have therefore evaluated the tissue microarray technique for immunohistochemical
staining in cervical adenocarcinoma using the following antigens, carcinoembryonic
antigen (CEA), Cytokeratin7 (CK7), Cyto-keratin20 (CK20), oestrogen receptor (ER),
progesterone receptor (PgR), phosphatase and tensin homolog deleted on
chromosome ten (PTEN), MIB-1 proliferation marker, and p53 suppressor gene.
These antigens were chosen to represent known positive (CK7), expected negative
(CK20), steroid receptors (ER and PgR) as examples of potentially heterogeneous
expression- to compare staining in whole sections with those in TMA; CEA and p53
to investigate their expression in a large series; and PTEN to evaluate it in differential
diagnosis between primary endocervical adenocarcinoma and primary endometrial
adenocarcinoma. All tumours showed a concordant presence or absence of staining in
all tumours investigated. Thus, good correlation was obtained between the results
from the whole tissue sections and the tissue microarray studies indicating that tissue
microarrays may be reliable tools for high-throughput clinicopathological and
immunohistochemical analyses of cancer specimens. Similar results have been
reported in previous evaluations of the tissue microarray technique in different cancer
specimens and cell lines (Hoos & Cordon-Cardo, 2001; Hoos et al, 2001b).
However, in this series, analysis of TMA cores was comparable to a whole tissue
section in all of cases for morphological study of cervical adenocarcinomas and in
more than 97% of cases for immunohistochemical staining. In 5% of cases, the core
biopsy sections were nonevaluable because of loss of material during sectioning and
staining. This loss of data, due to tissue loss or inconclusive data, has been reported in
previous evaluations of the tissue microarray technique in soft tissue tumours
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(Engellau et al., 2001; Hoos et al., 2001) and in rectal cancer (Fernebro et al, 2002)
where 17% of the core biopsy sections were nonevaluable.
The main problem to broad acceptance of tissue microarrays is that they reduce the
amount of tissue analyzed from a whole tissue section to a core, 0.6 mm in diameter
that may not be representative of the protein expression patterns of the entire tumour
because of tissue heterogeneity. In this study, we constructed microarray blocks using
0.6 mm core biopsy which was representative in 100% for morphological study of
cervical adenocarcinoma and in 97% for immunohistochemical staining of different
antigens. The process of selecting representative viable tumour regions from which to
obtain the core biopsy specimens is crucial and should be performed by an
experienced pathologist. Therefore TMAs are constructed by careful selection of these
regions especially in a morphologically heterogeneous tumour to provide more
representative results.
Although the development of TMA technology started using 3 mm needles, it is felt,
that increasing the needle size will be of limited value in the assessment of
heterogeneous tumour markers since tumour heterogeneity is likely to a minor degree
within a still very small tissue fragment measuring 3 mm in diameter. However, it
would be more advantageous to array two or more samples from different areas of
each tumour if a better representation of an individual tumour is required. Similar
results were reported by Bubendorf et al (2001). Large diameter punches (typically 2-
4 mm) have been used by some investigators in an effort to provide more
representative samples for TMA analysis. Although this approach multiplies the
amount of tissue analyzed, there is little practical evidence that such a sampling
strategy is more representative than 0.6-mm punches. Therefore, the acquisition of
multiple small "tissue cores" from distinct, perhaps histologically different, regions of
the tumour is dramatically more effective than increasing the size of a single punch to
improve the sampling efficiency. Based on these considerations, the 0.6-mm sample
size is preferable. In addition, the substantial disadvantage of using larger (2-4-mm
samples) is it greatly reduces the number of samples that can be arrayed on a single
slide and the number of punches that can be taken from 1 original tumour block.
These results and suggestions were supported in previous evaluations of the tissue
microarray technique in different cancer specimens and cell lines (Hoos & Cordon-
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Cardo, 2001; Hoos et al, 2001b). Moreover, Camp et al., (2000) concluded that the
tissue microarray technique, with 2-fold redundancy, in breast cancer is a valuable
and accurate method for analysis of protein expression in large archival cohorts.
To determine the number of tissue cores required to obtain a result equivalent to a
conventional tissue section, we constructed an array with 2 pairs of cores from each of
119 cases of invasive cervical adenocarcinoma, 20 adenocarcinoma in situ and 16
normal endocervical tissues. Cores were scored if at least 10% of the core area
contained tumour. Then we analyzed each core separately and graded it as either
positive or negative. Most cases had two scorable cores for each antibody tested.
However, most cases had more than 3 cores with sufficient tumour for evaluation. In
the majority of cases, staining was uniform across all the cores and consequently the
chance of adequately representing the tumour in one punch was 100%. Moreover, the
results of this analysis demonstrate that, despite the variability of antigen expression
between cores, analysis of two disks achieve greater than 97% representation.
Therefore we suggest that a minimum of 2 usable cores was required to be included in
the analysis. For practical purposes, therefore, it is desirable to identify the minimal
number of core biopsy specimens needed to achieve good accuracy. With a loss of 5%
of the core biopsy specimens and since using 4 core biopsy specimens only
marginally affected the accuracy level, we suggest that 4 tissue biopsy specimens
should be taken from each tumour. This conclusion is in concordance with the results
obtained from validation of the tissue microarray technique for immunohistochemical
staining in soft tissue tumours (Engellau et al, 2001; Hoos et al, 2001), in rectal cancer
( Fernebro et al, 2002) and in breast cancer (Camp et al,2000). These studies have
suggested that analysis of triplicate core biopsy specimens per tumour increases the
number of concordant readings, lowers the number of lost cases, and provides a
reliable immunohistochemical expression profile.
According to this data and our experience, we have developed a standard procedure in
which 2 pairs of cores are punched in various regions of the tumour mass, including
both the leading edge and the tumour centre. This process ensures that at least two,
and in most cases three, punches are available for evaluation, resulting in adequate
representation of the whole-section staining pattern in more than 97% of cases.
Although expression of some antigens such as oestrogen receptor, and progesterone
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receptor, in cervical adenocarcinoma is regarded as particularly heterogeneous, it is
possible that other antigens in other tumour types may exhibit even greater
heterogeneity. Consequently, similar analyses may be required to validate the use of
tissue microarrays in other tumour types. A similar suggestion is reported in tissue
microarray evaluation in breast cancer by Camp et al, (2000).
The question of how many core punches it takes to reliably achieve two readable cores
in each case was affected by several factors. Foremost among these was the ability to
identify areas of tumour distinct from desmoplastic stroma, normal epithelium, and/or
in situ adenocarcinoma. Although some histological detail was retained in microarray
cores, it could be difficult to distinguish certain types of in situ from invasive
carcinoma. In invasive adenocarcinoma there was in situ adenocarcinoma component
admixed with the invasive component, increasing the chances of spurious readings. To
reduce this confounding effect, areas of invasive carcinoma were outlined distinctly
from the in situ component on the slide by indelible marker. This process was
performed by a gynaecological pathologist. Other factors include the technical
expertise of the individual constructing the array blocks and slides. In our laboratory,
one person performed these tasks. Presently our rate of usable cores exceeds 97%.
Finally, the thickness (depth) of the original embedded tissue sections can affect the
number of usable slides able to be cut from the master array block. Therefore, efforts
were made to select blocks that had sufficient residual tissue in the archival tissue
blocks to ensure an adequate sample for TMA construction.
Conclusions
We conclude that the tissue microarray technique is a rapid and tissue-saving method,
yields staining of good quality and is feasible for immuno-histochemical studies in
cervical adenocarcinoma. Four cores are sufficient to produce representative sampling
of the morphology of tumours even if occasional cores are lost on slides. TMAs will
substantially accelerate studies associating novel molecular discoveries in the field of
genomics and proteomics with specific pathologic, demographic, clinical and follow-
up information of cancers and cancer patients. TMAs containing well-characterized
tissues enable researchers to perform studies involving thousands of patient specimens
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with substantial increases in speed, quality of data, information content and savings of
cost and time. Since the diagnostic tumour biopsy specimens are often small, the use
of the tissue microarray contributes to tissue preservation, but because of the risk for
tumour loss, multiple (4) biopsy specimens should be taken. Furthermore, the tumour
areas from which the tissue core biopsy specimens are obtained must be carefully
selected to reduce the number of nonevaluable core biopsy sections containing
nonrepresentative tissue.
2.2 Immunohistochemical Results of Cervical Adenocarcinomas Using TMA
Technology
Over the last several decades the relative proportion of both endocervical
adenocarcinoma and its precursor lesion cervical glandular intraepithelial neoplasia to
invasive squamous cell carcinomas of the cervix has been increasing and several
studies have reported an increase in the absolute number of cervical adenocarcinomas
(Shingleton et al, 1981; Vesterinen et al, 1989). These increases have heightened
interest in the diagnosis, pathogenesis, and management of women with invasive
adenocarcinoma of the cervix (Chilvers et al, 1991; Prempree et al, 1985). As well as
recognizing cervical glandular intraepithelial neoplasia per se, it is also necessary to
distinguish this from non-neoplastic endocervical glandular lesions such as tubo-
endometrial metaplasia, endometriosis and microglandular hyperplasia. Therefore, if a
panel of antibodies was of value in the distinction of invasive adenocarcinoma of the
cervix, cervical glandular intraepithelial neoplasia from non-neoplastic endocervical
glandular lesions, this would be extremely useful (Cameron et al, 2002).
Excluding results from second sample for 22 patients with two samples,
immunohistochemical results for 139 patients with cervical adenocarcinomas are
summarised in the following table.
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Positive Cases Negative Cases
N % N %
CK7 3 136 132 97% 4 3%
CK20 5 134 4 3% 130 97%
CEA 3 136 92 68% 44 32%
ER 2 137 64 47% 73 53%
PgR 4 135 50 37% 85 63%
MIB1 5 134 119 89% 15 11%
PTEN 2 137 121 88% 16 12%
P53 4 135 37 27% 98 73%
Table 20 showing immunohistochmical results of eight antigens for 139 patients with
cervical adenocarcinomas using TMAs. Number of positive, negative, available and
not available cases in each antigen.
2.2.1 CK7 &CK20
Cytokeratins are constituents of the intermediate fdaments of epithelial cells which
are expressed in various combinations depending on the epithelial type and the degree
of differentiation. Simple epithelia generally express the simple epithelial keratins 7,
18, 19, and 20, while complex epithelia express complex epithelial keratins 5/6, 10,
14 and 15. When an epithelium undergoes malignant transformation, its keratin
profile usually remains constant. The constitution and expression patterns of keratin
filaments in human epithelial neoplasms are complex and often distinctive (Chu
&Weiss 2002). The keratin expression pattern of cervical adenocarcinoma is
considerably more complex than expected from the results obtained with
adenocarcinomas arising in other tissues (Moll et al, 1992).
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In the present study, the expression of CK7 was positive in almost all cases of cervical
adenocarcinoma, 100% of AIS cases, and 97% of invasive cases. In contrast, the
expression of CK20 was negative in 100% of AIS cases, and 97% of invasive cases.
Similar results were reported by Chu &Weiss (2002) who reported that cervical
adenocarcinoma contains K7, K8, K18 and K19, like other gynaecological
adenocarcinomas, but it is also frequently positive for K17 and K14. None of these
above keratins is present in the normal columnar cells lining the endocervical canal.
Because of this, it has been speculated that cervical adenocarcinoma does not usually
arise from columnar cells, but instead derives from reserve cells. Squamous cell
carcinoma in situ may thus make the transition to an adenocarcinoma (Smedts et al,
1993). It may be difficult to distinguish histologically between a primary cervical
adenocarcinoma and a metastatic adenocarcinoma arising from the bowel,
endometrium, mesothelium, or ovary. This dilemma may be addressed by determining
the keratin phenotype of these adenocarcinomas. Colonic adenocarcinomas have a
simple keratin expression pattern consisting of K8, K18, K19 and K20, whereas
cervical adenocarcinoma contains K7, K17, and frequently K14, and usually lacks
K20. Although arising from the same epithelium, cervical dysplasia and invasive
carcinoma have different keratin profiles in comparison with normal cervical non-
keratinizing epithelia. Normal cervical epithelium expresses K10, but not K7, K8,
K17 and K18. In contrast, cervical dysplasia (cervical intraepithelial neoplasia (CIN))
or cervical squamous cell carcinoma tends to express K7, K17 and K18, but not K8
and K10 (Smedts et al, 1993; Smedts et al, 1992, Chu et al, 2000).
Conclusion
Our findings show that expression of CK7 was positive and CK-20 was negative in
most of cases of cervical adenocarcinoma.
2.2.2 CEA
Previous studies have investigated the value of other markers in the distinction of
cervical glandular intraepithelial neoplasia from histological mimics. Antibodies
employed have included carcinoembryonic antigen (CEA), which is usually positive
in neoplastic, but not benign lesions ( Gilks et al, 1989; Micheal et al, 1984). Negative
immunohistochemical staining for CEA supports a diagnosis of MGH (Speers et al.,
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1983; Steeper & Wick, 1986). In the present study, the expression rate of CEA was
positive in 68% of all cervical adenocarcinoma cases, AIS and invasive, 72 % of AIS
cases, and 67% of invasive cases. Similar results were reported by van Nagell et al.,
(1978) who found that, plasma CEA levels were more commonly elevated in patients
with endocervical adenocarcinoma than in those with squamous cell carcinoma.
Moreover, we found that there was no statistically significant difference in the
expression of CEA in different subtypes of invasive cervical adenocarcnoma (table
39). However, caution should be exercised since adenocarcinomas are occasionally
negative or only focally positive for CEA. Mesonephric adenocarcinomas are
typically CEA-negative. Accordingly, a negative stain for CEA should be cautiously
interpreted but intense positive staining throughout the cytoplasm is unlikely in a
benign lesion and strongly favours carcinoma. Negative CEA staining is also seen
with the other pseudoneoplastic glandular lesions considered here but experience with
CEA staining of many of them is limited and a diagnosis should not be rendered
solely on the basis of immunohistochemical staining results. In our study, we
considered CEA is positive when the cytoplasm of the malignant endocervical cells
stained diffusely. This is because CEA is a type of intracytoplasmic protein. However,
in some cases, there was diffuse delicate luminal staining with CEA but this postivity
considered as negative if there is no cytoplasmic staining because CEA is not one of
intramembranous components. Normal endocervical glands and those of
pseudoneoplastic lesions may exhibit a glycocalyceal pattern of CEA staining that
contrasts with the diffuse cytoplasmic staining typically seen in cervical
adenocarcinomas (Jones et al., 1991). The pattern of CEA distribution in endocervical
adenocarcinoma of endometrioid type was not similar to that observed for primary
endometrial adenocarcinoma (Toki et al., 1985).
Cina et al., (1997) confirmed that the combination of cytoplasmic CEA positivity in
glandular cells and a moderate-to-high MIB-1 (Ki-67) proliferative index is diagnostic
of malignancy in endocervical lesions. With the exception of florid microglandular
hyperplasia, p53 expression is only seen in neoplastic lesions of the endocervix.
Therefore, a combination of CEA, MIB-1 and p53 staining was found to be useful in




Our findings confirm that expression of CEA is a potential biomarker for diagnosis of
cervical adenocarcinoma.
2.2.3 ER&PgR
Most studies have reported that risk factors and prognostic indicators for women with
adenocarcinomas are similar to those for women with squamous cell carcinomas of
the cervix (Kjaer et al, 1993; Parazzini & La Vecchia, 1990).The major prognostic
indicators for both histological types include FIGO clinical stage, histological grade,
size of the lesion, lymph-vascular space involvement, and lymph node metastases
(Attanoos et al, 1995; Ireland et al, 1985). One possible prognostic indicator that
might be expected to be more important for cervical adenocarcinomas than for
squamous cell carcinomas is steroid hormone receptor status (Fujiwara et al, 1997).
Several studies have measured ER and PgR in cervical carcinomas. In the present
study, using immunohistochemical assays, ER has been detected positive for 64
(47%) of cervical carcinomas and PgR in 50 (37%). However, the prognostic
significance of hormone receptor status remains unclear. Some studies have found
that ER or PgR status has no significant impact on either disease free survival or
length of overall survival in women with primary invasive cervical carcinoma,
whereas other studies have found hormone receptor status to be a significant
prognostic indicator (Hunter et al, 1987, Martin et al 1986). Potish et al, (1986)
reported that both ER and PgR positivity were independently associated with
enhanced overall survival in premenopausal, but not postmenopausal, women with
invasive cervical carcinoma, whereas Hunter et al, (1987) found a weak association
between survival and PgR positivity, but not with ER positivity However, these
studies were of women with all histological types of cervical carcinoma, and
relatively few cases of primary invasive adenocarcinoma of the cervix were included.
Only two previously published studies have specifically analyzed the clinical
significance of ER and PgR status in primary invasive adenocarcinomas of the cervix.
Masood et al, (1993) assessed ER and PgR status in a series of 54 women with
primary cervical adenocarcinoma and found that patients with either ER or PgR
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positive tumours had significantly improved overall survival compared with patients
with ER and PgR negative tumours. However, another study of ER and PgR status in
47 women with primary cervical adenocarcinoma found an increase in disease free
survival among women with ER positive tumours but not with PgR positive tumours
(Ghandour et al, 1994).
The current series assessed hormone receptor status in 119 women with primary
invasive cervical adenocarcinoma and 20 women with AIS. In the current series 47%
of the cases were classified as ER positive whereas 30% of the cases in the series of
Masood et al, (1993) and 26% of the cases in the series of Ghandour et al, (1994)
were classified as ER positive. In the current series ER positivity was more frequent
in invasive (50%) and early invasive (56%) cervical adenocarcinomas than in AIS
(28%) which suggest that high ER levels are possibly associated with more advanced
disease. However, this finding contradicted the study of Geisinger et al, (1986) who
reported that high ER and PgR levels are more frequent in well-differentiated
adenocarcinomas and is possibly associated with a better prognosis. Moreover, we
found that high ER and PgR levels are more frequent with MDA and adenosquamous
adenocarcinomas (tables 34, 35) which support that ER and PgR are a useful
prognostic factor and are more likely to be more frequent in the tumours of worse
prognosis. In the series of Masood et al,(1993) ER positivity was inversely associated
with histological grade, whereas no association between histological grade and ER
positivity was observed by Ghandour et al,(1994). However, Masood et al, (1993);
Ghandour et al, (1994) reported the associations between specific histological
subtypes of invasive cervical adenocarcinoma and hormone receptor positivity.
Mucinous adenocarcinomas of the endocervical type and endometrioid carcinomas
have the highest rate of ER and PgR positivity. Mucinous adenocarcinomas of the
intestinal type, clear cell carcinomas, and glassy cell carcinomas have been found to
be uniformly ER and PgR negative.
Conclusion
High ER and PgR levels were more frequent with MDA and adenosquamous
adenocarcinomas than in other histological subtypes therefore further studies in larger
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case series are needed. There is, however, evidence of altered distribution and
intensity of ER and PgR expression in cervical adenocarcinoma cells compared with
normal endocervical cells. Also, there was marked heterogeneity of the intensity and
the distribution between and within tumours in the same section. There is no
significant difference in distribution or intensity of ER and PgR expression between
adenocarcinoma in situ and invasive adenocarcinoma. Also, different histological
subtypes of cervical adenocarcinoma showed no significant differences in ER and
PgR expression. In addition, larger studies will also allow a more detailed analysis of
the role of hormone receptor status in less frequent histological subtypes that showed
interesting patterns of steroid hormone receptor status.
2.2.4 MIB-1
The proliferative nuclear antigen Ki-67 is found in proliferative cells and is expressed
in cells in the Gl, S, G2 and M phases of the cell cycle. The MIB-1 murine
monoclonal antibody, which reacts with the Ki-67 antigen, is a marker for
proliferating cells (Graflund et al, 2002). Several studies have investigated the value
of MIB1 in distinguishing between cervical glandular intraepithelial neoplasia and
benign histological mimics( Pirog et al, 2002; Hockenberry et al, 1990). It should be
noted that in such cases, the endocervical glands may exhibit a high MIB1
proliferation index as a result of regenerative activity (Pirgo et al 2002).
Determination of MIB-1 (proliferation factor) is a good prognostic marker in many
malignant tumours, particularly in breast (Wintzer et al, 1991) and ovarian cancer
(Kerns at el, 1994). High proliferative activity, measured using MIB-1, reflects a
greater malignancy of these carcinomas, resulting in a high frequency of recurrences
and metastases. In cervical cancer, the association between this marker and prognosis
is still controversial (Nakano et al, 1997). Nakano and Oka (1993) showed
significantly greater histology responses to radiation with high Ki-67 than with a
lower index. Avall-Lundqvist and Silfversward (1997) found no predictive value of
MIB-1 for long-term survival in SCCs. ter Hamsel and Muden (1998) examined 159
stage I-II cervical cancers, and the study revealed no association between MIB-1
activity, the prognosis of the patient, stage of disease, or lymph node status. These
results were also confirmed by Graflund et al, (2002).
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In the present study, MIB-1 expression rates of AIS and invasive adenocarcinoma
were 94% and 88%, respectively. The expression rates of AIS and invasive
adenocarcinoma were 47.5% and 60.0%, respectively (McCluggage et al, 1997), and
30 to 80% of positive rate in adenocarcinoma was reported (van Hoeven et al 1997).
Cina et al, 1997 reported no MIB-1 reactivity in EGD. However, Leteutre et al 1998,
endocervical glandular atypia showed focal expression with 40% of labelling index,
but endocervical glandular dysplasia displayed diffuse expression with more than
50% of labelling index. Our results were consistent with all these previous reports
which support that high MIB-1 could be a suggestive finding for malignancy.
Conclusion
Level of MIB-1 expression was high in cervical adenocarcinomas therefore,
quantification would be necessary to get the proliferation fraction in the cervical
samples but time and resources did not permit this to be performed in this study.
2.2.5 PTEN
PTEN, a recently discovered tumour suppressor gene, appears to cooperate in tumour
suppression and stimulate tumour cell proliferation, with decreased survival being
related to allelic loss (Di Cristofano et al, 2001). Somatic PTEN mutations are
involved in a variety of tumours, including endometrial carcinomas, where PTEN
expression is diminished (Mutter et al, 2000). There are likely to be multiple but
distinct tissue-related pathways involved in tumour genesis and tumour progression.
In prostate and breast cancers, it appears that loss of PTEN function may be
compounded by loss of protein expression by transcriptional or translational
mechanisms. In prostate tissues, genetic aberrations and expression losses have been
reported (Taniyama et al, 2001) and in a recent immunohistochemical study of
sporadic breast carcinomas, 15% of cases had complete loss of PTEN protein, a
phenomenon that appeared to correlate with monoallelic deletion of the gene (Perren
et al, 1999). Although loss of heterozygosity (LOH) of PTEN can be found in
sporadic colon cancer (Frayling et al, 1997), studies have not found PTEN mutations
to be as frequent as is found in tumours of the brain and the prostate. Guanti et al,
(2000) studied 32 cases of sporadic colon cancer, but observed only one case with a
biallelic genomic alteration that caused loss of function of the gene and Wang et al,
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(1998) found only one somatic mutation of the PTEN gene in 72 colon cancer cases.
Taniyama et al, (2001) reported the analysis of PTEN RNA transcripts during
colorectal tumour progression confirming that both PTEN transcriptional and
translational mechanisms are operative in colorectal cancer. However, it remains
possible that PTEN protein function is compromised via peptide structure or by
inefficient interaction with co-factors, but such studies will require the development
of a reliable enzyme activity assay. In accordance with mutational and LOH analyses
performed on sporadic colon cancer specimens, these findings suggest that PTEN
expression is maintained in sporadic colon cancers.
In this study we examined expression of PTEN in a series of cervical
adenocarcinomas and precursors. In 137 patients with invasive or preinvasive
adenocarcinoma, PTEN expression was negative in 16 (12%) and positive in 121
(88%). Moreover, there was no difference in distribution or intensity of PTEN
expression between adenocarcinoma in situ and invasive adenocarcinoma. Also,
different histological subtypes of cervical adenocarcinoma showed no significant
differences in PTEN expression. Moreover, in all cases, normal endocervical cells and
normal stromal cells of the cervix stained weakly positive for PTEN. The staining
pattern in the tumour cells was stronger than that observed in the normal endocervical
cells and was restricted to the nucleus. In addition, the intensity and distribution of
PTEN staining in the tumour tissue were more heterogeneous than that observed in the
normal tissues. There was marked heterogeneity with respect to the intensity and the
distribution of PTEN staining pattern between and within tumours in the same section
However, Halvorsen et al, (2003) reported on their studies on prostate cancer that lack
of PTEN protein expression was found in 27% of the cases, comparable with 20%
negative cases in a study of McMenamin et al, (1999). PTEN expression was found to
be associated with increasing tumour diameter and advanced primary tumour stage, as
indicated by carcinomatous infiltration of the seminal vesicles, and was also related to
time to local recurrence, supporting the importance of PTEN for prostate cancer
growth and local invasion, possibly reflecting changes in cell cycle regulation,
migration, or loss of cell cohesion influenced by PTEN (Tamura et al, 1999). These
data strongly suggest an important role of PTEN for the progressive growth and local
invasion of prostate cancer in series of patients treated with radical prostatectomy for
localized and presumed organ-confined tumours (Halvorsen et al, 2003).
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In surgical pathology practice, immunohistochemistry may be required to distinguish
primary endocervical adenocarcinomas from primary endometrial tumours. A panel of
antibodies is commonly used which includes oestrogen receptor (ER) and vimentin
(both usually positive in endometrial carcinomas and negative in endocervical) and
CEA (usually negative in endometrial and positive in cervical). However, immuno-
phenotypes vary, and occasional cases remain problematic. For example, our own
(unpublished) results with ER staining in this series of cervical adenocarcinomas
indicate that around 50% of cervical adenocarcinomas show positive ER staining.
Published results from other studies report CEA staining to be found in a majority
(62%) of endocervical adenocarcinomas (Casrillon et al., 2001), but a significant
proportion are negative, we therefore suggest that PTEN may be a useful addition to
the panel of antibodies used to make this distinction. The results of this study have
shown that 88% of cervical adenocarcinomas show positive PTEN staining,
contrasting with published results for PTEN expression in endometrial
adenocarcinomas, in which diminution of expression has been found in 97%, with
complete absence in 61% of endometrial adenocarcinomas (Mutter, 2000).
Conclusion
In conclusion, our findings show that unlike the case in most endometrial carcinomas,
PTEN expression is retained during the process of carcinogenesis in the glandular
cervix. PTEN expression was positive in 105 of 119 patients (88%) with invasive
cervical adenocarcinoma and 16 of 18 patients (89%) with adenocarcinoma in situ.
Therefore, PTEN expression could be a potential biomarker for diagnosis of cervical
adenocarcinoma and for distinguishing between primary cervical adenocarcinoma and
primary endometrial adenocarcinoma. There is, however, evidence of altered
distribution and intensity of PTEN expression in cervical adenocarcinoma cells
compared with normal endocervical cells. Also, there was marked heterogeneity of
the intensity and the distribution between and within tumours in the same section.
There is no significant difference in distribution or intensity of PTEN expression
between adenocarcinoma in situ and invasive adenocarcinoma. Also, different
histological subtypes of cervical adenocarcinoma showed no significant differences in
PTEN expression.
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2.2.6 p53 suppressor gene
The role of p53 change in cervical neoplasia has been extensively studied. p53
inactivation has been found to be important in the development of cervical cancer
(Miwa et al 1995; Manek & Wells 1996; Thomas et al 1999) although p53 is
frequently wild type in cervical cancers. A significantly higher frequency of p53
mutation was found among cervical carcinomas with no or low HPV load (Helland et
al, 1998; Skyldberg et al, 1999). P53 immunoreactivity has been demonstrated to be
different between normal cervical epithelium, CIN or invasive cancer independent of
HPV infection (Jeffers et al 1994, Hunt et al 1996; Troncone et al 1998; Lie et al
1999; Ngan et al 1999a). The finding of increased p53 expression in adenocarcinoma
compared to squamous cell carcinoma confirms the biologic difference between the
two subtypes (Quinn 1997). The expression of p53 in cervical adenocarcinoma in the
literature was less frequent than its squamous counterpart (Abd El All et al, 1999).
In the present study, we found that P53 expression rate is higher in invasive
adenocarcinoma (29%) than in AIS (17%). Similar findings were reported by (Yoon
et al, (2001). Moreover, McCluggage et al, 1997 reported that the expression of p53
protein was 70% in invasive adenocarcinoma and 20% in AIS but negative in benign
glandular lesions, and these findings suggested that p53 gene mutation might be the
late event in the endocervical carcinogenesis. However, Cina et al, (1997) reported
that p53 protein expression was negative in AIS but positive in cases showing florid
microglandular hyperplasia, and p53 protein expression did not mean malignant
nature. In our study, there was significant statistical difference of p53 expression
between AIS and villoglandular papillary adenocarcinoma (p = 0.014). However,
there were no significant statistical differences of p53 expression between AIS and the
other different subtypes of invasive adenocarcinoma (table 38)
There is controversy regarding the prognostic value of P53 in cervical carcinoma. In
our study we found p53 expression to be higher in invasive cervical cases than non
invasive cases. Similar finding was reported (Uchiyama et al 1997, Crawford et al
1998). However, some studies found no association between p53 overexpression or
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the presence of mutant p53 protein and clinical outcome (Hunt et al 1996, Pillai et al
1999). Other studies failed to demonstrate staining in 13 adenocarcinoma examined
(Mittal et al, 1995).
Conclusion
We have documented p53 immunoreactivity was associated more with invasive
adenocarcinoma than AIS. This supports that p53 overexpression is usually associated
with frankly invasive cases. There was significant statistical difference of p53
expression between AIS and villoglandular papillary adenocarcinoma (p=0.014).
However, there were no significant statistical differences of p53 expression between
AIS and the other different subtypes of invasive adenocarcinoma.
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Chapter 3
Human papilloma viruses 16 and 18 in cervical adenocarcinoma
Cervical cancer is the second most common type of cancer in females worldwide,
with over 500,000 new cases diagnosed each year. It has been shown that HPV is
associated with a continuum of genital tract disease from dysplasia to invasive
squamous cell carcinoma. A high prevalence of HPV DNA, predominantly types
16,18,31,33 and 35, has been detected in several previous studies in women with
cervical carcinoma (Chen et al, 1994; Wu CH et al, 1994; Liaw et al, 1995).
Tenti et al (1996) reported a higher prevalence of HPV DNA in cervical adeno¬
carcinomas when compared to most previous reports and similar to that reported for
cervical squamous cell carcinoma (Bosch et al, 1993). The relative difficulty in
detecting HPV DNA in adenocarcinomas, in contrast to squamous cell carcinomas,
may be attributed to a lower viral load in glandular lesions as compared to squamous
lesions. Premalignant and malignant squamous lesions, in particular those associated
with HPV 16, contain a large number of episomal viral particles, in addition to
integrated HPV sequences (Stoler et al, 1992). Glandular epithelium does not support
productive viral infection and HPV DNA in endocervical neoplasms (notably HPV
18), is usually present in the integrated form (Park et al, 1997). As a result, detection
of HPV DNA in adenocarcinomas requires a sensitive detection assay. Further, as the
successful amplification of HPV DNA in a PCR assay depends on the presence of
intact DNA target sequences, two additional factors may reduce the efficiency of HPV
detection: 1) DNA fragmentation as a result of formalin fixation and storage in
paraffin; and 2) loss of portions of the viral genome during integration. Integration of
HPV DNA may result in deletion of the viral genome containing the sequences
targeted in the PCR reaction. In such cases, the detection of HPV DNA in the assay
will depend on the presence of intact episomal HPV copies. The absence of an
episomal HPV genome in the majority of glandular tumours, as opposed to squamous
tumours (Park et al, 1997) may result in a significant underestimation of HPV DNA
prevalence in adenocarcinomas (Pirog et al, 2000).
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In this study, sensitive detection of HPV has been achieved by the utilization of PCR.
In PCR for HPV-DNA, consensus primers targeting E6 and E7 regions are most
widely used for comprehensive detection. In general, LI region primers provide
higher sensitivities with wider coverage of HPV types than E6 and E7 region primers.
However, it is well known that frequent deletion of the LI region occurs when HPV is
integrated. This was elucidated in recent study (Yamaguchi et al, 2002), where it
noted that a number of cases, which could not be detected using LI primers
(Yashikawa et al, 1991), were clearly identified as HPV types 16, 18 and 31 using E6
and E7 primers (Fujinaga et al, 1991). Therefore we used consensus primers targeting
E6 and E7 regions not LI region for HPV-DNA detection.
Our findings show that HPV infection was absent in all cases of normal cervical
biopsies, contrasting some previous studies in other countries, which also employed
the PCR technique and showed quite high prevalence rates for HPV infection in
normal cervical tissues (Meanwell et al, 1987;Tidy et al,1989). Such differences may
be partly due to some geographical and/or racial factors. One must also be cautious
about PCR results, since the technique is notorious for false-positivity due to
laboratory contamination. Furthermore, PCR techniques with higher detection
sensitivities, such as two-step PCR, might increase the rate of HPV detection. Indeed,
some of the papers were later retracted (Tidy et al, 1989).
We found HPV 16 or 18 infections in 87 cases (62.6%) out of a total of 257 cervical
biopsies from 139 women with various cervical adenocarcinomas lesions. This result
was somewhat lower than other reports showing 68 to 84% positivity (Chen et al,
1993; Williamson et al, 1994; Van den Brule et al, 1989; Kristiansen et al, 1994).
HPV DNA was identified in 87 cases (62.6%) in which, HPV16 positive for 65 (47%)
patients and HPV18 positive for 41 (29%) patients. Genotyping by RFLP and PCR
revealed that, HPV type 16 was the most frequent type of infection comprising 46
cases (33%), followed by HPV type 18 in 22 cases (16%), and both HPV type 16 and
HPV type 18 in 19 cases (14%). There were 52 (38%) of 139 of patients with various
cervical adenocarcinomas lesions with HPV typel6 and HPV type 18 both negative.
The association of HPV with cervical adenocarcinoma has been reported (Maier and
Norris, 1980; Tenti et al, 1998). A comparison of the prevalence of HPV 16 and/or 18
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infection in cervical adenocarcinoma in different countries using different techniques
is summarized in (Lee et al, 1993) (Table 39). In the present studies, the detection rate
of HPV 16 (33%) in cervical adenocarcinoma was higher than that reported in parts of
Europe and the USA, and we found HPV 16 to be the predominant type in cervical
adenocarcinoma. Only a few studies concluded that the rates of HPV 16 DNAs were
higher than HPV 18, 80% (4/5) (Griffin et al, 1991), 71.4% (5/7) (Das et al, 1993),
66.7 % (2/3) (Lee et al 1993) and 55% (6/11) (Uchiyama et al, 1997) in cervical
adenocarcinoma. However, many studies reported that HPV 18 is the predominant
type (Leminen et al, 1991; Duggan et al, 1993; Johnson et al, 1992; Chen et al, 1994;
Yamakawa et al 1994; Heller et al, 1991). It might be attributed in part to
geographical and or/ racial differences.
Table 39 Frequency of HPV16 and 18 in different countries.
Author Country Pat Techniques HPV HPV HP HP






Leminen Finland 106 ISH (16,18) 18 2 14 2
Duggan Canada 77 DBH (16,18) 44 18 23 nm
Das India 12 ISH (16,18) 58.3 41.6 16 0
Griffin England 16 PCR (16,18&S) 31.3 25 6.3 0
Bjersing Sweden 26 PCR (E6/E7&S) 42.0 15 27 0
Johnson US,Michigan 22 PCR (E6/E7&S) 82 23 59 0
Hording Denmark 50 PCR (16,18&DBH) 70 18 52 0
Lee US,Vermont 20 PCR(16,18&S) 15 10 5 0
Chen Taiwan 42 PCR(L 1 ,E6/E7,MY09,MY11) 67 19 48 0
Yamakawa Japan 43 PCR (16,18&S) 56 21 33 2
Tenti Italy 138 PCR(16,18&S) 85 28 30 27
Iwasawa Finland 108 PCR (16,18& MY09,MY 11) 75 17 56 3
Parker US,Washington 32 PCR (16,18) 50 22- 28 0
Uchiyama Japan 32 PCR (LI, 16,1 S&Msea&Rsal) 34 19 12 3
Ferguson Us,Michigan 27 PCR (Ll&Mse/I&Rsal) 59 26 26 nm
Tenti Italy 74 PCR (16,18&S) 76 20 33 23
Lee Taiwan 69 PCR(MY09,MY1 \&S&Rsal) 32 16 14 1.5




Table 39 Showing frequency of HPV 16 and /o r 18 DNA in cervical adenocarcinoma
by in situ hybridization and PCR. ISH: in situ hybridization, S: Southern, DBH: dot
blot hybridization (Modified from Lee et al, 1993).
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In the present study, the difference between prevalence of HPV infection caused by
HPV 16 only, HPV 18 only or/and both in adenocarcinoma in situ and the invasive
cervical adenocarcinoma was not statistically significant (Table 39). It was reported
that expression rate of AIS was 70% and endocervical glandular dysplasia adjacent to
AIS also showed the presence of HPV, therefore HPV might be the causative agent in
the development of endocervical glandular dysplasia and AIS (Leary et al, 1991).
Higgins et al, (1992) reported that HPV expression rate in CGIN was 95.2% and HPV
might be involved in the early stage of carcinogenesis because higher grade lesions
showed stronger expression. In another report (Farnsworth et al, 1989), HPV was
expressed in AIS lesion, but negative in endocervical glandular atypia and normal
endocervix. Tase et al, (1989) regarded endocervical glandular dysplasia as a reactive
lesion because HPV expression rate of endocervical glandular dysplasia was only 6%
in contrast to 64% of coexisting AIS, microinvasive adenocarcinoma and CIN lesion.
AIS lesion was not infrequently associated with CIN and both lesions expressed HPV
16/18, which suggested that HPV plays a role in the development of both squamous
and glandular lesions (Alejo et al, 1993). Duggan et al, (1994) studied HPV16/18 in
AIS associated with CIN, and HPV expression rate was 66% and concluded that HPV
18 might be more important in the development of AIS. According to Anciaux et al,
(1997) adenocarcinoma showed similar HPV expression rate regardless of coexistent
squamous neoplasia; however, HPV expression rate of endocervical glandular
dysplasia associated with squamous neoplasia was 64.2% and that of endocervical
glandular dysplasia without squamous neoplasia was 16.7%. Their results indicated
that squamous and glandular neoplasia of cervix might have different pathways in
carcinogenesis. In our study using PCR, high expression rate of HPV16/18 in
malignant endocervical glandular lesions indicates that HPV may be involved in the
development of endocervical adenocarcinoma.
In this study, HPV 16/18 prevalence in all subtypes of invasive adenocarcinoma has
shown that there are no significant differences between different subtypes. The
comparison of all histological subtypes of invasive adenocarcinoma concerning HPV
16/18 infection is presented in table 38.
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However, several previous studies have found a high HPV prevalence in cervical
mucinous tumours, especially in those with endocervical morphology (Ferguson et al,
1998; Duggan et al, 1993; Tenti et al, 1996). Other investigators have reported a
highly variable prevalence of HPV DNA in clear cell carcinoma (Duggan et al, 1993;
Tenti et al, 1996). Of note, CCC of the cervix has to be differentiated from clear-cell
squamous carcinoma and clear-cell adenosquamous carcinoma, as both of the latter
tumours are associated with HPV (Fujiwara et al, 1995). The histological subtypes of
adenosquamous (not otherwise specified), adenoid basal, adenoid cystic, glassy cell,
and clear-cell adenosquamous carcinoma have been found to be associated with HPV
in a high percentage of cases (Yamakawa et al, 1994; Kenny et al, 1992). Another
group of cervical tumours which display focal glandular and squamous differentiation
are neuroendocrine carcinomas. These tumours also have a high prevalence of HPV
DNA, ranging from 53 to 85%, and are associated with both HPV 16 and 18;
however, HPV 18 seems to be the most predominant in the small-cell carcinoma
histological subtype (Ambros et al 1991).
Results of LCM were unsatisfactory, this might be due to different factors such as,
little amount of DNA, degredation of DNA particles and an absence of episomal HPV
genome in the majority of the glandular tumours as opposed to squamous tumours,
may results in a significant underestimation of HPV DNA prevalence in
adenocarcinoma (Park et al 1997 and Pirog et al 2000).
It remains the fact however that there are few studies that have assessed type-specific
HPV prevalence and diversity in invasive adenocarcinoma and its precursors (An et
al., 2005). Due to the comparative rarity of adenocarcinoma, related HPV prevalence
data are often lumped together with SCC cases, without being teased out or are not
included at all (due to their absence) in studies of smaller cohorts. Thus the potential
of HPV testing and vaccination on the reduction of adenocarcinoma per se is less
clearly defined by this "swamping" effect. The remits of this study were therefore to
assess the prevalence of HPV "vaccine type" (16 and 18) in a large set of cervical
adenocarcinoma using PCR methods. Another dimension was to evaluate any
potential HPV type specific association with histological type of preinvasive (High
grade CGIN/ Adenocarcinoma in situ) and invasive cervical adenocarcinoma.
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In terms of the potential usefulness of a prophylactic vaccine in the prevention of
adenocarcinoma, the results that we present are extremely positive. We have shown
that both HPV 18 (as detected by other investigators) and perhaps more interestingly,
HPV 16 are indeed prevalent in pre-invasive and invasive adenocarcinomas. Phase 3
trails of two commercial vaccines, which are designed to be protective for HPV 16
and 18 infection are ongoing. If the findings are positive (as the results of the phase 2
trails would indicate (Villa et al., 2005), we can speculate from that the vaccines have
the potential of reducing the incidence of adenocarcinoma significantly.
In terms of using adjunctive HPV testing in cytology screening, our results again
would suggest that adenocarcinoma, undetected by cytology, could potentially be
detected/exposed by the use of a commercially available HPV test. For example, the
Hybrid Capture® 2 (HC II) Test (Digene), which is currently the only HPV test that
has FDA approval and is used in the US for screening and triage, includes both types
18 and 16 within its detection remit. Although we exclusively looked at AIS or worse,
Derchain et al, (2004) also found a high prevalence of HR-HPV in atypical glandular
cells (AGC), which some argue, are the precursors of AIS. Again, the authors
postulate the beneficial role that HR-HPV screening could have on the improved
detection of glandular abnormalities at an early stage.
Our results combined with data from epidemiological, clinicopathological, and
molecular studies indicate that squamous cell carcinomas and adenocarcinomas of the
cervix share a common pathogenesis that involves infection with oncogenic HPV
types. Although little is known about the molecular genetic events involved in the
pathogenesis of cervical adenocarcinoma after HPV infection, it is well-established
that expression of the high-risk HPV E6 and E7 oncoproteins in keratinocytes
(squamous cells) disrupts the function of the cell cycle-regulating proteins p53 and
pRB, respectively (Wemess et al, 1990; Dyson et al, 1989). The same mechanism of
HPV-related carcinogenesis may occur in cervical glandular epithelium.
Conclusions
Typing of HPV is likely to be helpful in predicting the consequence of endocervical
atypia, since HPV 16 and 18 have both been shown to be more related to cancer
presence than the other HPV types. HPV typing by PCR has typically been performed
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by restriction enzyme analysis. However, such a technique may not be suitable for
routine use due to the additional necessary procedures and relatively expensive
running cost. Consequently, we chose type-specific PCR and tried to establish an
optimized condition for the two major types of HPV. Laser capture microdissection is
not a good method for extraction and detection of HPV DNA in cervical
adnocarcinoma samples. Thus, the combined type-specific PCR, followed by agarose
electrophoresis, can be effectively applied for detection of HPV DNA.
Of 87 HPV -positive specimens (62.6%), HPV type 16 was the most frequent type of
infection comprising 46 cases (33%), followed by HPV type 18 in 22 cases (16%),
and both HPV type 16 and HPV type 18 in 19 cases (14%). Moreover, the difference
between prevalence of HPV infection caused by HPV 16 only, HPV 18 only or/and
both in adenocarcinoma in situ and the invasive cervical adenocarcinoma was not
statistically significant. However, 16/18 prevalence in all subtypes of invasive
adenocarcinoma has showed that there are no big differences between each other.
Nevertheless, HPV 16 and HPV 18 DNAs were detected with significant frequency in
the tissue sections obtained from cervical adenocarcinoma patients. Taken together,
our findings support that HPV 16, along with HPV 18, may play a possible role in the
pathogenesis of adenocarcinoma of the uterine cervix. More than 22 HPV types have
been found in the genital tract and the possibility of tumour specimens containing
HPV types other than those screened for here can not be excluded. Therefore, it is
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ABSTRACTS (Published)
1- DETECTION OF HUMAN PAPILLOMAVIRUS DNA TYPES 16 AND 18 IN
CERVICAL ADENOCARCINOMA AND ITS PRECURSORS BY PCR
Magdy Tawfik El-Mansi, ARW Williams, RG Morris
Department of pathology, Royal Infirmary of Edinburgh and University of Edinburgh,
51 Little France Crescent, Edinburgh, EH 16 4SA, Scotland, UK
ABSTRACT published in British Journal of Cancer, Vol 91, supplement 1, July 2004
Objective: To determine the prevalence of human papillomavirus (HPV) types 16 and
18 in cervical adenocarcinoma and its precursors of Scottish patients. Methods: HPV
DNA was extracted from paraffin-embedded, formalin-fixed tissues of 161 specimens
of 139 patients, including x cases of invasive adenocarcinoma and x of pre-invasive
precursors (high grade CGIN). .HPV DNA was detected by PCR test using type
specific primers from the E6 gene and E7 gene of HPV type 16 and HPV type 18
followed by restriction enzyme digestion. Results: Out of a total of 139 women with
various cervical adenocarcinomas lesions, HPV DNA was identified in 87 cases
(62.6%) in which, HPV16 was negative for 74 (53%) and positive for 65 (47%)
patients and HPV18 was negative for 98 (71%) and positive for 41 (29%) patients.
Genotyping by RFLP and PCR revealed that HPV type 16 was the most frequent type
of HPV detected, comprising 46 cases (33%), followed by HPV type 18 in 22 cases
(16%), and HPV typel6 and HPV type 18 in 19 cases (14%). There were 52 (38%) of
139 of patients with various cervical adenocarcinoma lesions with HPV type 16 and
HPV type 18 both negative. HPV typing in all cases of 16 normal cervical biopsies
was negative with both HPV type 16 and HPV type 18.Conclusions: Our findings
support that HPV 16 (mainly), along with HPV 18, may play a role in pathogenesis of
cervical adenocarcinoma and its precursors.
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2-Validation of Tissue Microarray Technology using Cervical Adenocarcinoma
and its Precursors as a Model System
Magdy Tawfik El-Mansi, ARW Williams,
Department of pathology, Royal Infirmary of Edinburgh and University of Edinburgh,
51 Little France Crescent, Edinburgh, EH 16 4SA, Scotland, UK
ABSTRACT published in The Journal of Pathology, July 2004
The recent development of tissue microarray (TMA) technology has potentiated large-
scale retrospective cohort studies using archival formalin-fixed, paraffin-embedded
tissues. One obstacle to broad acceptance of TMAs is that they reduce the amount of
tissue analyzed from a whole tissue section to a disk of 0.6mm diameter. In this study,
we used a large series of cervical adenocarcinomas to investigate TMA technology in
assessment of immunohistochemical staining. A TMA was constructed using 273
archival paraffin blocks from a series of 139 patients with 119 invasive and 20
preinvasive cervical adenocarcinomas, and 16 normal controls. Two paired of tissue
cores were obtained from specific regions of donor blocks selected at histological
review, and subsequently were arrayed into a recipient block. The novel array blocks
and some whole donor blocks were sectioned and used for immunohistochemical
analysis for CEA, CK7 and CK20. We compared staining in the microarray disks with
the whole tissue sections. The TMA was found to yield good immunohistochemical
staining which was concordant with that of the whole section from which it
originated. Two paired of TMA cores achieved representation of the whole section in
immunohistochemical studies in over 97% of cases. Our results suggest that TMAs
can be successfully used for immunohistochemical studies of cervical adeno¬
carcinomas. The TMA technique is a rapid, cost effective, and tissue-saving method
for high-throughput immunohistochemical studies. The areas sampled from donor
blocks must be selected by careful review of sections from the original blocks, and we
have shown the cores to accurately represent the morphology of the tumour in all
cases. Two paired of TMA cores will provide representative immunohistochemical
results in over 97% of cases.
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3-EvaIuation of PTEN Expression in Cervical Adenocarcinoma By Tissue
Microarray
Magdy Tawfik El-Mansi, ARW Williams,
Department of pathology, Royal Infirmary of Edinburgh and University of Edinburgh,
51 Little France Crescent, Edinburgh, EH16 4SA, Scotland, UK
ABSTRACT published in American Journal of clinical pathology (AJCP) October
issue, 2004
PTEN, a recently discovered tumour suppressor gene, appears to negatively control
the phosphoinositide 3-kinase signalling pathway for regulation of cell proliferation
and cell survival. Somatic PTEN mutations are involved in a variety of tumours,
including endometrial carcinomas, where PTEN expression is diminished. In this
study we examined expression of PTEN in a series of cervical adenocarcinomas and
precursors, using tissue microarray (TMA) technology. TMA blocks were constructed
using paraffin-embedded, formalin-fixed tissues from 273 samples derived from 16
normal cervical biopsies, 119 cases of invasive adenocarcinoma and 20 high grade
CGIN. Fresh 3-Mjm sections were cut and immunostained with PTEN antibody and
expression was correlated with clinicopathological variables, including histological
subtypes of adenocarcinoma. In 137 patients with invasive or preinvasive
adenocarcinoma, PTEN expression was negative in 16 (12%) and positive in 121
(88%). In all cases, normal endocervical cells and normal stromal cells of the cervix
stained weakly positive for PTEN. The intensity and distribution of PTEN staining in
the tumour tissue were more heterogeneous than that observed in the normal tissues.
There was no difference in distribution or intensity of PTEN expression between
adenocarcinoma in situ and invasive adenocarcinoma. Also, different histological
subtypes of cervical adenocarcinoma showed no significant differences in PTEN
expression. Our findings show that unlike the case in most endometrial carcinomas,
PTEN expression is retained during the process of carcinogenesis in the glandular
cervix. There is, however, evidence of altered distribution and intensity of PTEN
expression in cervical adenocarcinoma cells.
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4- Immunohistochemical Expression of Oestrogen Receptor (ER) and
Progestrone Receptor (PgR) in Cervical Adenocarcinoma and its precursors
Using Tissue Microarray (TMA) Technology
Magdy Tawfik El-Mansi, ARW Williams,
Department of pathology, Royal Infirmary of Edinburgh and University of Edinburgh,
51 Little France Crescent, Edinburgh, EH 16 4SA, Scotland, UK
ABSTRACT published in The Journal of Pathology, July 2005
Few studies have investigated the expression and clinical significance of (ER) and
(PgR) in adenocarcinoma of the cervix. In this study, we examined expression of ER
and PgR in a series of cervical adenocarcinomas and precursors, using TMA
technology. TMA blocks were constructed using paraffin-embedded, formalin-fixed
tissues from 273 samples derived from 16 normal cervical biopsies, 119 cases of
invasive adenocarcinoma and 20 high grade CGIN. Fresh 3-H-m sections were cut and
immunostained with ER and PgR antibodies, and expression was correlated with
clinicopathological variables, including histological subtypes of adenocarcinoma. In
139 patients with invasive or preinvasive adenocarcinoma, ER expression was
positive in 64 (47%) with 2 cases not available and PgR was positive in 50 (37%)
with 4 cases not available. In all cases, normal endocervical cells and normal stromal
cells of the cervix stained weakly for ER and PgR. The intensity and distribution of
ER and PgR staining in the tumour tissue were more heterogeneous than that
observed in the normal tissues. ER positivity was more frequent in invasive (50%)
and early invasive (56%) cervical adenocarcinomas than in AIS (28%) which suggest
that high ER levels are possibly associated with more advanced lesions. Moreover,
high ER and PgR levels were more frequent in minimal deviation adenocarcinoma
and adenosquamous carcinomas, consistent with the suggestion that ER and PgR
expression are more frequent in tumours of worse prognosis. Our findings suggest
that ER and PgR status may be useful markers in women with cervical
adenocarcinoma. Further assessment of the impact of ER and PgR status on the
clinical outcome of patients with primary invasive adenocarcinoma of the cervix in
larger case series is needed.
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Receptor (PgR) in Cervical Adenocarcinoma and its Precursors using tissue
microarray technology.
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Validation of tissue microarray technology using
cervical adenocarcinoma and its precursors as
a model system
M. TAWFIK EL-MANSI & A.R.W. WILLIAMS
Department of Pathology, Royal Infirmary of Edinburgh and University of Edinburgh, Edinburgh,
Scotland, United Kingdom
Abstract. Tawfik El-Mansi M, Williams ARW. Validation of tissue microarray technology using cervical
i adenocarcinoma and its precursors as a model system. Int ] Gynecol Cancer 2006;16:1225-1233.
The tissue microarray (TMA) technology has potentiated large-scale retrospective cohort studies using
archival formalin-fixed, paraffin-embedded tissues. We used a large series of cervical adenocarcinomas to
investigate TMA technology in assessment of immunohistochemical staining. A TMA was constructed
using 273 archival paraffin blocks from 139 patients with 119 invasive and 20 adenocarcinoma in situ and
16 normal controls. Two paired cores were obtained from specific regions of donor blocks selected at histo¬
logic review and were arrayed into a recipient blocks. The novel array blocks and some whole donor
blocks were sectioned and used for immunohistochemical analysis for carcinoembryonic antigen, cytoker-
atin 7, and cytokeratin 20 antibodies as potential diagnostic markers. We compared staining in the micro-
array disks with the whole tissue sections. Two paired TM cores were found to yield good
immunohistochemical staining that was concordant with that of the whole section from which it originated
in about 97% of cases, and the cores accurately represented the morphology of the tumor with respect to
tumor typing and differentiation in all cases. Our results suggest that TMAs can be successfully used for
immunohistochemical studies of cervical adenocarcinomas. The areas sampled from donor blocks must be
selected by careful review of sections from the original blocks.
keywords: CEA, cervical adenocarcinoma, CK7, CK20, tissue microarray (TMA) technology,
immunohistochemistry.
Cervical cancer is the second commonest type of can¬
cer in females worldwide, with an estimated annual
incidence of up to 500,000 new cases. Although its
incidence is declining in developed countries owing to
established cytologic screening programs, it is still
responsible for significant morbidity in industrialized
nations'1'. The two most common histologic types of
cervical cancer are squamous cell carcinoma, which
comprises approximately 75% of cases, and endocer-
vical adenocarcinoma, which comprises approxi¬
mately 20% of cases®. To date, there has been less
emphasis on glandular lesions of the cervix, and
less information is available regarding the natural his¬
tory, pathology, and clinical aspects of cervical adeno-
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carcinoma. An absolute increase in prevalence of
adenocarcinoma and its precursors has been docu¬
mented, both in the United States and in the Europe®.
In addition, because immunohistochemistry is com¬
monly used for identification of molecular markers
that predict patient survival'4'5', newer markers may
become increasingly useful clinically in early diagno¬
sis and treatment of cervical adenocarcinoma<6).
The standard method of histopathologic analysis is
microscopic examination of sections of formalin-fixed,
paraffin-embedded tissue®. The tissue microarray
(TMA) technique was described in 1998 by Kononen et
al}8) and allows immunohistochemical analysis of
500-1000 samples simultaneously. TMA uses 0.6-mm-
diameter tissue core biopsy specimens that are
retrieved from selected regions of archival donor
blocks and subsequently arrayed into a recipient par¬
affin array block. On average, the novel array block
can yield 100 sections and can be used for techniques
#6 M.T. El-Mansi & A.R.W. Williams
jch as immunohistochemical analysis and fluores-
®t in situ hybridization®-13*.
iMAs have a number of advantages compared with
aventional techniques that require the processing
jd staining of hundreds of slides. Microarray technol-
y enables the study of an entire cohort of cases by
jalyzing just one (or a few) master slide(s), and all
jecimens are processed at one time using identical
auditions. Moreover, it markedly reduces the amount
iarchival tissue required for a particular study, thus
^serving ample remaining tissue for other research or
iagnostic needs(14,15). Furthermore, the technique has
iten demonstrated to be efficient and applicable to var¬
us tumor types; therefore, most of the applications of
leTMA technology have come in the field of cancer
[search but methodologic evaluations are few06-18*.
Although conferring technical advantages, the
[eduction of the amount of tumor analyzed is also the
greatest potential disadvantage of this new technol-
ogy. Thus, it is important to determine how many tis-
sue disks are required to adequately represent the
expression of a particular antigen by a tumor and to
ietermine antigen survival. Specifically, it is important
to determine whether archival tissues retain their anti-
genirity in this technique, despite decades of storage
as paraffin blocks and very small volume tissue sam¬
ples. There is evidence to suggest that such tissues
main antigenically intact09,20*. The results of two
studies showed that twofold redundancy can lead to
greater than 95% concordance between the two meth-
sds and that the addition of more cores increases con-
rordance to 99.5% with five cores per specimen05*.
Moreover, the impact of data discrepancies between
array and full section has been evaluated, and it has
teen reported that this comparison has not shown any
significant change in clinicopathologic correlations
between the two methods, indicating that TMAs may
be reliable tools for clinicopathologic analyses of can-
ffir specimens'21,17*.
Previous immunohistochemical studies of cervical
adenocarcinoma have used whole tissue sections, and
very few studies have used TMA technology in evalu¬
ation of immunoprofile of cervical adenocarcinoma'22*,
h this study, we chose to examine immunohistochem¬
ical expression of three antigens—carcinoembryonic
antigen (CEA), cytokeratin 7 (CK7), and cytokeratin 20
(CK20) in a large set of cervical adenocarcinomas.
Those markers have been shown to have differing pat¬
terns of expression in cervical adenocarcinomas and
allowed comparison between TMA and whole-section
staining. CK7, a low molecular weight cytokeratin, is
homogeneously expressed in the great majority of cer-
v'cal adenocarcinomas, while CK20 is negative'23*.
® 2006 IGCS, International Journal of Gynecological Cancer 16, 1225-1233
CEA is positive in the majority but not in all cervical
adenocarcinomas, and there may be heterogeneity of
expression within different areas of a tumor'24*. By
examining these markers, we aimed to investigate
sampling requirements for demonstration of these an¬
tigens in cervical adenocarcinoma using TMAs and to
compare the TMA technique with whole-tissue stain¬
ing in regard to quality of staining, reproducibility,
and the impact of tissue heterogeneity. Moreover, we
evaluated expression patterns of these antigens as
potential diagnostic markers in cervical adenocarci¬
nomas and its precursors, comparing the profile of




A computerized search was conducted for all patients
diagnosed with cervical adenocarcinoma at the Uni¬
versity of Edinburgh, Pathology Department, from
1991 to 2001. Ethical approval for this study was
granted by the local research ethics committee. Surgi¬
cal cervical specimens were obtained from the archival
collections. A total of 273 samples (paraffin-embedded
blocks) were obtained from 177 biopsies composed of
16 normal cervical samples taken from patients suffer¬
ing from different noncervical pathologies and speci¬
mens from 139 different patients with endocervical
adenocarcinomas. Pathology reports and cervical
smear history reports were reviewed. Only primary
cervical adenocarcinomas were included. The final set
of study cases consisted of samples of glandular tis¬
sues including normal endocervical mucosa (16), high-
grade cervical glandular intra-epithelial neoplasia
(CGIN)/AIS (20), and invasive adenocarcinoma
(119) of which 16 were early invasive, meeting FIGO
criteria for stage IA1. Three-micrometer serial sections
from the routinely processed formalin-fixed, paraffin-
embedded tissue blocks were prepared.
TMA construction and hematoxylin and eosin
All sections available were reviewed histologically,
and areas of morphologically representative, nonne-
crotic sites in the tumor were marked with colored
indelible marker on the glass slides of sections stained
with hematoxylin and eosin (H&E). From each corre¬
sponding paraffin block, two paired tissue cores (0.6
mm in diameter) were sampled from each marked
area in the "donor" block and mounted into a "recipi¬
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Figure 1. Diagram of TMA organization chart that used in this
study. Tissue samples were distributed and located in TMA chart
using (x:y) relationship.
instrument (Beecher Instruments, Silver Springs, MD).
In the ensuing paraffin array block, the tissue cylin¬
ders were aligned and marked for identification
according to a chart (Fig. 1). The final set of tissue
samples consisted of 542 tissue cylinders in five TMA
blocks that included samples of normal endocervical
mucosa (32 cores) in one TMA block, AIS (59 cores) in
duplicate TMA blocks, and invasive adenocarcinoma
(196 cores) in duplicate TMA blocks. The recipient par¬
affin blocks (TMA blocks) were baked at 56°C for 10
min before sectioning, and 3-pm paraffin sections were
then made by standard technique (Fig. 2). Finally, TMA
sections stained with H&E were compared with whole
sections to investigate whether TMAs are representa¬
tive of the morphology of cervical adenocarcinoma.
Immunohistochemistry
Fresh 3-pm sections were cut from each microarray
and the original paraffin-embedded block and trans¬
ferred to glass slides. Following deparaffinization in
xylene and rehydration through descending graded
ethanol, the sections were washed well with tap water
for 2 min. Antigen retrieval for CEA and CK20 anti¬
bodies was performed by immersing tissue sections in
ethylenediaminetetraacetic acid (pH 8) and heating
them for 15 min in a microwave oven at 750 W, while
for the sections to be stained for CK7, antigen retrieval
was performed by immersing tissue sections in citrate
buffer (pH 6) with pressure-cooking for 6 min at 1 m
bar. The sections were washed well in water and then
loaded onto Shandon Sequenza staining apparatus.
Endogenous peroxidase was then blocked by treatment
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Figure 2. A) TMA paraffin block and B) TMA slide stained with
H&E.
with 1% hydrogen peroxide. Using Dako EnVision
System, the tissue sections were stained with the
following monoclonal primary antibodies for 30 min:
CEA (clone 11-7, DakoCytomation, Denmark A/S,
Denmark; 1:300 dilution), CK20 (clone Ks20.8, Dako¬
Cytomation, Denmark A/S; 1:350 dilution), and CK7
(clone OV-TL 12/30, DakoCytomation, Denmark A/S;
1:10 dilution). Negative controls contained samples in
which the primary antibody was omitted and washed
in phosphate-buffered saline solution and positive
control tissues of known positivity to CEA, CK7, and
CK20 were performed. The positive tissue control for
CK7 was breast carcinoma and for CK20 and CEA was
colonic carcinoma. The sections were washed well,
incubated with Dako EnVision/horseradish peroxidase
(HRP) rabbit/mouse polymer for 30 min, and then
washed well again. Sections were then incubated at
room temperature with 3,3'-diaminobenzidine solution
for 5 min and washed in tap water. Finally, the sections
were counterstained with hematoxylin, washed, dehy¬
drated, cleared well with xylene, and mounted by DPX.
© 2006 IGCS, International Journal of Gynecological Cancer 16, 1225-1233










Figure 3. TMA cores are representative
morphologically of different cervical le¬
sions. A) Whole tissue section of AIS after
removal of tissue core (X100). B) TMA-
core biopsy specimen representative of the
whole section in A (X200). C) TMA-core
biopsy specimen of adenosquamous carci¬
noma (X100). D) A higher power of C
(X400).
Evaluation of tissue staining
Is determine how many cores are required to adequately
epresent a cervical adenocarcinoma histologically, each
IMA core stained with H&E was analyzed separately
and in relation to its original whole section. We decided
tot in order for an immunohistochemical result to be
considered reliable, a minimum of two TMA cores
torn the tumor should show concordant staining
patterns. If divergent staining patterns were obtained,
results from third or subsequent cores were assessed,
and the case was considered to show positive staining
if a minimum of two cores showed specific staining.
In the evaluation of staining, cores were scored if at
tost 10% of the core area contained tumor, and each
core analyzed separately and graded as either positive
or negative. However, staining for CEA, CK7, and
CK20 was considered positive when the tumor cell
cytoplasm showed diffuse staining in at least two valu¬
able cores to confirm the similar expression patterns in
both. Also, the staining reaction was compared
between the cores and some of the whole sections. All
■necroscopy was performed with a Zeiss microscope
(KPI10X eyepiece with a high-power field) (X40).
Results
With respect to how many cores are required to ade¬
quately represent a cervical adenocarcinoma histologi¬
cally, we found that histologic subtype and degree of
® 2006 IGCS, International Journal of Gynecological Cancer 16, 1225-1233
differentiation were accurately represented in all cases
when two duplicate cores were examined, and it was
always possible to determine histologic subtype and
degree of differentiation from examination of the TMA
core alone, but this always needed to be confirmed by
reference to the original section (Fig. 3A-D). In cases
of AIS, early invasive adenocarcinoma, and well-
differentiated adenocarcinoma, it was often not possi¬
ble from the TMA cores to determine whether the
lesion was invasive or in situ. This is not surprising as
the histologic criteria for diagnosis of invasive disease
are often focal. Other important histologic features
that rely on extensive tissue sampling, such as lym-
phovascular space invasion, cannot be diagnosed reli¬
ably in TMA cores.
Microarrays and the original block from which they
were derived were stained for CEA, CK7, and CK20.
Comparison of immunohistochemical staining for
CK7, CK20, and CEA of TMA cores and parent sec¬
tions showed that for all three antigens, in about 97%
of cases, two paired TMA cores showed staining that
was concordant (Fig. 4). In three cases, one TMA core
was discordant with the average staining pattern of
the whole section but the other TMA core was concor¬
dant. In such cases, analysis of two paired cores was
necessary. If positive staining was identified in a mini¬
mum of two cores, the case was considered positive.
Thus, analysis of two paired TMA cores provided
staining results that were consistent with the original
whole section in about 97% of cases (Table 1).
Validation of TMA technology 1229
V'"
Figure 4. Immunohistochemical demon¬
stration of CK7, CK20, and CEA in cervical
tissues. Three CK20-stained cervical tissues
show no staining: A) normal cervical tissue
(X100), B) whole tissue section of AIS after
removal of tissue core (X100), C) TMA-core
biopsy specimen shows the same staining
reaction as the whole section in B (X200),
D) TMA-core biopsy specimen of normal
cervical tissue shows no staining with CEA.
Three CK7-stained cervical tissues: E) nor¬
mal cervical tissue shows diffuse delicate
membrane staining, but much of the cyto¬
plasm is unstained (X100), F) whole tissue
section of invasive adenocarcinoma after
removal of tissue core shows strong posi¬
tive cytoplasmic staining (X100), G) TMA-
core biopsy specimen shows the same
staining reaction as the whole section in F
(X100), H) two CEA-stained TMA cores of
different invasive adenocarcinomas, one
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In 139 patients with invasive adenocarcinoma or
preinvasive disease (high-grade CGIN/AIS), immuno¬
histochemical staining patterns for CK7, CK20, and
CEA were cytoplasmic only and were positive in 132
patients (97%) for CK7, 4 (3%) for CK20, and 92 (68%)
for CEA. Generally, the cytoplasm of the malignant en-
docervical cells was stained diffusely for CK7, CK20,
and CEA (Fig. 4F-H). However, in normal endocer-
vical glands, there was diffuse delicate membrane
staining with CK7, but much of the cytoplasm was
unstained (Fig. 4E). This is in contrast to cells of high-
grade CGIN/AIS and invasive adenocarcinoma,
where there was diffuse strong cytoplasmic staining.
Normal endocervical glands were negative, and there
was no positivity in all cells. Endocervical stromal
cells were negative, and there was no positivity in all
kinds of stromal cells (Fig. 4A-H). In up to 4% of cases
overall, the core biopsy sections were nonevaluable
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[able 1. Details on number of positive, negative, and not
available cases for each antigen
Total number Positive, Negative, Not available,
Antigen of cases N (%) N (%) N (%)
|CK7 139 132 (97) 4(3) 3(2)bo 139 4(3) 130 (97) 5(4)
CEA 139 92 (68) 44(32) 3(2)
because of loss of material during sectioning and
staining. There were no significant differences in dis¬
tribution or intensity of CK7, CK20, and CEA expres¬
sion between AIS and invasive adenocarcinoma. Also,
different histologic subtypes of cervical adenocarcinoma
showed no significant differences in CK7, CK20, and
I CEA expression patterns (Table 2). Correlation
between CK7, CK20, and CEA expression and patho-
1
logic variables of cervical adenocarcinomas is shown
in Table 2. There was diffuse cytoplasmic staining of





Archival formalin-fixed, paraffin-embedded tissues are
the most widely used source of tumor material for
TMAs, but there has been little consideration given in
the literature to the sampling issues of the technique.
We performed this study to investigate sampling re¬
quirements in order for TMA cores to be adequately
representative of whole tumors in cervical adenocarci¬
noma and to determine whether TMA technique was
appropriate for immunohistochemical assessment of
antigens with differing distributions in this tumor
type.
The question of how many cylinders need to be
taken in order to obtain two readable cores is influ¬
enced by several factors. Foremost among these is the
ability to identify areas of tumor tissue distinct from
stroma, normal epithelium, and/or AIS. Although
good histologic detail is usually retained in microarray
cores, it is often difficult or impossible to distinguish
AIS from better differentiated variants of invasive ade¬
nocarcinoma. Moreover, other important histologic
features such as lymphovascular space invasion,
which are essential for staging of cervical adenocarci¬
noma, cannot be diagnosed reliably in TMA cores. We
found that it is crucial to perform careful assessment
of the original sections, and to mark the slide with
indelible marker prior to core sampling of the corre¬
sponding paraffin block. Other important factors
include the technical expertise of the individual con-
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structing and sectioning the array blocks. In our labo¬
ratory, one person performed these tasks. Currently,
our rate of usable cores is about 97%. Finally, the
thickness (depth) of the original embedded tissue sec¬
tions can affect the number of usable slides able to be
cut from the master array block. Therefore, efforts
were made to select blocks that had sufficient residual
tissue in the archival tissue blocks to ensure an ade¬
quate sample for TMA construction.
In this study, we evaluated immunohistochemical
staining for CEA, CK7, and CK20 of cervical adenocar¬
cinoma in TMAs. These antigens were chosen, in part,
because they are potentially useful in diagnostic speci¬
mens of cervical adenocarcinomas and also because
their expression patterns in this tumor type show sig¬
nificant differences. We were able to compare the
staining patterns of these antigens in the whole sec¬
tions with TMA cores from the corresponding blocks.
Thus, discordant staining between TMA cores and
whole sections would most probably represent techni¬
cal artifact. Similar results have been reported in previ¬
ous evaluations of the TMA technique in different
cancer specimens and cell lines<21'17).
CK7 was found to show strong uniform expression
in epithelium in sections of normal glandular endocer-
vix, cervical AIS, and most invasive adenocarcinomas
of cervix and would therefore be expected to show
similar patterns in TMAs. In contrast, CK20 does not
stain normal cervical glandular epithelium, and stain¬
ing is absent in the majority of invasive adenocarci¬
nomas. CEA shows heterogeneous staining, being
positive in the majority of cervical adenocarcinoma
but is negative in a proportion'24'. The distribution of
staining is commonly heterogeneous in positive cases,
with some areas of tumor showing strong staining,
while other areas are negative. We were interested to
investigate how this heterogeneity would be reflected
in the TMA cores
We found that staining results from two readable
TMA cores were the same as those of the whole section
in about 97% of cases. In up to 4% of cases overall,
the core biopsy sections were nonevaluable because of
loss of material during sectioning and staining. This
loss of data, due to tissue loss or inconclusive data,
has been reported in previous evaluations of the
TMA technique in soft tissue tumors'16,5' and in rectal
cancer'6' where 17% of the core biopsy sections were
nonevaluable.
The main problem of TMAs is that they reduce the
amount of tissue analyzed from a whole tissue section
to a core, 0.6 mm in diameter, that may not be repre¬
sentative of the protein expression patterns of the
entire tumor because of tissue heterogeneity'21'. In this
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Table 2. Showing immunohistochemical results of CK7, CK20, and CEA in AIS and subtypes of invasive adenocarcinoma.
AIS, N (%) A-NOS, N (%) ADSQ, N (%) VGC,N(%) MDA, N (%) Others, N(%)
CK7
Negative 0(0) 2(4) 1(5) 0(0) 0(0) 1(6)
Positive 18 (100) 47 (96) 21 (95) 23 (100) 8 (100) 15 (94)
Total 18 (100) 49 (100) 22 (100) 23 (100) 8 (100) 16 (100)
CK20
Negative 18 (100) 46 (96) 21 (95) 23 (100) 8 (100) 14 (93)
Positive 0(0) 2(4) 1(5) 0(0) 0(0) 1(7)
Total 18 (100) 48 (100) 22 (100) 23 (100) 8 (100) 15 (100)
CEA
Negative 5(28) 21 (42) 6(27) 4(17) 2(25) 6(40)
Positive 13 (72) 29 (58) 16 (73) 19 (83) 6(75) 9(60)
Total 18 (100) 50 (100) 22 (100) 23 (100) 8 (100) 15 (100)
ADSQ, adenosquamous carcinoma; MDA, minimal deviation adenocarcinoma; NOS, not otherwise specified; A-NOS, adenocarci¬
noma NOS; VGC, villoglandular papillary adenocarcinoma; others, other types of adenocarcinoma.
study, 0.6-mm cores accurately represented tumor
morphology in all cases of cervical adenocarcinoma.
TMAs should not be constructed from randomly
or blindly selected regions of each tumor. Careful
selection of the regions of interest in a morphologi¬
cally heterogeneous tumor provides more representa¬
tive results. This process of selecting representative,
viable tumor regions from which to obtain the core
biopsy specimens is crucial and should be performed
by an experienced pathologist.
A frequent question is whether a larger diameter
of the needle used for TMA construction (eg, 3 mm
instead of 0.6 mm) could help minimize sampling
errors caused by heterogeneity. Although the devel¬
opment of TMA technology started using 3-mm
needles, it is considered that increasing the needle
size is of limited value in the assessment of heteroge¬
neous tumor markers since tumor heterogeneity is
likely to a minor degree within a still very small tis¬
sue fragment measuring 3 mm in diameter. If a better
representation of an individual tumor is required, it
would be more advantageous to array two or more
samples from different areas of each tumor. Similar
results were reported by Bubendorf et al.<25). Some in¬
vestigators have been tempted to use larger diameter
punches (typically 2-4 mm) in an effort to provide
more representative samples for TMA analysis. Al¬
though this approach multiplies the amount of tissue
analyzed by a factor of 10-45, there is little mathe¬
matical or practical evidence that such a sampling
strategy is more representative than 0.6-mm punches.
Typical primary tumors often measure 2-15 cm in
diameter. Even if the concept holds that small sub-
populations are critical for tumor behavior, the likeli¬
hood of detecting the decisive clone in a 3-mm
sample is not much larger than detecting it in a 0.6-mm
area. To improve the sampling efficiency, the acquisi¬
tion of multiple small tissue cores from distinct, per¬
haps histologically different, regions of the tumor is
more effective than increasing the size of a single
punch. Based on these considerations, the 0.6-mm
sample size is preferable. Using larger (2- to 4-mm)
samples also has the substantial disadvantage that it
greatly reduce the number of samples that can be
arrayed on a single slide (only about fifty 4-mm
biopsies fit on a single TMA slide) and the number of
punches that can be taken from one original tumor
block. These results and suggestions were supported
in previous evaluations of the TMA technique in dif¬
ferent cancer specimens and cell lines(21,17). Moreover,
Camp et a/.(15> concluded that the TMA technique,
with twofold redundancy, in breast cancer is a valu¬
able and accurate method for analysis of protein
expression in large archival cohorts.
To determine the number of tissue cores required
to obtain an immunohistochemical result equivalent
to a conventional tissue section, we constructed an
array with two pairs of cores from each of 119 cases
of invasive cervical adenocarcinoma, 20 AIS, and 16
normal endocervical tissues. We analyzed each core
separately and graded it as either positive or nega¬
tive. About 97% of cases had at least two scorable
cores for each antibody tested. However, most cases
had more than three cores with sufficient tumor for
evaluation. In the majority of cases, staining was
uniform across all the cores, and consequently, the
chance of adequately representing the tumor in one
punch was 100%. Moreover, the results of this analy¬
sis demonstrate that microscopic analysis of two
disks achieves about 97% representation. Therefore,
we suggest that staining results from a minimum of
two cores should be included in immunohistochemical
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cessment of TMA technique in cervical adenocarci-
■;ma. For practical purposes, therefore, it is desirable
.identify the minimal number of core biopsy sped-
jens needed to achieve two readable cores for
bmunohistochemistry. With a loss of up to 4% of
Je core biopsy specimens, we suggest that four
issue cores should be taken from each tumor. This
snclusion is in concordance with the results ob-
lained from validation of the TMA technique for
inmunohistochemical staining in soft tissue tu¬
mors116'^ in rectal cancer(6i and in breast cancer(15).
These studies have suggested that analysis of tripli¬
cate core biopsy specimens per tumor increases the
cumber of concordant readings, lowers the number
of lost cases, and provides a reliable immunohisto-
chemical expression profile.
According to all of these data and our experience,
.we have developed a standard procedure in which
two pairs of cores are punched in various regions of
I the tumor mass, including both the leading edge and
the tumor center. This process ensures that at least
two, and in most cases three, punches are available for
evaluation, resulting in adequate representation of the
j whole-section staining pattern in about 97% of cases.
I Although expression of some antigens, such as estro¬
gen receptor and progesterone receptor, in cervical
adenocarcinoma is regarded as particularly heteroge¬
neous, it is possible that other antigens in other tumor
types may exhibit even greater heterogeneity. Conse¬
quently, similar analyses may be required to validate
the use of TMAs in other tumor types. A similar sug¬
gestion is reported in TMA evaluation in breast cancer
j by Camp et a/.(15).
In conclusion, the TMA technique is a rapid, cost-
effective, and tissue-saving method, yields staining of
good quality, and is feasible for immunohistochemical
studies in cervical adenocarcinoma. Four cores are suf¬
ficient to produce representative sampling of the mor¬
phology of tumors even if occasional cores are lost on
slides. TMAs will substantially accelerate studies asso¬
ciating novel molecular discoveries in the field of ge¬
nomics and proteomics with specific pathologic,
demographic, clinical, and follow-up information of
cancers and cancer patients. TMAs containing well-
characterized tissues enable researchers to perform
studies involving thousands of patient specimens, with
substantial increases in speed, quality of data, infor¬
mation content, and savings of cost and time. Since
the diagnostic tumor biopsy specimens are often small,
the use of the TMA contributes to tissue preserva¬
tion. Furthermore, the tumor areas from which the
tissue core biopsy specimens are obtained must be
carefully selected to reduce the number of non-
© 2006 IGCS, International Journal of Gynecological Cancer 16, 1225-1233
evaluable core biopsy sections containing nonrepre-
sentative tissue.
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Evaluation of PTEN expression in cervical
idenocarcinoma by tissue microarray
H.TAWFIK EL-MANSI & A.R.W. WILLIAMS
]ipartment of Pathology, University of Edinburgh, Edinburgh, Scotland, United Kingdom
Abstract. Tawfik El-Mansi M, Williams ARW. Evaluation of PTEN expression in cervical adenocarcinoma
ijtissue microarray. Int J Gynecol Cancer 2006;16:1254-1260.
TEN, a tumor suppressor gene, appears to negatively control the phosphoinositide 3-kinase signaling
pthway for regulation of cell proliferation and cell survival. Somatic PTEN mutations are involved in a
variety of tumors, including endometrial carcinomas, where PTEN expression is diminished. We examined
(xpression of PTEN in a series of cervical adenocarcinomas and precursors, using tissue microarray (TMA)
technology. TMA blocks were constructed using paraffin-embedded, formalin-fixed tissues from 273 sam¬
ples derived from 16 normal cervical biopsies, 119 cases of invasive adenocarcinoma, and 20 high-grade cer-
lical glandular intraepithelial neoplasia (CGIN). Fresh 3-pm sections were cut and immunostained with
WEN, and expression was correlated with clinicopathologic variables, including histologic subtypes of adeno¬
carcinoma. In 137 patients, PTEN expression was positive in 121 (88%). The intensity and distribution of
WEN staining in the tumor tissue were more heterogeneous than those observed in the normal tissues. There
[were no significant differences in distribution or intensity of PTEN expression between adenocarcinoma in
|situ and subtypes of invasive adenocarcinoma. Our findings show that unlike the case in most endometrial
carcinomas, PTEN expression is retained during the process of carcinogenesis in the glandular cervix. There is,
however, evidence of altered distribution and intensity of PTEN expression in cervical adenocarcinoma cells.
keywords: cervical adenocarcinoma, immunohistochemistry, PTEN, tissue microarray (TMA).
IWEN (phosphatase and tensin homolog deleted on
t chromosome 10) is a tumor suppressor gene that
appears to negatively control the phosphoinositide
3-kinase signaling pathway for regulation of cell sur¬
vival and cell proliferation by dephosphorylating phos-
phatidylinositol 3,4,5-triphosphate (PIP-3)'1'. The loss of
PTEN function results in an increased concentration of
PIP-3, and this in turn leads to Akt hyperactivation. This
suggests that the tumor suppressor function of PTEN is
exerted through the negative regulation of the phospha-
Mylinositol-3(PI3)-kinase/Akt cell survival pathway'2,3'.
Ike protein phosphatase activity of PTEN is not consid¬
ered to be as important as its lipid phosphatase activity
for tumor suppression. However, PTEN function as pro¬
tein phosphatase has been implicated in the inhibition of
cell migration and invasion via dephosphorylation of
focal adhesion kinase, a molecule critical in the regula-
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tion of integrin signaling'4,5' and also in the inhibition of
cell cycle progression'6'.
To date, 110 germ line PTEN mutations have been
reported in patients affected with rare multiple ha¬
martoma syndromes'7,8'. PTEN has also been found to
be defective in a large number of sporadic human tu¬
mors of breast, prostate, brain, and endometrium'7,9,10'.
PTEN is a good candidate for involvement in the path¬
ogenesis of sporadic colon cancer. However, to date,
few somatic PTEN mutations or deletions have been
identified in sporadic colon cancers'10-13'. Somatic PTEN
mutations are more particularly involved in two types
of human cancers: endometrial carcinomas'14' and
glioblastomas'15,16'. In most cases, these somatic muta¬
tions result in protein inactivation, and as with germ
line mutations, recurrent somatic mutations are found
in CpG dinucleotides. A mutagenesis by insertion-
deletion in repetitive elements is, however, specifically
observed in endometrial carcinomas'17'.
Being one of the initial genetic changes seen in en¬
dometrial carcinogenesis, the PTEN gene acts as a gate¬
keeper for this process'18'. In normal endometria, isolated
© 2006, Copyright the Authors
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PTEN-negative glands may well be the earliest detect¬
able phases of endometrial tumorigenesis yet seen, but
the clinical relevance of such small lesions remains to
be determined'19,2®. It is anticipated that similar high
rates of initiation will be seen in other tissues because
comparable biomarkers for neoplastic initiation be¬
come available in other tissue sites. Lesions have now
fulfilled most of those postulates predicted for clini¬
cally relevant precancerous disease. Loss of PTEN func¬
tion occurs quite frequently within the endometrial
regenerative pool, at such a high rate that they can be
considered part of background "normal" genetic events.
These mutant clones remain indistinguishable from
nonmutant glands in normal cycling and anovulatory
endometrium. Involution or expansion of mutant
clones due to nongenetic factors is one possible mech¬
anism whereby the ambient hormonal state may mod¬
ify the risk of endometrial cancer'211. Interestingly, the
PTEN gene appears to be hormonally regulated, with
greatest physiologic endometrial gland expression in
an estrogen-rich environment'191. Thus, the diminished
PTEN tumor suppressor function effects are probably
accentuated under the very circumstances known to
increase endometrial cancer risk: protracted estrogen
exposure unopposed by progestins'22,231. Mutant glands
then acquire additional genetic damage and sub¬
sequently become recognizable as focal lesions by
their crowded architecture and altered cytology'211.
The role of PTEN in cervical carcinogenesis is un¬
clear and has not been investigated before. Therefore,
in this study, we examined PTEN expression immuno-
histochemically in a large set of cervical adenocarcino¬
mas, comparing the profile of adenocarcinoma in situ
(AIS) with invasive subtypes of cervical adenocarci¬
nomas using tissue microarray (TMA) technology to
assess its expression in this common human cancer
type and its potential as a prognostic factor.
Materials and methods
Tissue samples
A computerized tumor registry search was conducted
for all patients diagnosed with cervical adenocarcinoma
at the University of Edinburgh, Pathology Department,
from 1991 to 2001. Ethical approval for this study was
granted by the local research ethics committee. Surgical
cervical specimens were obtained from the archival col¬
lections. A total of 273 samples (paraffin-embedded
blocks) were obtained from 177 biopsies composed of 16
normal cervical samples and specimens from 139 differ¬
ent patients with endocervical adenocarcinomas. Pathol¬
ogy reports and cervical smear history reports were
reviewed. Nonprimary cervical adenocarcinomas were
excluded. The final set of study cases included samples
of glandular tissues including normal endocervical mu¬
cosa (16), high-grade cervical glandular intraepithelial
neoplasia (CGIN)/AIS (20), and invasive adenocarci¬
noma (119) of which 16 were early invasive, meeting
FIGO criteria for stage IA1. Three-micrometer serial sec¬
tions from the routinely processed formalin-fixed, par¬
affin-embedded tissue blocks were prepared. Before
deparaffinizing the sections, they were baked overnight
at 60°C and stained using hematoxylin and eosin method
to choose the morphologically representative areas.
Tissue arrays and immunohistochemistry
Areas of morphologically representative, nonnecrotic
sites in the tumor were marked with colored indelible
marker on the glass slides. From each corresponding
paraffin block, two paired tissue cores (0.6 mm in
diameter) were sampled from each marked area in the
"donor" block and mounted into a "recipient" paraffin
block by the use of a custom-made instrument (Beecher
Instruments, Silver Springs, MD). In the ensuing paraf¬
fin array block, the tissue cylinders were aligned and
marked for identification according to a chart. The
"recipient" paraffin blocks (TMA blocks) were baked
at 56°C for 10 min before sectioning, and 3-gm paraf¬
fin sections were then made by standard technique.
After that, TMAs sections were stained with phospha¬
tase and tensin homolog deleted on chromosome 10
(PTEN) antibody. In addition, some slides from the
whole tissue blocks were stained.
Fresh 3-pm sections were cut from each microarray
and the original paraffin-embedded block and trans¬
ferred to glass slides (BDH Superfrost plus microscope
slides, 75 mm, BDH Laboratory Supplies). Following
deparaffinization in xylene (two times, 5 min each time)
and rehydration through descending graded ethanol,
100%, 95%, and 70% (2 min each time), the sections
were washed well with tap water for 2 min. Antigen
retrieval was performed by immersing tissue sections
in citrate buffer pH 6, with pressure-cooking for 6 min
at lm bar. The sections were washed well in water
and then loaded onto Shandon Sequenza staining
apparatus. Endogenous peroxidase was then blocked
by treatment with 1% hydrogen peroxide for 5 min,
followed by washing in distilled water and then
phosphate-buffered saline (PBS). Using Dako Envision
System, the tissue sections were stained with PTEN
(clone 28H6, NovoCastra Laboratories Ltd., UK) for
30 min and incubated at 1:100 dilution. Negative con¬
trol (omission of the primary antibody) and positive
control tissues of known positivity to PTEN were
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Id. The positive tissue control for PTEN was tonsil,
je sections were washed well in PBS (two times, 5 min
;ch time). The tissue sections were incubated with
Mco EnVision/HRP rabbit/mouse polymer for 30 min
jd then washed well in PBS (two times, 5 min each
Lie). After that, the sections were incubated at room
•mperature with 3,3'-diaminobenzidine solution for
min and washed in tap water. Finally, the sections
ere counterstained with hematoxylin, washed in tap
later, "blued" in Scott's Tap Water Substitute (STWS),
ihydrated in ascending graded ethanol, 70%, 95%, and
i0% (5 seconds each time), and cleared well with xylene
Ld mounted by DPX.
[valuation of tissue staining
fe decided that in order for an immunohistochemical
isult to be considered reliable, a minimum of two TMA
sres from the tumor should show concordant staining
atterns. If divergent staining patterns were obtained,
ssults from third or subsequent cores were assessed,
aid the case was considered to show positive staining if
i minimum of two cores showed specific staining.
In the evaluation of staining, cores were scored if at
bast 10% of the core area contained tumor, and each
tore analyzed separately and graded it as either pos-
|iive or negative. However, PTEN staining was con¬
sidered positive when the tumor cell nuclei showed
staining in at least two valuable TMAs. Also, the
staining reaction was compared between the cores and
some of the whole sections. Moreover, we compared
lie staining reaction of invasive and preinvasive cases
wth that of normal tissue with respect to the intensity
and distribution of PTEN expression. All microscopy
tvas performed with a Zeiss microscope (KPI10X eye¬
piece with a high-power field) (X40).
Statistical analysis
Associations between pathologic variables and expres¬
sion of PTEN were analyzed using StatXact-4 package.
Fisher's exact test was used in comparison between
A1S and invasive adenocarcinoma, while Chi-square
lest was used in comparison between different sub¬
types of invasive adenocarcinoma. P value of <0.05
ivas judged to be significant.
Results
PTEN expression in the cervix
There were two patients where PTEN result was not
'
available. In the other 137 patients, the result was neg-
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ative for 16 (12%) and positive for 121 (88%). Immuno¬
histochemical staining for PTEN was nuclear only. In
all cases, normal endocervical cells and normal stro¬
mal cells of the cervix stained weakly positive for
PTEN (Fig. 1A). The nuclei of malignant endocervical
cells were stained diffusely either as fine or as coarse
granular dots. Generally, the staining reaction of
malignant endocervical cells was stronger than that
observed in the normal endocervical cells and was
also restricted to the nucleus. In addition, the intensity
and distribution of PTEN staining in the tumor tissue
were more heterogeneous than those observed in the
normal tissues. Also, there was marked heterogeneity
of the intensity and the distribution between and
within tumors in the same section (Fig. 1D-H). There
was strong nuclear staining of positive controls in all
cases, but no staining of negative controls.
Correlation between PTEN expression and
pathologic variables of cervical adenocarcinomas
High-grade CGIN/AIS
Excluding 2 patients from 20 patients with AIS where
PTEN result was not available, 16 of 18 patients (89%)
with AIS were positive with PTEN, and the other 2 pa¬
tients (11 %) were negative. There was no significant dif¬
ference in distribution or intensity of PTEN expression
between AIS and invasive adenocarcinoma (Fig. IB, D).
PTEN results of AIS in comparison to those of invasive
subtypes of adenocarcinoma are shown in Table 1.
Invasive adenocarcinoma
A total of 105 of 119 patients (88%) with invasive cer¬
vical adenocarcinoma were positive with PTEN. In
addition, different histologic subtypes of cervical ade¬
nocarcinoma showed no significant differences in
PTEN expression (Fig. 1D-H). PTEN results of all sub¬
types of invasive adenocarcinoma in comparison to each
other and in comparison to AIS are shown in Table 1.
Early invasive adenocarcinoma
Sixteen of 119 patients with invasive adenocarcinoma
had early invasive adenocarcinoma that meet criteria
for FIGO stage IA1 carcinoma of the cervix. The PTEN
result was negative for 2 (13%) and positive for 14
(88%) patients.
Discussion
A recently discovered tumor suppressor gene, PTEN,
encodes a dual activity phosphatase and has been
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Figure 1. Immunohistochemical dem¬
onstration of PTEN in cervical tissues.
A) In normal cervical tissue, there is
weak positive staining of stromal cells
and nuclei of cervical glandular cells
(X200). B) In AIS, there is strong posi¬
tive nuclear staining (X200). C) In en-
docervical adenocarcinoma, signet ring
cell type, there is no nuclear staining
with positive stromal cells (X400). D)
In AIS, there is strong positive nuclear
staining (X400). In endocervical ade¬
nocarcinoma of all other subtypes,
there is strong positive nuclear stain¬
ing: E) villoglandular papillary adeno¬
carcinoma (X400), F) adenosquamous
carcinoma (X400), G) microglandular
carcinoma (X400), and H) intestinal-
type adenocarcinoma (X400). Note:
The intensity and distribution of PTEN
staining in the tumor tissue are stron¬
ger and more heterogeneous than
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involved in cell cycle regulation and cell adhesion
properties including migration'245. Loss of PTEN func¬
tion leads to increased Akt activity and, subsequently,
cell survival'35. Somatic mutations of PTEN are
involved in a variety of tumors such as endometrial
carcinomas where PTEN expression is diminished'235.
There are likely to be multiple but distinct tissue-
related pathways involved in tumorigenesis and
tumor progression. Loss of PTEN function in prostate
and breast cancers may be compounded by loss of
protein expression by transcriptional or translational
mechanisms. In prostate tissues, genetic aberrations
and expression losses have been reported'115, and in
breast carcinomas, a recent immunohistochemical study
showed that 15% of cases had complete loss of PTEN
protein, a phenomenon that appeared to correlate
with monoallelic deletion of the gene'265. Although
loss of heterozygosity of PTEN can be found in
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Me 1. PTEN expression of all subtypes of invasive adeno-
jcinoma and AIS. There are no significant differences between
Anocarcinoma subtypes and between AIS and invasive ade-
itarcinoma. There were two patients where PTEN result was'
jt available (two AIS)
'm Negative, N (%) Positive, N (%) Total, N (%)
S 2(11) 16 (89) 18 (100)
6-nos 8(16) 42 (84) 50 (100)
IDSQ 2(9) 20 (91) 22 (100)
i'GC 0(0) 23 (100) 23 (100)
IDA 0(0) 8 (100) 8 (100)
Others 4(25) 12 (75) 16 (100)
total 16 (12) 121 (88) 137 (100)
I.C0S, not otherwise specified; A-NOS, adenocarcinoma NOS;
SDSQ, adenosquamous carcinoma; VGC, villoglandular papil-
iiy adenocarcinoma; MDA, minimal deviation adenocarci-
ioma; others, other types of adenocarcinoma.
sporadic colon cancer<12), studies have not found
PTEN mutations to be as frequent as is found in tu¬
mors of the brain and the prostate. Guanti et al.(27)
studied 32 cases of sporadic colon cancer but observed
only one case with a biallelic genomic alteration that
□used loss of function of the gene and(13) found only
one somatic mutation of the PTEN gene in 72 colon
cancer cases. Taniyama et al.(11) reported, during colo-
rectal tumor progression, the analysis of PTEN RNA
.transcripts confirming that both PTEN transcriptional
and translational mechanisms are operative in colorec¬
tal cancer. However, it remains possible that PTEN pro-
i lein function is compromised via inefficient interaction
with cofactors or by peptide structure, but such studies
will require the development of a reliable enzyme
| activity assay. Subsequently, with mutational and loss
of heterozygosity analyses performed on sporadic
colon cancer specimens, these findings suggest that
fTEN expression is maintained in sporadic colon
cancers.
In this study, we examined expression of PTEN in
a series of cervical adenocarcinomas and precursors.
In 137 patients with invasive or preinvasive adenocar¬
cinoma, PTEN expression was negative in 16 (12%)
and positive in 121 (88%). Moreover, there was no sig¬
nificant difference in distribution or intensity of PTEN
expression between AIS and invasive adenocarcinoma.
Also, different histologic subtypes of cervical adeno¬
carcinoma showed no significant differences in PTEN
expression. In all cases, normal endocervical cells and
normal stromal cells of the cervix stained weakly posi¬
tive for PTEN. The staining pattern in the tumor cells
Was stronger than that observed in the normal endo¬
cervical cells but was still restricted to the nucleus. In
addition, the intensity and distribution of PTEN stain¬
ing in the tumor tissue were more heterogeneous than
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those observed in the normal tissues. There was marked
heterogeneity with respect to the intensity and the dis¬
tribution of PTEN staining pattern between and within
tumors in the same section.
Halvorsen et al.{2S) reported on their studies on pros¬
tate cancer that lack of PTEN protein expression was
found in 27% of the cases comparable with 20% nega¬
tive cases in a study of McMenamin et al.G9\ PTEN
expression was found to be associated with advanced
primary tumor stage and increasing tumor diameter,
as indicated by carcinomatous infiltration of the semi¬
nal vesicles, and was also related to time to local
recurrence, supporting the importance of PTEN for
prostate cancer growth and local invasion, possibly re¬
flecting changes in cell cycle regulation, migration, or
loss of cell cohesion influenced by PTEN*3®. These data
strongly suggest an important role of PTEN for local
invasion and the progressive growth of prostate can¬
cer in series of patients treated with radical prostatec¬
tomy for localized and presumed organ-confined
tumors(29). In addition, Minaguchi et al.GV> observed
that PTEN mutation was frequently detected in HPV-
negative adenocarcinomas of the cervix and the most
prevalent occurrence of PTEN mutation in endome¬
trioid subtype is keeping with endometrial and ovar¬
ian carcinomas. Also, it was reported that there was
a significant difference in stage III versus IV between
the wild-type PTEN patients and the mutant PTEN
patients. In addition, there was a significant difference
in survival between the wild-type PTEN patients and
the mutant PTEN patients. These results suggest that
the PTEN gene mutation rate increases with tumor
progression and that the PTEN gene may play a role
in both progression of cervical carcinoma and treat¬
ment outcome(32).
In surgical pathology practice, immunohistochem-
istry may be required to distinguish primary endo¬
cervical adenocarcinomas from primary endometrial
tumors. A panel of antibodies is commonly used that
includes estrogen receptor (ER) and vimentin (both
usually positive in endometrial carcinomas and nega¬
tive in endocervical carcinomas) and carcinoembry-
onic antigen (CEA) (usually negative in endometrial
and positive in cervical carcinomas). However, immu-
nophenotypes vary, and occasional cases remain prob¬
lematic. For example, our own (unpublished data)
results with ER staining in this series of cervical ade¬
nocarcinomas (Tawfik El-Mansi & Williams, April 2005)
indicate that around 50% of cervical adenocarcinomas
show positive ER staining. Published results from other
studies report CEA staining to be found in a majority
(62%) of endocervical adenocarcinomas(33>, but a sig¬
nificant proportion are negative. A recent study showed
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that pi 6 may also be of some value in distinguishing
between an endocervical and an endometrial adeno¬
carcinoma. Strong diffuse positivity involving 100% of
cells is the rule in primary endocervical adenocarci¬
noma, whereas endometrial adenocarcinoma usually
exhibits a lesser degree of staining(34). Many of benign
mimics such as tuboendometrial metaplasia and endo¬
metriosis are most likely to be confused with CGIN. It
is stressed that pi 6 may be of use in the distinction
between CGIN and benign mimics. Cases of CGIN
almost invariably show strong diffuse positivity for
pi6, while most benign mimics are negative or show
focal positivity®5'. Immunohistochemical expression
of CD44 has also been investigated in endocervical
glandular lesions. It was concluded that CD44 immu-
noreactivity may be a useful diagnostic marker of en¬
docervical neoplasia®4'35'. We therefore suggest that
PTEN may be a useful addition to the panel of anti¬
bodies used to make this distinction. The results of
this study have shown that 88% of cervical
adenocarcinomas show positive PTEN staining, con¬
trasting with published results for PTEN expression in
endometrial adenocarcinomas in which diminution of
expression has been found in 97%, with complete
absence in 61% of endometrial adenocarcinomas<25).
In conclusion, our findings show that unlike the
case in most endometrial carcinomas, PTEN expres¬
sion is retained during the process of carcinogenesis in
the glandular cervix. PTEN expression was positive in
105 of 119 patients (88%) with invasive cervical adeno¬
carcinoma and 16 of 18 patients (89%) with AIS.
Therefore, PTEN expression could be a potential bio-
j marker for diagnosis of cervical adenocarcinoma
and for distinguishing between primary cervical
adenocarcinoma and primary endometrial adenocar¬
cinoma. There is, however, evidence of altered distri¬
bution and intensity of PTEN expression in cervical
adenocarcinoma cells compared with normal endo¬
cervical cells. Also, there was marked heterogeneity
of the intensity and the distribution between and
within tumors in the same section. There is no signif¬
icant difference in distribution or intensity of PTEN
expression between AIS and invasive adenocarci¬
noma. Also, different histologic subtypes of cervical
adenocarcinoma showed no significant differences in
PTEN expression.
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Prevalence of human papillomavirus types 16
and 18 in cervical adenocarcinoma and its
precursors in Scottish patients
M. TAWFIK EL-MANSI, K.S. CUSCHIERI, R.G. MORRIS & A.R.W. WILLIAMS
Department of Pathology, University of Edinburgh, Edinburgh, Scotland, United Kingdom
Abstract. Tawfik EI-Mansi M, Cuschieri KS, Morris RG, Williams ARW. Prevalence of human papillomavirus
types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer 2006;
16:1025-1031.
Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical ade¬
nocarcinoma (and its precursors) in Scottish patients. Nucleic acid was extracted from paraffin-embedded,
formalin-fixed tissues. We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in
situ, and 16 cases of normal glandular epithelium. HPV DNA was detected by polymerase chain reaction
using type-specific primers for the E6 and E7 genes of HPV-16 and HPV-18 with conformation of HPV
genotype by subsequent restriction fragment length polymorphism. HPV DNA was identified in 87 (62.6%)
cases, with HPV-16 being detectable in 65 (47%) cases and HPV-18 in 41 (29%) cases. All the cases of nor¬
mal tissue tested negative for HPV-16 and/or HPV-18. No significant relation between infecting HPV type
(16 or 18) and subtypes of disease (within the invasive category and between the preinvasive and the inva¬
sive categories) was noted. Our findings support that HPV-16, along with HPV-18, are likely to play a signif¬
icant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that
incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for
the reduction of adenocarcinoma and associated glandular precursors.
keywords: cervical adenocarcinoma, human papillomavirus (HPV), polymerase chain reaction (PCR), screening.
Cervical cancer is the second commonest type of can¬
cer in females worldwide, with an estimated annual
incidence of up to 500,000 new cases1. The two most
common histologic types of cervical cancer are squa¬
mous cell carcinoma, which comprises approximately
75% of cases, and endocervical adenocarcinoma,
which comprises approximately 20%z. Although this
latter type is rare, it is considered a more aggressive
neoplasm with a worse associated prognosis. More¬
over, an absolute increase in prevalence of adenocarci¬
noma and its precursors has been documented, both
in the United States and in the Europe3.
It is widely accepted that squamous cell carcinoma
and adenocarcinoma of the cervix share a common
pathogenesis that involves persistent genital infection
with an oncogenic human papillomavirus (HPV) type
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or types4. There are over 30 HPV types that can infect
the genital tract; the types that cause benign genital
warts are classified as "low-risk" (LR) types, the most
common of which are HPV types 6 and 11. The types
that are found in premalignant and malignant tissue
are termed as high-risk (HR) types. HPV-16 and HPV-
18 are the most frequently detected HR types, although
a large number of less common HR-HPV types (in¬
cluding HPV-31 HPV-33, and HPV-45) are thought to
have a similar pathogenesis5. Although HPV-16 and
HPV-18 are regarded as essentially similar, it should
be noted that these two viruses only share 50% homol¬
ogy at the nucleotide level6.
Type of HPV might influence the histologic subtype
of invasive adenocarcinoma, as HPV type 16 has been
found to predominate in adenosquamous carcinomas,
with HPV type 18 more frequently found in all other
subtypes7. HPV oncogene expression was not depen¬
dent on histologic subtype of in situ or invasive ad¬
enocarcinomas. Normal glandular epithelia and
glandular dysplasias were always negative concerning
026 M.T. El-Mansi et al.
IPV oncogene expression. Interestingly, Riethdorf
>J8 suggested that HPV E6/E7 expression of the
ime HPV type in both in situ or invasive ad-
iiocarcinomas and associated cervical intraepithelial
aplasia II/III indicates that these lesions might be
istogenetically related. A recently reported study
lowed that HPV DNA was identified in more than
ft of in situ and invasive mucinous adenocar-
inomas that encompass endocervical, intestinal, and
idometrioid morphology and account for 95% of all
ervical adenocarcinomas. Cases of minimal deviation
idenocarcinoma were negative for HPV DNA9.
With respect to cancer prevention, organized,
ytology-based cervical screening has reduced the inci-
lence of cervical cancer significantly10 and although
i clinical success story, there is evidence to suggest it
;ould be improved by incorporation of adjunctive
HPV testing. Although less specific than cytology
Specially in young sexually active women), HPV
isting is more sensitive for the detection of underly-
ing cervical abnormalities; indeed, HPV testing has
ieen introduced (in combination with cytology) in the
United States, for women over 30 years of age, in pri¬
mary screening11. In addition, the UK pilot studies
(due to report later this year) were designed to assess
Ihe utility of using HPV testing for the triage of
.women with low-grade abnormalities to colposcopy
(www.cancer-screening.nhs.uk). There is also good
evidence to suggest that HPV testing (in the context of
a negative result) could be used as a "test-of cure" of
treatment for women with high-grade cervical disease,
with the potential to reduce the intensity of posttreat-
ment follow-up12. Further improvements in the diag¬
nostic accuracy of cytology-based screening, such as
HPV testing, could be particularly prescient for the
reduction of adenocarcinoma as it and its precursor
stage are reportedly more likely to be "missed" than
squamous cell cytologic abnormalities13.
Moreover, two prophylactic HPV vaccines are cur¬
rently in phase 3 trials, both of which are designed to
target HPV-16 and HPV-18 infection. Initial results
from these trials would suggest that the vaccines are
highly immunogenic, well tolerated, and induce sero¬
conversion in more than 99% of vaccinees. They there¬
fore constitute a very exciting prospect for the future
of cervical cancer prevention globally14.
However, it remains the fact that there are few stud¬
ies that have assessed type-specific HPV prevalence
and diversity in invasive adenocarcinoma and its
precursors15. Due to the comparative rarity of adeno¬
carcinoma, related HPV prevalence data are often
lumped together with squamous cell carcinoma (SCC)
cases, without being teased out, or are not included at
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all (due to their absence) in studies of smaller cohorts.
Thus, the potential of HPV testing and vaccination on
the reduction of adenocarcinoma per se is less clearly
defined by this "swamping" effect. The remits of this
study were therefore to assess the prevalence of
HPV "vaccine type" (HPV-16 and HPV-18) in a large
set of cervical adenocarcinoma using polymerase
chain reaction (PCR) methods. Another dimension
was to evaluate any potential HPV type-specific asso¬
ciation with histologic type of preinvasive (high-grade
cervical glandular intraepithelial neoplasia (CGIN)/




A computerized search was conducted for all patients
diagnosed with cervical adenocarcinoma at the Uni¬
versity of Edinburgh, Pathology Department, from
1991 to 2001. Consequently, surgical cervical specimens
in the form of paraffin-embedded, formalin-fixed blocks
were obtained from the archival collections. Pathology
reports and cervical smear history reports were re¬
viewed, and nonprimary cervical adenocarcinomas
were excluded. Ethical approval for this study was
granted by the local research ethics committee. The
final study set of cases constituted 119 cases of inva¬
sive carcinoma (of which 16 were early invasive, meet¬
ing FIGO criteria for stage LAI), 20 cases of AIS, and
16 cases of normal endocervical tissue.
DNA extraction from paraffin blocks
Three 10-um sections of formalin-fixed, paraffin-
embedded tissue were collected into tubes after cutting
deep into the block. The microtome blade was changed
after each case. Paraffin removal and rehydration of
sections were achieved by 2- X 10-min incubations in
xylene prior to 3- X 10-min incubations in absolute eth-
anol, followed by 2- X 10-min incubations in distilled
water. Tissue samples were incubated with lysis buffer
containing (1 mg/mL) proteinase K (400 pL/sample)
for 18 h at 55°C and boiled for 20 min to denature
the DNA and to inactivate the proteinase K. A volume
of 10 pL was used from each sample for subsequent
detection of HPVs using the PCR methods16.
HPV PCR methods
Amplification of E6 and E7 HPV DNA of HPV-16 and
HPV-18 was performed according to the method of
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Hwang17. Primer sequences used were (F) 5'-TGTCA
AAAGCCACTGTGTCC-3' and (R) 5'-GAGCTGTCA
TTTAATTGCTC-3' for HPV-16 and (F) 5'-TGCCA-
GAAACCG TTGAATCC-3' and (R) 5'-TCTGAGTC
GCTTAATTGCTC-3' for HPV-18.
PCR reactions were performed using sterile 0.5-mL
RNAse-/DNAse-free tubes, and each PCR reaction
was made up to a final volume of 50 pL. A typical
50 pL of PCR reaction contained 100 mM KCL, 20 mM
Tris-HCL pH 8.0, 2.0 mM MgCl2, 2.5 mM of dNTPs,
1.5 units of Taq polymerase (Invitrogen, Paisley, UK),
25 pmol of each primer, and 10 pL of sample. To
avoid false positives, a negative control tube that
contained no DNA sample and a positive control tube
that contained DNA from HPV immortalized cell
lines (HeLa for HPV-18 and SiHa for HPV-16) were
used. After thermal cycling (initially for 90 sec at
94°C for 1 cycle; then 40 cycles at 55°C for 1 min,
72°C for 1 min, and 94°C for 1 min; and finally 1
cycle at 72°C for 10 min), 10 pL of the PCR re-
action(s) were analyzed by agarose gel electrophore¬
sis for identification of a 250 nt amplicon. All HPV-
negative adenocarcinomas were retested for HPV-16
and HPV-18 using the methods described previously
to ensure that a positive result had not been
"missed" initially.
Restriction digestion of genomic DNA
For confirmation of type-specific identification of
HPV-16 and HPV-18 DNA, all HPV-positive samples
were collected and subjected to restriction fragment
length polymorphism (RFLP). Reactions consisted of
3 pL of restriction enzyme buffer, 14 pL of sterile
distilled water, 10 pL of PCR product, and 3 pL
(10 units/mL) of restriction enzyme Avail, according
to the method described by Hwang17. Using this
technique, an HPV-16-specific pattern is evident as
157 nt and 81 nt fragment, and its total length is 238
bp. An HPV-18-specific pattern is evident as 172 nt
and 96 nt fragments, and its total length is 268 bp17
on a 2% agarose gel.
Statistical analysis
The association of HPV types 16 and 18 with
pathologic variables of cervical adenocarcinoma was
analyzed using StatXact-4 package. The Chi-square
test was used to assess if HPV type distribution dif¬
fered between preinvasive and invasive disease and
within the different subtypes of invasive adeno¬
carcinoma. A P value of <0.05 was judged to be
significant.
Results
HPV detection and typing
Out of the 139 women with various cervical adenocar¬
cinoma lesions (119 with invasive disease and 20 with
AIS), HPV DNA was identified in 87 cases (62.6%),
with HPV-16 being detected in 65 (47%) cases (Fig. 1)
and HPV-18 in 41 (29%) cases (Fig. 2). Coinfection of
HPV-16 and HPV-18 was evident in 19 cases (14%). A
total of 52/139 patients (38%) with various cervical
adenocarcinoma lesions tested HPV negative for both
HPV-16 and HPV-18. All normal cervical biopsies
tested negative for HPV-16 and/or HPV-18.
Correlation between HPV-16 and HPV-18
infection and pathologic variables
of cervical adenocarcinomas
High-grade CGIN/AIS
In the 20 AIS patients, there were 7 (35%) patients
with HPV-16 only positive, 5 (25%) with HPV-18 only
positive, 3 (15%) with both HPV-16 and HPV-18 pos¬
itive, and the remaining 5 (25%) with both HPV-16
and HPV-18 negative. There was no significant differ¬
ence between AIS and invasive adenocarcinoma with
respect to HPV-16 and HPV-18 infection (Fig. 3)
Invasive adenocarcinoma
In the 119 invasive adenocarcinomas patients, there
were 39 (33%) patients with HPV-16 only positive, 17
Figure 1. Showing determination and confirmation of HPV type 16
by RFLP pattern and PCR using specific primers. Lane M, kilobase
DNA marker; lane 1, PCR products of HPV-16 extracted from paraf¬
fin section (uncut); lane 2, AVaJI fragments of lane 1 (cut); lane 3,
positive control SiHa (uncut); lane 4, AVall fragments of lane 3 (cut).
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igure 2. Showing determination and confirmation of HPV type 18
y RFLP pattern and PCR using specific primers. Lane M: kilobase
)NA marker; lane 1, positive control HeLa (uncut); lane 2, AVall
agments of lane 1 (cut); lane 3, PCR products of HPV-18 extracted
am paraffin section (uncut); lane 4, AVall fragments of lane 3 (cut).
14%) with HPV-18 only positive, 16 (13%) with both
HPV-16 and HPV-18 positive, and the remaining 47
B9%) with both HPV-16 and HPV-18 negative. The
Prevalence of HPV varied with different histologic
iubtypes. However, there was no significant difference
ietween all subtypes of invasive adenocarcinoma in
iomparison to each other and in comparison to AIS
nth respect to prevalence of HPV-16 and HPV-18
iifection (Table 1).
Early invasive adenocarcinoma
In the 16 early invasive adenocarcinomas patients,
Ihere were 5 (31%) patients with HPV-16 only positive,
Comparsion between AIS & invasive cervical
adenocarcinoma regarding to HPVs infection
HPV16&HPV18
Figure 3. Showing no significant differences between AIS and inva¬
sive adenocarcinoma with respect to HPV-16 and HPV-18 infection
using Chi-square test (P = 0.53). Invasive, invasive adenocarcinoma.
3 (19%) with HPV-18 only positive, 2/16 (13%) with
HPV-16 and HPV-18 both positive, and 6/16 (38%)
patients with HPV-16 and HPV-18 both negative. In
general, in early invasive adenocarcinomas patients,
HPV-16 was negative for 9 (56%) and positive for 7
(44%) patients and HPV-18 was negative for 11 (69%)
and positive for 5 (31%) patients.
Discussion
We found HPV-16 and/or HPV-18 infections in 87/
139 women with various cervical adenocarcinoma
lesions (62.6%). PCR and RFLP showed that HPV-16
was the most abundant type in this neoplasm, being
detected (in the absence of HPV-18) in 46 cases (33%).
Comparatively, HPV type 18 was detected (in the ab¬















Table 1. Showing no significant differences between all subtypes of invasive adenocarcinoma in comparison to each other and in
comparison to AIS with respect to HPV-16 and HPV-18 using Chi-square test (P = 0.12)
Villoglandular Minimal
papillary deviation Other types of
AIS, Adenocarcinoma Adenosquamous adenocarcinoma, adenocarcinoma, adenocarcinoma,
HPV-16 and HPV-18 N(%) NOS, N (%) carcinoma, N (%) N (%) N (%) N (%)
HPV-16 negative 5(25) 20 (40) 6(27) 6(26) 4(50) 11 (69)
and HPV-18 —ve
HPV-16 positive 7(35) 16 (32) 10 (45) 7(30) 1(13) 5(31)
and HPV-18 negative
HPV-16 negative 5(25) 9(18) 3(14) 5(22) 0(0) 0(0)
and HPV-18 positive
HPV-16 positive 3(15) 5(10) 3(14) 5(22) 3(38) 0(0)
and HPV-18 positive
Total 20 (100) 50 (100) 22 (100) 23 (100) 8 (100) 16 (100)
EJOS, not otherwise specified.
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of HPV-16 and HPV-18 being detected in 19 cases
(14%). A total of 52 of 139 (38%) of patients with vari¬
ous cervical adenocarcinoma lesions tested negative
for both HPV-16 and HPV-18. Our HPV prevalence
rates are somewhat lower than prevalence rates of
other reports that have shown from 68% to 84% posi-
tivity18"21. In our series, we did not perform PCR of
a housekeeping, cellular gene that controls for cellular
adequacy such as beta-globin. It could be the case that
some of the nucleic acid was excessively degraded for
successful amplification (DNA fragmentation as
a result of formalin fixation and storage in paraffin),
which was reflected, in our comparatively lower prev¬
alence rate. Moreover, our remit was to assess the
prevalence of HPV-16 and HPV-18 exclusively, and it
could be that other HR-HPV types were present in the
biopsies that could not be detected by the (HPV-16
and HPV-18 type specific) PCR used in this study.
The relative difficulty in detecting HPV DNA in
adenocarcinomas, in contrast to squamous cell carci¬
nomas, may also be attributed to a lower viral load in
glandular lesions as compared to squamous lesions.
Premalignant and malignant squamous lesions, in par¬
ticular those associated with HPV-16, contain a large
number of episomal viral particles, in addition to inte¬
grated HPV sequences22. Glandular epithelium that
does not support productive viral infection and HPV
DNA in endocervical neoplasms (notably HPV-18) is
usually present in the integrated form23. As a result,
detection of HPV DNA in adenocarcinomas requires
a sensitive detection assay. Potentially, the application
of a PCR strategy designed to amplify an even smaller
HPV target sequence than the 250-nt region targeted
by the PCR described here could have increased our
HPV detection rate. The GP5 + 6 + primers, for exam¬
ple, amplify a sequence of approximately 150 nt24.
Our findings show that HPV infection was absent in
all cases of normal cervical biopsies, and this finding
contradicts some previous studies (undertaken out-
with the UK) that also employed PCR techniques and
showed quite high prevalence rates for HPV infection
in normal cervical tissues25,26. However, this disparity
could be explained by virtue of the fact that the num¬
ber of normal biopsies that were tested in our series
was small (n = 16).
There is evidence of geographical variation in preva¬
lence of associated HR-HPV subtypes17. A comparison
of the prevalence of HPV-16 and/or HPV-18 infection
in cervical adenocarcinomas in different countries
(using different techniques) is shown in Table 227. In
this study, the detection rate of HPV-16 in cervical
adenocarcinoma was higher than that reported in
Table 2. Showing frequency of HPV-16 and/or HPV-18 DNA in cervical adenocarcinoma in different countries by in situ
hybridization and PCR (Lee et al.27)
Patient HPV HPV-16 HPV-18 HPV-16/18
Author Country number Techniques (%) (%) (%) (%)
Leminen et al.30 Finland 106 ISH (16,18) 18 2 14 2
Duggan et al.7 Canada 77 DBH (16,18) 44 18 23 Nm
Das et al.28 India 12 ISH (16,18) 58.3 41.6 16 0
Griffin England 16 PCR (16,18 and S) 31.3 25 6.3 0
Bjersing Sweden 26 PCR (E6/E7 and S) 42.0 15 27 0
Johnson et al?1 United States, 22 PCR (E6/E7 and S) 82 23 59 0
Michigan
Hording Denmark 50 PCR (16,18 and DBH) 70 18 52 0
Lee et al?7 United States, 20 PCR (16,18 and S) 15 10 5 0
Vermont
Chen Taiwan 42 PCR (LI, E6/E7, MY09, MY11) 67 19 48 0
Yamakawa et al?3 Japan 43 PCR (16,18 and S) PCR (16,18) 56 21 33 2
Tenti Italy 138 PCR (16,18 and S) 85 28 30 27
Iwasawa Finland 108 PCR (16,18 and MY09, MY11) 75 17 56 3
Parker United States, 32 PCR (16,18 and S) 50 22 28 0
Uchiyama et al.29
Washington
Japan 32 PCR (LI, 16,18 and Msell and Rsal) 34 19 12 3
Ferguson et al.9 United States, 27 PCR (LI and Msell and RsaD 59 26 26 Nm
Michigan
Tenti Italy 74 PCR (16,18, and S) 76 20 33 23
Lee et al?7 Taiwan 69 PCR (MY09, MY11 and S and Rsaf) 32 16 14 1..
M. Tawfik El-Mansi Scotland 139 PCR (16,18) 62.6 33 16 14
Current study
ISH, in situ hybridization; S, Southern; DBH, dot blot hybridization.
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arts of Europe and the United States; indeed, we
:und HPV-16 to be the predominant type in cervical
Jenocarcinoma. Only a few other studies have
jown HPV-16 to be the most frequently detected type
i cervical adenocarcinoma28'29, with many studies re-
orting that HPV-18 predominates7,30-34. This phe-
omenon could be attributed in part to geographical
id/or racial differences between settings; different
.metic and environmental factors may contribute dif-
erently to the pathology of cervical adenocarcinoma
iduction by HR-HPV types.
In our study, HPV-16 and HPV-18 were prevalent in
11 subtypes of invasive adenocarcinoma, and no sig-
lificant relation between type of HPV and subtype of
fcease was noted. Accumulated evidence would sug-
>est that HPV type is not predictive of tumor grade,
illume, depth of invasion, lymphvascular space
iivolvement, age at presentation, or year of diagno¬
sis7, and on the basis of our data, we would include
histologic subtype of adenocarcinoma to this list.
In terms of the potential usefulness of a prophylactic
raccine in the prevention of adenocarcinoma, the re-
salts that we present are extremely positive. We have
shown that both HPV-18 (as detected by other investi¬
gators), and perhaps more interestingly, HPV-16 are
indeed prevalent in preinvasive and invasive adeno¬
carcinomas. Phase 3 trails of two commercial vaccines
lhat are designed to be protective for HPV-16 and
HPV-18 infection are ongoing. If the findings are posi-
five (as the results of the phase 2 trials would indi¬
cate14), we can speculate from that the vaccines have
the potential of reducing the incidence of adenocarci¬
noma significantly.
In terms of using adjunctive HPV testing in cytol¬
ogy screening, our results again would suggest that
adenocarcinoma, undetected by cytology, could
potentially be detected/exposed by the use of a com¬
mercially available HPV test. For example, the
Hybrid Capture® 2 (HC II) Test (Digene, Gaithersburg,
MD), which is currently the only HPV test that has
Food and Drug Administration (FDA) approval and is
used in the US for screening and triage, includes both
types HPV-18 and HPV-16 within its detection remit.
Although we exclusively looked at AIS or worse, Der-
chain et al.35 also found a high prevalence of HR-HPV
in atypical glandular cells, which some argue, are the
precursors of AIS. Again, the authors postulate the
beneficial role that HR-HPV screening could have on
the improved detection of glandular abnormalities at
an early stage.
In summary, our findings support that HPV-16,
along with HPV-18, may play a possible role in the
pathogenesis of adenocarcinoma of the uterine cervix
© 2006 IGCS, International Journal of Gynecological Cancer 16, 1025-1031
and the concept that proposed HPV screening and
vaccination strategies are likely to have a positive
impact on the reduction of adenocarcinoma. For future
studies, it will be of importance to investigate HPV
type-specific diversity in preinvasive and invasive
adenocarcinoma beyond types HPV-16 and HPV-18 in
order to evaluate their importance in pathogenesis of
this disease.
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